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Hippocampal metabolic hyperactivity and neural disinhibition, i.e. 
reduced GABAergic inhibition, have been associated with 
schizophrenia, although a causal link between disinhibition and 
metabolic hyperactivity remains to be demonstrated. Regional neural 
disinhibition might also disrupt neural activation in projection sites, 
such as the prefrontal cortex and striatum, which may contribute to 
cognitive impairments and positive symptoms characteristic of 
schizophrenia. To further examine the brain-wide impact of 
hippocampal disinhibition and the associated behavioural and 
cognitive changes, we combined ventral hippocampal infusion of the 
GABA-A antagonist picrotoxin with translational neural imaging and 
behavioural methods in rats.  
 
First, we used a conditioned emotional response paradigm to assess 
the impact of hippocampal disinhibition on aversive conditioning and 
salience modulation in the form of latent inhibition (chapter 2), both 
of which have been reported to be disrupted in schizophrenia. These 
experiments demonstrated hippocampal disinhibition caused 
disrupted cue and contextual fear conditioning, whilst we found no 
evidence that hippocampal disinhibition affects salience modulation 
as reflected by latent inhibition of fear conditioning. The disruption of 
fear conditioning resembles aversive conditioning deficits reported in 
schizophrenia and may reflect disruption of neural processing at 
hippocampal projection sites.  
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Second, we used SPECT imaging to map changes in brain-wide 
activation patterns caused by hippocampal GABA dysfunction 
(chapter 3). SPECT experiments revealed increased neural activation 
around the infusion site in the ventral hippocampus, resembling 
metabolic hippocampal hyperactivity consistently reported in 
schizophrenia. In contrast, activation in the dorsal hippocampus was 
significantly reduced. This resembles the finding of anterior 
hippocampal hyperactivity coupled with reduced posterior 
hippocampal activation in patients with schizophrenia. Hippocampal 
disinhibition also caused marked extra-hippocampal activation 
changes in neocortical and subcortical sites, including sites implicated 
in fear learning and anxiety such as the medial prefrontal cortex 
(mPFC), septum, lateral hypothalamus and extended amygdala which 
may contribute to the disruption of fear conditioning demonstrated in 
chapter 2. Importantly, increased activation in the mPFC corresponds 
with previously reported prefrontal-dependent attentional deficits 
caused by hippocampal disinhibition.  
 
Third, to complement these findings we used magnetic resonance 
spectroscopy (MRS) to determine the effects of hippocampal 
disinhibition on neuro-metabolites within the mPFC (chapter 4). Using 
MRS, we demonstrated that hippocampal disinhibition causes 
metabolic changes in the mPFC, reflected by increased myo-inositol 




Overall, our results demonstrate ventral hippocampal disinhibition 
causes regional metabolic hyperactivity, supporting a causal role 
between GABA dysfunction and increased anterior hippocampal 
activity. In addition, hippocampal disinhibition causes activation and 
metabolic changes at distal sites, which may contribute to clinically 
relevant behavioural deficits, including impaired aversive 
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Chapter 1: Introduction 
Dysfunctional inhibitory neurotransmission has been linked to the 
pathophysiology of a number of psychiatric disorders including 
Alzheimer’s disease, autism spectrum disorder and schizophrenia 
(Ambrad Giovannetti and Fuhrmann, 2019, Marin, 2012). Inhibitory 
gamma-aminobutyric acid (GABA) transmission plays a key role in 
balancing and controlling excitatory neurotransmission (Isaacson and 
Scanziani, 2011) and the processing of information requires precise 
spatio-temporal control of excitatory neurons (Letzkus et al., 2015, 
Panzeri et al., 2015). In addition, GABA input to excitatory pyramidal 
neurons play a significant role in the synchronisation of large scale 
neural networks (Cobb et al., 1995) which is important for 
behavioural and cognitive function (Uhlhaas et al., 2009). Specifically 
increased hippocampal neural disinhibition, i.e. reduced inhibitory 
GABA transmission, has emerged as a key characteristic of 
schizophrenia pathophysiology and has been linked to both cognitive 
impairments and psychosis (Heckers and Konradi, 2015). 
Hippocampal disinhibition has also been linked to age related 
cognitive decline (Nava-Mesa et al., 2014), although the evidence for 
the involvement of GABA dysfunction is more compelling in 
schizophrenia (Heckers and Konradi, 2015). Recent evidence has 
provided a causal link between hippocampal disinhibition and some 
of the characteristic cognitive impairments of schizophrenia including 
deficits in attention and everyday-type memory (McGarrity et al., 
2017). Whilst hippocampal disinhibition has been linked to some 
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clinically relevant cognitive deficits, a more detailed understanding of 
the role hippocampal GABA dysfunction may play in the generation of 
psychosis and disruption of wider neural networks has yet to be 
established.   
 
Hippocampal dysfunction in schizophrenia: regional 
hyperactivity and GABA dysfunction 
 
The hippocampus has been implicated in schizophrenia for decades, 
with early post-mortem morphometric studies reporting reductions in 
hippocampal regional volume (Brown et al., 1986, Falkai and Bogerts, 
1986). This evidence was later confirmed with the use of structural 
neuroimaging, where consistent hippocampal volume deficits have 
been reported (Roeske et al., 2020, Steen et al., 2006). Studies which 
have investigated hippocampal volume deficits in more anatomical 
detail have found volume reductions are more prominent in the 
anterior region of the hippocampus, as compared to the posterior 
section (Lieberman et al., 2001, Narr et al., 2004, Schobel et al., 
2009a). The more pronounced volume reduction in anterior compared 
to posterior hippocampus is particularly evident in early stage 
schizophrenia. Comparison of hippocampal volume deficits in acute 
versus chronic schizophrenia demonstrate that acute patients have 
anterior but not posterior hippocampal volume reductions, whilst both 
anterior and posterior volume deficits are present in chronic 
schizophrenia (Ho et al., 2017, McHugo et al., 2018). Significantly, 
structural hippocampal changes are also correlated with cognitive 
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deficits. For example, patients with hippocampal grey matter loss 
demonstrate deficits in hippocampal-dependent spatial memory 
compared to healthy controls (Ledoux et al., 2014). A more recent 
study by Vargas et al. (2018) also showed that hippocampal volume 
reductions correlate with both visual learning and working memory 
deficits. In addition, studies utilising in vivo magnetic resonance 
spectroscopy (MRS) have reported consistent reductions in the 
concentration of hippocampal N-acetyl aspartate (NAA), which is 
associated with neurodegeneration and is therefore viewed as a 
marker of neuronal integrity (Brugger et al., 2011, Kraguljac et al., 
2012). These findings are consistent with the prominent volume 
reductions reported in structural and morphometric analyses. Overall, 
hippocampal volume reductions are a key pathological feature of 
schizophrenia with deficits correlating with cognitive impairments, 
and changes in the anatomical locus of volume reductions linked to 
the duration of the disorder.  
 
In addition to volume deficits in the hippocampus, the use of 
functional imaging techniques has revealed resting regional 
hyperactivity within the hippocampus in schizophrenia (Friston et al., 
1992, Kawasaki et al., 1992, Liddle et al., 1992a, Molina et al., 2005). 
Importantly, increased cerebral blood flow is correlated with 
increased metabolic demand (Logothetis et al., 2001, Ogawa et al., 
1990) and thus higher neuronal activity, linking increases in brain 
perfusion with increased excitatory neurotransmission. More recent, 
higher resolution imaging studies have also reported a differentiation 
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in activity between the anterior and posterior hippocampus, 
comparable to the volumetric changes. Hyperactivity of the anterior 
section of the hippocampus has been consistently reported in both 
chronic and acute schizophrenia (McHugo et al., 2019, Schobel et al., 
2009b, Schobel et al., 2013, Talati et al., 2014). Schobel et al. (2013) 
also demonstrated that hyper-metabolism in the anterior 
hippocampus spatially coincides with anterior hippocampal atrophy in 
patients with schizophrenia. It has been hypothesised that neuronal 
hyperactivity driven by an excitation-inhibition imbalance, due to 
dysfunction of GABAergic inhibitory interneurons (see next 
paragraph), leads to the volume deficits reported in structural 
imaging studies (Heckers and Konradi, 2015, Lieberman et al., 2018). 
Hippocampal hyperactivity is also associated with the clinical 
symptoms of schizophrenia. A seminal study by Liddle et al. (1992b) 
reported a significant positive correlation between cerebral blood flow 
in the parahippocampal gyrus and reality distortion in a group of 
patients with schizophrenia. Subsequently, more recent studies have 
replicated this finding, whereby increased hippocampal activity 
correlates with positive symptom severity (Lahti et al., 2006, Molina 
et al., 2003, Schobel et al., 2013). Hippocampal hyperactivity is also 
associated with poor cognitive performance including on assays of 
attention and memory  (Tregellas et al., 2014).  
 
As outlined in the preceding paragraph, hippocampal hyperactivity is 
a significant feature of both acute and chronic schizophrenia and 
studies have suggested dysfunctional inhibitory GABA transmission is 
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a major contributing factor to hippocampal volume loss and 
hyperactivity. Early histological studies from the hippocampus of 
patients with schizophrenia revealed cellular abnormalities including 
reduced neuronal size (Arnold et al., 1995, Benes et al., 1991), 
although in many studies the overall number of neurons within the 
hippocampus was not reduced compared to controls (Dwork, 1997, 
Heckers et al., 1991, Walker et al., 2002). However a recent meta-
analysis of post-mortem studies reported selective reductions in 
neuronal number in the left, but not right hippocampus, with no 
parallel differences in neuron density across the hippocampus 
(Roeske et al., 2020). The overall decreases in neuronal number 
appear to be driven by specific reductions in inhibitory neuron 
populations. An early study by Benes et al. (1998) investigating 
specific cell-type populations, reported reductions in the number of 
non-pyramidal cells in the CA2 and CA3 subfields of the hippocampus. 
Later analysis has shown this reduction in non-pyramidal cells in the 
hippocampus is restricted to selected subtypes of interneurons. 
Specifically, there is a reduction in the number of parvalbumin and 
somatostatin-positive neurons, but not calretinin positive neurons, in 
the hippocampus of schizophrenia patients (Konradi et al., 2011, 
Torrey et al., 2005, Zhang and Reynolds, 2002). In addition, Konradi 
et al. (2011) also reported reduced parvalbumin and somatostatin 
mRNA levels, whilst seeing no reduction of cells in the pyramidal cell 
layer. Significantly, parvalbumin-positive interneurons constitute 
approximately 20%, and somatostatin-positive neurons between 30-
50% of all GABAergic neurons within the hippocampus (Freund and 
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Buzsaki, 1996). Parvalbumin and somatostatin-positive cells both 
play key roles in the control of pyramidal cell activity (Bartos et al., 
2007, Viollet et al., 2008) and a reduction in the number of these 
inhibitory neurons could be responsible for the hyperactivity seen in 
the hippocampus of schizophrenia patients. 
 
In addition to changes in the numbers and density of specific types 
of interneurons within the hippocampus, alterations in the genes 
involved in GABA transmission have also been reported in post-
mortem studies. Studies examining the gene expression profile of 
hippocampal subfields using laser microdissection, have shown 
significant reductions in the expression of both GAD67 and GAD65 in 
CA3/2 and GAD67 in the CA1 hippocampal subfield. GAD67 and 65 
are isoforms of the enzyme glutamate decarboxylase which is 
responsible for converting glutamate into GABA. Additionally, these 
studies also identified a number of genes which are implicated in 
synaptic transmission including genes involved in GABA and kainate 
receptors (Benes et al., 2007, Benes et al., 2008). Changes at the 
synaptic level itself have also been found in post-mortem studies of 
the hippocampus. Relatively consistent reductions in the presynaptic 
proteins synaptophysin, SNAP-25, and synapsin have been reported, 
with these reductions affecting both the level of protein and mRNA 
expression (Harrison, 2004). With dysfunctional inhibitory 
neurotransmission in the hippocampus being strongly implicated in 
the pathophysiology of schizophrenia, several studies have analysed 
the concentrations of the excitatory and inhibitory neurotransmitters 
15 
 
glutamate and GABA in vivo using MRS (although it should be noted 
that the glutamate and GABA pools measured by MRS do not only 
include the extracellular neurotransmitter pool, but also intracellular 
pools of the compounds, including pools stored in vesicles and 
involved in metabolic pathways), however the data from these 
studies is somewhat inconsistent (see chapter 4 for further discussion 
of the findings of clinical MRS studies). Increased hippocampal glx 
(combined glutamine and glutamate) has been reported in patients 
with schizophrenia, and this increase correlated with hippocampal 
volume reductions (Kraguljac et al., 2013). A study of first episode 
psychosis (FEP) however, found no increase in glx, although patients 
who had a long duration without treatment had significantly increased 
glx (Briend et al., 2020), but this did not correlate with changes in 
hippocampal volume. In addition, a study comparing individuals with 
a high risk of psychosis (UHR) and FEP patients found decreased 
hippocampal glx in UHR individuals but not in FEP (Shakory et al., 
2018). A further study of FEP showed no significant changes in 
hippocampal glx concentrations, nonetheless higher levels of glx 
correlated with decreased hippocampal functional connectivity to 
regions of the default mode network (Nelson et al., 2020). 
Considering glutamate alone, a meta-analysis by Marsman et al. 
(2013) reported no change in glutamate in the hippocampus, 
however decreased glutamate has been reported in a later study 
(Stan et al., 2015). Currently the study by Stan et al. (2015) is the 
only clinical MRS study to have measured GABA in the hippocampus 
in schizophrenia, and this study reported no differences in 
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hippocampal GABA concentration in the patient sample compared to 
controls. Although the authors do note the measurements may lack 
the sensitivity to detect changes in GABA when those changes may 
be limited to specific subfields. Overall the evidence from clinical 
neuroimaging studies strongly implicates hippocampal hyperactivity, 
possibly due to cellular and molecular abnormalities of inhibitory 
neurons, as a key feature of schizophrenia, which has been linked to 
psychotic and cognitive symptoms.  
 
Significantly, a number of rodent models of hippocampal 
hyperactivity provide evidence of a causal link between psychosis-
related and cognitive impairments (Katzel et al., 2020). Electrical or 
chemical stimulation of the ventral hippocampus causes increases in 
striatal dopamine, which is a key feature of schizophrenia, and also 
causes locomotor hyper-activity seen as a putative rodent correlate 
of positive symptoms (Bast et al., 2001c, Legault and Wise, 1999, 
Taepavarapruk et al., 2000). In addition, disinhibiting, i.e. reducing 
inhibitory GABA transmission, the ventral hippocampus also induces 
hyper-locomotion (Bast et al., 2001a, McGarrity et al., 2017, Nguyen 
et al., 2014). Furthermore, deficits in pre-pulse inhibition (PPI), which 
is often used as a psychosis related index in rodent studies (Arguello 
and Gogos, 2006, Bast and Feldon, 2003), are caused by hippocampal 
hyperactivity either via chemical/electrical stimulation or 
chemogenetic disinhibition (Bast et al., 2001c, Howland et al., 2004, 
Nguyen et al., 2014). Although PPI deficits may be strain sensitive 
with picrotoxin induced disinhibition having contrasting effects in 
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different rat strains (Bast et al., 2001a, McGarrity et al., 2017). 
Hippocampal hyperactivity is also associated with cognitive deficits 
including attentional and memory deficits in rodent models. 
Specifically ventral hippocampal disinhibition, via pharmacological or 
chemo- and optogenetic inhibition of GABA transmission, disrupts 
sustained attention (McGarrity et al., 2017, Tan et al., 2018) and 
short term working memory (McGarrity et al., 2017, Nguyen et al., 
2014). In addition, optogenetic activation of the ventral hippocampus 
incudes hyper-locomotion and disrupts hippocampus dependent short 
term memory (Wolff et al., 2018). Neurodevelopmental models of 
schizophrenia which cause similar hippocampal pathology also 
provide evidence of disrupted cognition. Animals with a cyclin-D2 
knockout exhibit working memory impairments and disrupted 
cognitive flexibility (Grimm et al., 2018). Whilst the gestational 
administration of methylazoxymethanol acetate (MAM) model 
demonstrates disrupted cognitive flexibility, reduced PPI and working 
memory impairments (Lodge and Grace, 2009). Overall these studies 
suggest that ventral hippocampal hyperactivity may contribute to 
both the positive symptoms and cognitive deficits characteristic of 
schizophrenia.     
 
Importantly, tonic neural disinhibition may not only effect local 
activity within that region but could disrupt activity and cognitive 
functions at distal sites by aberrant drive of neuronal projections 
(Bast et al., 2017). Hippocampal hyperactivity has been linked to 
several features of schizophrenia symptoms, including cognitive 
18 
 
deficits and psychosis, and these behavioural deficits likely involve 
disrupted coordination of several brain regions. The following sections 
discuss the intrinsic and extrinsic connectivity of the hippocampus 
and the potential relevance of this connectivity to the contribution 
that hippocampal hyperactivity may have in the manifestation of 
psychosis and cognitive deficits.  
 
Hippocampal function and connectivity  
 
The hippocampus is a region conserved across mammalian species 
organised into three distinct subfields: the hippocampus proper 
(consisting of CA1, CA2 and CA3) the dentate gyrus and subiculum. 
The hippocampus has long been linked to the formation of declarative 
memories, since the study of patient H.M. who suffered significant 
memory impairments after resection of the hippocampus to treat 
severe epilepsy (Scoville and Milner, 1957). In addition, there has 
been a longstanding link between the hippocampus and the control 
of emotion, and these diverse behavioural functions are differentially 
associated with different parts of the hippocampus along its 
longitudinal axis (posterior-anterior in humans and non-human 
primates and dorso-ventral or septo-temporal in rodents) 
(Bannerman et al., 2004, Bast et al., 2009, Fanselow and Dong, 
2010, Moser and Moser, 1998, Strange et al., 2014).   
 
The major source of neocortical neuronal inputs to the hippocampus 
is from the entorhinal cortex (Kerr et al., 2007, Steward, 1976, 
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Swanson and Kohler, 1986, Tamamaki and Nojyo, 1995, Tamamaki, 
1997, van Strien et al., 2009, Witter et al., 1988), which acts as a 
gateway for information transfer to the hippocampus. The entorhinal 
cortex receives monosynaptic input from multiple regions including 
the perirhinal, olfactory and gustatory cortices, amygdala and 
hypothalamus (Burwell, 2000, Burwell and Amaral, 1998, Pitkänen et 
al., 2000). Entorhinal inputs to the hippocampus are topographically 
ordered in a way such that dorsolateral areas of the entorhinal cortex 
provides input to the dorsal hippocampus and more ventromedial 
entorhinal cortex provides input to the ventral hippocampus (Dolorfo 
and Amaral, 1998, Insausti et al., 1997, Witter et al., 2000). 
Therefore the dorsal hippocampus largely receives information from 
visual and auditory cortices, relayed via the dorsolateral entorhinal 
cortex, while the ventral hippocampus receives information from the 
amygdala and hypothalamic nuclei via the ventromedial entorhinal 
cortex (Naber et al., 2001, Canto et al., 2008).  
 
Information is passed through the hippocampus through the 
‘trisynaptic pathway’ whereby the entorhinal cortex connects to the 
dentate gyrus through the perforant pathway, the dentate gyrus then 
connects to CA3 through mossy fibres, CA3 then projects to CA1 via 
Schaffer collaterals and subsequently CA1 projects to the subiculum. 
Although, a number of reciprocal projections have been reported 
within the hippocampal circuit. This includes projections from CA3 
back to the dentate gyrus and CA1 projections back to CA3, however 
the inhibitory or excitatory nature of these connections is not well 
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understood (Amaral et al., 1991, Li et al., 1994, Swanson et al., 
1978). The subiculum and CA1 subfields are the main output 
structures of the hippocampal formation and project back to the 
entorhinal cortex, in the same topographical manner as the input to 
the hippocampus, and also to numerous cortical and subcortical sites 
(Cenquizca and Swanson, 2007, Witter, 1993).  
 
As previously mentioned the hippocampus can be organised across 
the longitudinal axis with dorsal and ventral efferent projections 
preferentially connected to distinct regions. The dorsal hippocampus 
sends strong efferent connections to the retrosplenial cortex, the 
anterior cingulate cortices, and anterior thalamic and mammillary 
nuclei (Cenquizca and Swanson, 2007, Ishizuka, 2001, Kishi et al., 
2000, Van Groen and Wyss, 2003). These regions are heavily 
involved in the processing of visuospatial information, memory 
processes, environmental exploration and spatial navigation 
(Aggleton et al., 2010, Harker and Whishaw, 2004, Jones and Wilson, 
2005), and these connections are consistent with the role of the 
dorsal hippocampus in spatial learning and memory functions 
(Bannerman et al., 2014, Bast, 2007, Fanselow and Dong, 2010, 
Moser and Moser, 1998, Strange et al., 2014). Conversely, the 
ventral hippocampus sends strong efferent connections to the 
amygdala, prefrontal cortex, hypothalamus and ventral striatum 
(Cenquizca and Swanson, 2006, Cenquizca and Swanson, 2007, 
Groenewegen et al., 1987, Hoover and Vertes, 2007, Petrovich et al., 
2001), which is consistent with the role of the ventral hippocampus 
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in the regulation of emotional and affective behaviours (Bannerman 
et al., 2004, Bannerman et al., 2014). In rodents ventral hippocampal 
excitatory projections to the medial prefrontal cortex are 
unidirectional and strongly innervate the prelimbic, infralimbic and 
anterior cingulate cortices (Cenquizca and Swanson, 2007, Hoover 
and Vertes, 2007, Jay and Witter, 1991). This pattern of connectivity 
between the hippocampus and prefrontal cortex is also consistent in 
the primate brain, where anterior hippocampal neurons (homologous 
to ventral hippocampus) project to the anterior and medial prefrontal 
cortex (Aggleton, 2012, Barbas and Blatt, 1995, Roberts et al., 2007). 
The prefrontal termination points of ventral hippocampal projections 
are heterogeneous and are involved in numerous behaviours 
including working memory, cognitive flexibility and goal oriented 
learning (Euston et al., 2012, Kesner and Churchwell, 2011). In 
addition, the hippocampal-prefrontal circuit has been implicated in 
the control of spatial and working memory, decision making, 
conditioned fear and anxiety (Floresco et al., 1997, Padilla-Coreano 
et al., 2016, Sotres-Bayon et al., 2012, Spellman et al., 2015, Wallis 
et al., 2019, Wikenheiser et al., 2017, Zeredo et al., 2019). 
Significantly, disruption of this circuit has been proposed as a key 
feature of several psychiatric disorders (Godsil et al., 2013). In 
addition, the ventral hippocampus has strong bidirectional 
connectivity with the amygdala. Ventral hippocampal projections 
innervate the basolateral, basomedial and central amygdala (Kishi et 
al., 2006, Pitkänen et al., 2000), whilst the lateral and basolateral 
amygdala provide input to the ventral hippocampus. In addition, 
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some ventral hippocampal neurons projecting to the basolateral 
amygdala also project to the prefrontal cortex (Ishikawa and 
Nakamura, 2006). Importantly, the amygdala plays an essential role 
in the formation and expression of conditioned fear and anxiety 
(Tovote et al., 2015). Furthermore, the hippocampus also strongly 
innervates the lateral septum and hypothalamus (Kishi et al., 2000, 
Risold and Swanson, 1997, Swanson and Cowan, 1979) which have 
been proposed, alongside the amygdala and prefrontal cortex, to be 
part of the neural circuit mediating anxiety and conditioned fear 
(Adhikari et al., 2011, Anthony et al., 2014, Tovote et al., 2015). 
 
In addition, ventral CA1 and subiculum efferents also innervate the 
caudomedial parts of the nucleus accumbens (Groenewegen et al., 
1987, Voorn et al., 2004). The nucleus accumbens is a key region 
involved in reward processing, salience and novelty detection 
particularly when considering dopaminergic systems (Berridge, 2007, 
Legault and Wise, 2001, Lisman and Grace, 2005). Partly through the 
strong glutamatergic projections to the nucleus accumbens, the 
ventral hippocampus is part of a circuit which is able to modulate 
dopamine release within the striatum. It has been repeatedly shown 
that electrical and chemical stimulation of the ventral hippocampus 
induces dopamine release within the nucleus accumbens, which is 
mediated by increased activity of ventral tegmental area (VTA) 
dopamine neurons (Blaha et al., 1997, Brudzynski and Gibson, 1997, 
Floresco et al., 2001, Legault and Wise, 1999, Legault et al., 2000, 
Taepavarapruk et al., 2000). It is thought the ventral hippocampus 
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can modulate striatal dopamine release via a polysynaptic route. This 
involves glutamatergic input to the nucleus accumbens, subsequently 
increasing inhibitory GABA transmission to the ventral pallidum which 
removes the inhibitory effect of the ventral pallidum on dopamine 
neurons of the VTA (Floresco et al., 2001, Floresco et al., 2003, Grace 
et al., 2007, Legault and Wise, 2001).  
 
However several other brain regions can influence the release of 
dopamine in the striatum by interacting with hippocampal-midbrain 
circuitry. This includes areas of the medial prefrontal cortex 
(infralimbic and prelimbic), midline thalamic nuclei (nucleus 
reuniens), amygdala and medial septum (Sonnenschein et al., 2020). 
For example, studies have shown that the infralimbic cortex can 
regulate the proportion of active VTA neurons, but this is dependent 
on activity within the hippocampus and nucleus reuniens 
(Zimmerman and Grace, 2016). In addition, the medial septum also 
exerts modulatory control over midbrain dopamine neuron activity 
which is again dependent on ventral hippocampal activity (Bortz and 
Grace, 2018).  
 
Although there are strong similarities in hippocampal neural anatomy 
between rodents and primates there are apparent differences when 
considering midbrain connectivity. Rodents have a larger ventral 
striatum and VTA in comparison to primates, resulting in differences 
in the innervation of distinct striatal neuron populations (Joel and 
Weiner, 2000). It has been suggested that the pathway from the VTA 
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to the ventral striatum in rodents is partly homologous to the 
projections of midbrain dopamine neurons to the associative striatum 
in primates, a central region of the striatum encompassing parts of 
the caudate and putamen (Joel and Weiner, 2000, McCutcheon et al., 
2019). In rodents medial VTA neurons innervate the ventral striatum 
and neurons projecting from the substantia nigra innervate the dorsal 
striatum (Ikemoto, 2007), whereas neurons that lie at the transition 
between the lateral VTA and substantia nigra (SN) innervate the 
associative striatum (Joel and Weiner, 2000). In primates, the 
proportionally smaller VTA, projects to the ventral striatum with the 
dorsal SN innervating the associative striatum and the ventral tier of 
the SN innervating the motor related striatum (Duzel et al., 2009, 
Joel and Weiner, 2000, Lynd-Balta and Haber, 1994).  
 
Considering the anatomical connectivity between the hippocampus 
and midbrain dopamine circuits, it is possible that hippocampal 
disinhibition could lead to an increase in striatal dopamine release. 
Increased excitatory drive from the hippocampus to the striatum has 
been suggested as key contributor to the pathophysiology of 
schizophrenia (Grace, 2016). Increased excitatory activity is 
hypothesised to lead to increased striatal dopamine release, a key 
feature of schizophrenia (Howes et al., 2012), which subsequently 
leads to psychosis by causing an aberrant allocation of salience 
(Kapur, 2003, Katzel et al., 2020).  
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Aims of the PhD project 
The extensive connectivity from the hippocampus to cortical and 
subcortical sites suggests that hippocampal disinhibition may disrupt 
a range of behavioural functions beyond the specific memory 
functions typically associated with the hippocampus by disrupting 
neural processing both within the hippocampus and at projection 
sites.  
 
Therefore, to assess this idea, the aims of this project were to 
determine whether hippocampal disinhibition disrupts the modulation 
of salience and associative learning, in the form of aversive 
conditioning, and to assess the effect of hippocampal hyperactivity on 
brain-wide neural activity. To this end we used a combination of 
pharmacological manipulation, behavioural testing and translational 
in vivo neuroimaging. To model dysfunctional GABA transmission we 
utilised ventral hippocampal infusions of the GABA-A antagonist 
picrotoxin. Previous studies have shown that hippocampal picrotoxin 
infusions cause memory and attentional deficits (McGarrity et al., 
2017).  
 
Aim 1: Impact of hippocampal disinhibition on aversive conditioning 
and latent inhibition  
To test the hypothesis that hippocampal hyperactivity disrupts 
aversive conditioning and salience modulation we used a conditioned 
emotional response latent inhibition paradigm (Nelson et al., 2011a) 
(chapter 2). Disrupted latent inhibition reflects the hyper-associability 
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of stimuli which would normally be deemed as irrelevant and thus is 
seen as a disruption of salience processing, similar to which is 
hypothesised to cause hallucinations and delusions (Kapur, 2003). 
Using an aversive CER latent inhibition paradigm also enabled us to 
explore the effects of ventral hippocampal disinhibition on the fear 
conditioning response which has been shown to be disrupted by 
hippocampal hyperactivity (Zhang et al., 2001). Importantly, 
aberrant aversive conditioning has been reported in schizophrenia, 
alongside impairments in salience modulation (Jensen et al., 2008). 
In addition, we also performed locomotor activity testing (LMA), as 
ventral hippocampal disinhibition causes robust increases in 
locomotion and thus provided us with a positive control of behavioural 
output (chapter 2). We hypothesised ventral hippocampal 
disinhibition would abolish latent inhibition, thus disrupting salience 
modulation, whilst also disrupting fear conditioning.  
 
Aim 2: Brain-wide impact of hippocampal disinhibition as measured 
using SPECT 
To answer the question of whether hippocampal disinhibition causes 
regional hyperactivity, which is a key feature of schizophrenia 
pathophysiology, and to examine the distal impact in extra-
hippocampal sites, we combined local hippocampal picrotoxin 
infusions with functional whole brain SPECT imaging (Chapter 3). 
SPECT imaging allows the measurement of brain-wide patterns of 
neural activity in awake rats via imaging of cerebral blood flow. 
Briefly, this involves injection of a tracer in awake unrestrained 
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animals, which is subsequently mapped in anaesthetised animals, 
providing a measure of the spatial pattern of cerebral blood flow 
during the time of tracer injection (Oelschlegel and Goldschmidt, 
2020). Using SPECT imaging we can measure the brain wide effects 
on neural activity caused by hippocampal disinhibition. Because 
SPECT measures of regional cerebral blood flow are similar to non-
invasive imaging measures of brain activity used in clinical studies, 
we can also compare our data with the findings of human clinical 
imaging studies. 
 
Aim 3: Impact of hippocampal disinhibition on prefrontal 
neurochemistry as assessed using MRS 
We subsequently further investigated the effects of hippocampal 
disinhibition on neurochemistry in the medial prefrontal cortex, using 
proton magnetic resonance spectroscopy (1H-MRS) in chapter 4. MRS 
is a non-invasive technique, which enables the measurement of a 
neurochemical profile consisting of brain metabolites, which have 
distinct functions including neurotransmission and energy and 
membrane metabolism (Duarte et al., 2012). In addition, MRS is seen 
as a key tool in bridging the translation of basic research and clinical 
applications. MRS studies have recently more widely been used to 
reveal aberrant neurometabolites concentrations, including GABA and 
glutamate, levels in schizophrenia in several brain regions, including 
the prefrontal cortex (Egerton et al., 2017b, Marsman et al., 2013). 
However, findings from these studies are complex and the 
mechanisms underlying neuro-metabolite changes require 
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clarification. Using this technique we assessed the effect of 
hippocampal disinhibition on the underlying neuro-metabolism in the 
medial prefrontal cortex. Significantly, disruption of this circuit is 
thought to contribute to some of the cognitive symptoms of 




















Chapter 2: Hippocampal disinhibition 
reduces contextual and elemental fear 
conditioning whilst sparing the formation 
of latent inhibition  
 
Introduction 
Psychosis is a fundamental feature of psychiatric disorders, such as 
schizophrenia, and the characteristic symptoms of hallucinations and 
delusions are thought to be driven by aberrant salience processing 
(Gray et al., 1991, Kapur, 2003). Psychosis is hypothesised to be 
caused by elevated striatal dopamine (Howes and Kapur, 2009), 
which is a key feature of schizophrenia (Abi-Dargham et al., 2000, 
Howes et al., 2009, Laruelle and Abi-Dargham, 1999). Hippocampal 
hyperactivity, potentially caused by GABA dysfunction, is a key 
characteristic of the pathophysiology of schizophrenia (Lisman et al., 
2008, Tamminga et al., 2010, Heckers and Konradi, 2015) and is 
correlated with the onset of psychosis (Schobel et al., 2009b, Schobel 
et al., 2013). It has been hypothesised that hippocampal 
hyperactivity could disrupt neural circuitry leading to an increase in 







Dopamine dysregulation and aberrant salience processing 
Schizophrenia patients demonstrate increased attention to irrelevant 
cues (Morris et al., 2012) and alterations in salience processing 
(Knolle et al., 2018). Importantly, dysregulated modulation of 
dopamine, which has long been understood to be a major 
pathophysiological feature of schizophrenia, is thought to contribute 
to the emergence of psychotic symptoms by disrupting salience 
processing (Davis et al., 1991, Heinz and Schlagenhauf, 2010, Howes 
and Kapur, 2009, Kapur, 2003). Early evidence of dysregulated 
dopamine came from the observation that antipsychotic treatments 
have affinity for dopamine receptors (Creese et al., 1976, Seeman 
and Lee, 1975), and that pharmacological agents that trigger the 
release of dopamine cause psychosis like symptoms (Angrist and 
Gershon, 1970, Lieberman et al., 1987). Subsequently, clinical 
imaging studies using positron emission tomography (PET) or single-
photon emission computed tomography (SPECT) reported 
significantly elevated dopamine within the striatum of schizophrenia 
patients (Abi-Dargham et al., 1998, Laruelle and Abi-Dargham, 1999, 
Laruelle et al., 1996). Multiple studies have shown that striatal 
dopamine dysregulation is pre-synaptic which affects dopamine 
synthesis and baseline synaptic dopamine levels (Howes et al., 2012), 
and is associated with positive symptom severity and the onset of 
psychosis (Howes et al., 2011, Laruelle et al., 1999). More recent 
studies have shown the predominant dopamine increase to be within 
dorsal subdivisions of the striatum, with the greatest increase in the 
associative striatum (McCutcheon et al., 2018, McCutcheon et al., 
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2019). Whilst the predominant dopamine abnormality seems to be 
localised to the associative striatum several studies have reported 
alterations in reward related ventral striatal activation. Specifically, 
patients with psychosis demonstrate hypo-activation of the ventral 
striatum during reward anticipation and reward prediction error 
processing (Corlett et al., 2007, Ermakova et al., 2018, Murray et al., 
2008, Radua et al., 2015). 
 
Significantly, the ventral hippocampus sends strong projections to the 
NAc (Groenewegen et al., 1987) and indirect connections to the VTA 
which influence the release of dopamine in the striatum and midbrain 
(Floresco et al., 2001). The ventral hippocampal formation also sends 
some sparse projections to the medial dorsal striatum (Finch, 1996, 
Groenewegen et al., 1987, Hunnicutt et al., 2016). Through these 
connections stimulation of the ventral hippocampus can influence 
striatal dopamine. Electrical stimulation or chemical manipulation of 
ventral hippocampal neurons increases neuronal firing in the VTA and 
subsequently increases dopamine levels in the VTA and NAc (Floresco 
et al., 2001, Legault and Wise, 1999, Legault et al., 2000). Enhanced 
glutamatergic drive from the hippocampus to the striatum resulting 
in increased activation of striatum projecting midbrain dopamine 
neurons is hypothesised to be an important mechanism in the 
pathophysiology of schizophrenia (Katzel et al., 2020, Sonnenschein 




Phasic dopamine release is thought to encode the difference between 
expected and obtained reward outcomes, known as reward prediction 
errors, and these prediction errors allow for the updating of 
expectations based on prior experience (Schultz et al., 1997). Phasic 
dopamine release is thus thought to represent the assignment of 
incentive salience to sensory stimuli and internal representations 
(Berridge, 2007), and it is thought that dysregulated striatal 
dopamine release can lead to delusions and hallucinations which are 
the hallmarks of psychosis. Aberrant striatal dopamine transmission 
could lead to stimulus-independent release of dopamine which 
subsequently leads to the aberrant assignment of motivational 
salience or attention to irrelevant information (Heinz and 
Schlagenhauf, 2010, Gray et al., 1991, Kapur, 2003). The aberrant 
assignment of salience to an otherwise irrelevant stimulus thus leads 
to an updating of prior beliefs or representations based on faulty 
information (Fletcher and Frith, 2009). The subsequent delusions and 
hallucinations caused by the abnormal formation of associations are 
therefore thought to be a mechanism to contextualise and rationalise 
these unusual experiences and as a consequence often reflect prior 
experiences and beliefs (Kapur, 2003).   
 
To better understand the neuro-psychological abnormalities that 
underlie positive symptomology in schizophrenia, behavioural tasks 
have been adapted from earlier animal learning studies. One 
prominent behavioural paradigm that has been used for this purpose 
is latent inhibition (LI). LI refers to the effect of pre-exposing a 
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stimulus without consequence which is later established as a cue for 
an outcome. LI is demonstrated by retarded learning of a pre-
exposed cue compared to a non-pre-exposed cue during a 
subsequent test of learning (Lubow and Moore, 1959). LI can 
therefore be seen as the effective filtering of irrelevant information 
as reflected by the reduction in association of a previously 
inconsequential cue. Importantly, attentional deficits are thought to 
be a key feature of schizophrenia (Nuechterlein and Dawson, 1984), 
and it has been suggested that LI reflects selective attentional 
processes. It has been proposed that prior exposure to a stimulus 
results in reduced attention to that stimulus, which leads to slower 
associative learning of that stimulus with an outcome compared to a 
non-pre-exposed stimulus (Lubow and Gewirtz, 1995, Pearce and 
Hall, 1980, Wagner and Rescorla, 1972).  
 
In agreement with the notion that dysfunctional attentional 
processing is a key feature of schizophrenia, deficits in LI have been 
reported in schizophrenia patients. Deficits in LI are generally 
restricted to the acute phase of the disorder, with studies of chronic 
patients demonstrating similar or even enhanced LI compared to 
controls (Baruch et al., 1988, Gal et al., 2009, Gray et al., 1992, Gray 
et al., 1995a, Rascle et al., 2001, Vaitl et al., 2002). However, some 
studies have reported normal LI in both unmedicated and medicated 
acute patients (Williams et al., 1998, Swerdlow et al., 1996). 
Inconsistencies in findings may be explained by small sample sizes 
and differing behavioural paradigms used to assess LI (Schmidt-
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Hansen and Le Pelley, 2012). Overall, it seems likely that LI is 
abnormal in schizophrenia, although, depending on the chronicity of 
the disorder, this may reflect either an attenuation or a potentiation 
of LI.  
 
In the present study we used a latent inhibition paradigm to assess 
attentional allocation in a rodent model. Whilst a variety of 
behavioural paradigms are used to assess LI in rodents, they are all 
performed using the same basic procedure (Weiner and Arad, 2009). 
Initially animals are either pre-exposed to a stimulus or non-pre-
exposed to the same stimulus. Both of these groups are subsequently 
conditioned using pairings of the pre-exposed stimulus and a 
reinforcer. After conditioning performance is measured using a 
behavioural index, where LI is reflected as reduced conditioning in 
the pre-exposed group (see: Weiner and Arad (2009). 
 
Hippocampal and dopaminergic involvement in LI 
As discussed above, LI appears to be disrupted in acute schizophrenia 
patients and hippocampal hyperactivity is a key neurobiological 
feature of acute schizophrenia (Heckers and Konradi, 2015). 
However, it is unclear whether dysfunctional hippocampal activity 
contributes to these LI deficits. Early studies suggested hippocampal 
lesions disrupt LI (Kaye and Pearce, 1987, McFarland et al., 1978), 
but see (Clark et al., 1992). However later studies have demonstrated 
that LI is spared by more selective hippocampal lesions (Coutureau 
et al., 1999, Honey and Good, 1993, Reilly et al., 1993, Shohamy et 
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al., 2000) but see (Oswald et al., 2002). These contrasting findings 
are most likely due to the destruction of axons of regions outside of 
the hippocampus in earlier studies, as lesions of the retro-
hippocampus and entorhinal cortex both disrupt LI (Coutureau et al., 
1999, Yee et al., 1995). However, Honey and Good (1993) 
demonstrated that whilst LI is spared by selective cytotoxic 
hippocampal lesions, the contextual specificity of LI is disrupted by 
these lesions which suggests the hippocampus may play a specific 
role in the contextual modulation of LI. Interestingly, deactivation of 
the ventral subiculum during pre-exposure disrupts the formation of 
LI (Peterschmitt et al., 2005, Peterschmitt et al., 2008). In addition, 
analysis of neural activation patterns during an LI paradigm, using c-
fos immunocytochemistry, reported increased activity in the 
subiculum in animals that were pre-exposed to the conditioned 
stimulus (Sotty et al., 1996). 
 
Whilst evidence for the role of the hippocampus in LI is varied, 
projection sites of the hippocampus have been implicated in 
modulating LI, including the mesencephalic dopamine system, pre-
frontal cortex and thalamic nuclei (Young et al., 2005, George et al., 
2010, Perez-Diaz et al., 2017, Nelson et al., 2018). Significantly, 
animal and human experiments have shown dopamine plays a critical 
role in the formation of LI. Administration of the indirect dopamine 
agonist amphetamine abolishes LI in rats (Weiner et al., 1988) and 
healthy human volunteers (Kumari et al., 1999, Thornton et al., 
1996). Conversely LI is potentiated by anti-psychotic medication, 
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which act at dopamine receptors, in both rats and humans (Weiner 
et al., 1997, Williams et al., 1997). Further investigations into the 
underlying neurobiology of latent inhibition have implicated striatal 
dopamine transmission as a key mediator in the regulation of LI. 
Infusion of amphetamine into the nucleus accumbens, specifically the 
core sub-region, can disrupt latent inhibition, while the disruptive 
effect of systemic amphetamine administration, as mentioned above, 
is blocked by infusion of the antipsychotic haloperidol into the nucleus 
accumbens (Joseph et al., 2000, Nelson et al., 2011a). In addition, 
lesions of the shell sub-region of the nucleus accumbens, causing 
destruction of dopaminergic neurons, potentiate LI, whilst core 
dopaminergic lesions have no impact upon LI (Nelson et al., 2011b). 
In addition, in vivo measurement of dopamine using voltammetry has 
shown stimulus pre-exposure reduces dopamine within the nucleus 
accumbens shell (Jeanblanc et al., 2002, Murphy et al., 2000). 
Significantly, it is the effect of pre-exposure at conditioning which 
seems to be modulated by dopaminergic mechanisms. Systemic 
amphetamine administered during pre-exposure does not disrupt LI 
(Weiner et al., 1984), but does disrupt LI when administered before 
both pre-exposure and conditioning (Gray et al., 1997, McAllister, 
1997). Consistent with this finding, there is no change in striatal 
dopamine release during pre-exposure, however pre-exposure to the 
conditioned stimulus reduces the release of dopamine in the NAc 




In addition, amphetamine infusions into the dorsal region of the 
striatum can disrupt LI (Ellenbroek et al., 1997), although an earlier 
study did not find any effect of dorsal striatal amphetamine on LI 
(Solomon and Staton, 1982). However, more recent studies have 
suggested a functional dissociation exists within the dorsal striatum 
with respect to the formation of LI. For example, a study using in vivo 
voltammetry by Jeanblanc et al. (2003) revealed reduced dopamine 
release in the non-pre-exposed group compared to the pre-exposed 
group within the anterior dorsal striatum, whereas there were no 
differences in dopamine release in the posterior dorsal striatum. In 
addition, lesions of the dorsolateral striatum disrupt LI (Perez-Diaz et 
al., 2017), and an earlier study by the same authors’ demonstrated 
inactivation of the DLS impairs the retrieval of LI, while inactivation 
of the dorsomedial striatum has no effect on LI (Diaz et al., 2014). In 
addition, suppressing neuronal activity in the ventral subiculum with 
tetrodotoxin (TTX) alters LI related anterior dorsal striatal dopamine 
release (Peterschmitt et al., 2005). Altogether these findings raise 
the possibility that dopamine release in the striatum, which 
modulates LI, could be augmented by hippocampal GABA dysfunction 
and subsequently disrupt LI. 
 
Additional hippocampal projection sites and LI  
The hippocampus is also connected to the medial prefrontal and 
cingulate cortex (Conde et al., 1995, Jay and Witter, 1991), which in 
turn project to regions of the ventral and dorso-medial striatum (Guo 
et al., 2015, Hintiryan et al., 2016, Hunnicutt et al., 2016). Whilst 
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striatal dopamine has received significant attention for its role in LI, 
there is some evidence that prefrontal dopamine plays a modulatory 
role in LI, and ventral hippocampal NMDA stimulation can facilitate 
PFC dopamine transmission (Peleg-Raibstein et al., 2005). For 
example, dopaminergic lesions of the prelimbic cortex enhance LI 
(Nelson et al., 2010); whilst optogenetic activation of prelimbic 
dopaminergic axon terminals increases conditioned responding to a 
familiar CS (Morrens et al., 2020), which suggests prelimbic 
dopamine negatively modulates LI at conditioning. However, 
infusions of dopamine agonists and antagonists into the mPFC have 
been reported to have no impact on LI (Broersen et al., 1996, 
Ellenbroek et al., 1996, Lacroix et al., 2000a). These data suggest 
prefrontal dopamine projections may be involved in LI but this 
appears to be sub-region specific.  
 
In addition to the role of dopamine in LI, studies investigating the 
electrophysiological properties of LI revealed pre-exposure to a CS 
attenuates CS-evoked neural responses in the cingulate cortex (Talk 
et al., 2005). In addition, inactivation of the infralimbic (IL) cortex, 
using the NMDA antagonist DLAP-5 or GABA agonist muscimol, was 
reported to disrupt the formation of LI when administered during PE 
(Lingawi et al., 2017, Lingawi et al., 2018), the authors suggested 
the disruption of LI acquisition is driven by a loss of the encoding of 
a CS-no event association which is stored in the IL. Hippocampal 
stimulation can evoke neuronal responses in the medial prefrontal 
cortex (mPFC) (Degenetais et al., 2003, Liu and Carter, 2018, Thierry 
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et al., 2000) and disrupt attentional processes, which are dependent 
on balanced PFC activity (McGarrity et al., 2017, Tan et al., 2018). 
This raises the possibility that prefrontal control of LI acquisition could 
be disrupted by hippocampal hyperactivity. Similar to the effect of 
prefrontal manipulations, entorhinal cortex inactivation using TTX 
also disrupts LI when administered at pre-exposure (Jeanblanc et al., 
2004, Seillier et al., 2007). Overall, these studies suggest disruption 
of activity in hippocampal projection sites can disrupt the formation 
of LI, and thus hippocampal disinhibition may be expected to 
modulate LI.  
 
Aversive conditioning deficits  
In addition to deficits in attentional allocation seen in schizophrenia 
patients, as reflected by disrupted LI, deficits in the ability to process 
aversive stimuli have also been reported in schizophrenia patients 
(Jensen et al., 2008). Previous findings demonstrate that the ventral 
hippocampus plays an important role in aversive learning and this 
suggests ventral hippocampal disinhibition may disrupt aversive 
conditioning. This then needs to be considered when using aversive 
conditioning procedures to assess LI and the impact of ventral 
hippocampal disinhibition on LI. The ventral hippocampus is involved 
in anxiety and fear-related processes (Bannerman et al., 2004, 
Fanselow and Dong, 2010), with lesion and functional inactivation 
studies having implicated the ventral hippocampus in fear 
conditioning to both contextual and explicit cues (Bast et al., 2001b, 
Maren, 1999, Zhang et al., 2014). Additionally, NMDA stimulation of 
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the ventral hippocampus disrupts contextual and cue conditioning 
(Zhang et al., 2001), whilst blockade of neuronal activity, including 
the activity of fibres of passage, using TTX, also blocks fear 
conditioning to both context and tone (Bast et al., 2001b). However 
functional inhibition of neurons within the hippocampus using 
muscimol only disrupts contextual fear and not cue conditioning (Bast 
et al., 2001b, Zhang et al., 2014). Importantly, dopaminergic 
function in the nucleus accumbens seems to be involved in Pavlovian 
conditioning (Parkinson et al., 1999) and the ventral hippocampus 
has numerous reciprocal connections to the amygdala (Pitkänen et 
al., 2000), which is well known for its role in fear conditioning 
(Fanselow and LeDoux, 1999). These data suggest balanced 
hippocampal activity is necessary for the expression of fear 
conditioning. Therefore, GABA dysfunction, leading to hippocampal 
hyper-activity could disrupt the expression of fear conditioning in an 
aversive LI paradigm, and a similar mechanism may contribute to 
aberrant aversive conditioning seen in schizophrenia patients (Jensen 
et al., 2008). 
 
Aims 
We aimed to examine the effect of ventral hippocampal disinhibition, 
using the GABA-A antagonist picrotoxin (McGarrity et al., 2017) on 
aversive conditioning and LI. To assess these processes, we used a 
conditioned emotional response procedure designed to produce 
robust LI in controls (Nelson et al., 2011a). Considering enhanced 
dopamine during pre-exposure (PE) and conditioning disrupts LI we 
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first investigated whether ventral hippocampal picrotoxin prior to 
both PE and conditioning would disrupt the formation of LI as 
reflected by the diminution of the PE effect (experiment 1). Secondly, 
we examined whether disrupting ventral hippocampal GABA function 
during PE only would disrupt the formation of LI, due to afferent 
connections to regions which control information processing during 
PE (experiment 2).  
 
In experiment 1 we expected that hippocampal picrotoxin would 
reduce LI, which could be driven by several mechanisms. This 
includes the potential of the hippocampus to influence dopamine 
release in the striatum and PFC during conditioning, and the effect of 
aberrant prefrontal cortex activity during PE as mentioned above. 
Given the implication of ventral hippocampal activity in the 
modulation of fear conditioning, we also expected that hippocampal 
picrotoxin would disrupt fear conditioning, although fear conditioning 
may be sufficiently spared to detect LI and any disruption of LI. 
However, hippocampal picrotoxin during conditioning completely 
abolished fear conditioning in both PE and non-pre-exposed rats, so 
we were unable to examine changes in LI. Therefore, in experiment 
2, we focused on the effect that ventral hippocampal disinhibition 
might have on LI at the PE stage. We hypothesised that picrotoxin 
infusion during PE would disrupt LI, possibly by disrupting attentional 







Animals were male Lister hooded rats (Charles River, UK) weighing 
310-400g (9-12 weeks old) at start of experiments. In Experiment 1, 
72 rats were used for latent inhibition and locomotor activity 
experiments. These rats were tested in 3 batches of 24 rats. In 
Experiment 2, 32 rats were used in a single batch for latent inhibition 
testing only. See experimental design for further detail and for a 
sample size justification. 
Rats were housed in groups of 4 in 2 level “double decker” cages 
(462mm x 403mm x 404mm; Techniplast, UK) with temperature and 
humidity control (21 ±1.5 °C, 50% ±8%) and an alternating 12h light 
dark cycle (lights on at 0700). They had ad libitum access to food and 
water (Teklad global 18% protein diet, Harlan, UK). All rats were 
habituated to handling by experimenters for at least 5 days prior to 
any experimental procedure. All experimental procedures were 
conducted during the light phase. All procedures were conducted in 
accordance with the requirements of the United Kingdom (UK) 
Animals (Scientific Procedures) Act 1986.  
 
Stereotaxic implantation of guide cannula into the ventral 
hippocampus 
Rats were anesthetised using isoflurane delivered in oxygen (induced 
with 5% and maintained at 1.5-3%; flow rate 1L/min) and then 
placed in a stereotaxic frame. A local anaesthetic (EMLA cream, 
AstraZeneca, UK) was applied to the ear bars to minimise discomfort. 
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A gel was used (Lubrithal; Dechra, UK) to prevent the eyes drying 
out during surgery. After incision of the scalp, bilateral infusion guide 
cannula (stainless steel, 26 gauge, 8.5mm below pedestal, Plastics 
One, USA) were implanted in small pre-drilled holes in the skull. The 
stereotaxic coordinates for the injection site were 5.2mm posterior, 
±4.8mm lateral from the midline and 6.5mm ventral from the dura 
for infusions into the ventral hippocampus, as in McGarrity et al. 
(2017). Stainless steel stylets, complete with dust cap, were placed 
into the guide cannula, which protruded 0.5mm beyond the tips of 
the guide cannula to prevent occlusion. Dental acrylic (flowable 
composite; Henry Schein, Germany) and four stainless steel screws 
were used to fix guide cannulae to the skull. The scalp incision was 
stitched around the acrylic pedestal to reduce the open wound to a 
minimum. All rats were injected with perioperative analgesia 
(Rimadyl, Large Animal Solution; 1:9 dilution; 0.1ml/100g s.c). After 
surgery rats were injected with 1ml of saline (i.p) to prevent 
dehydration. Antibiotics were administered on the day of surgery and 
subsequently every 24h for the duration of the study (Synolux; 
140mg amoxicillin, 35mg clavulanic acid/ml; 0.02ml/100g s.c, 
Pfizer). After surgery, rats were allowed at least 5 days of recovery 
before any further experimental procedures were carried out. During 
this period rats underwent daily health checks and were habituated 






Intracerebral microinfusion procedure    
Rats were manually restrained throughout the infusion process. 
Stylets were replaced with infusion injectors (stainless steel, 33-
gauge, Plastics One, USA), which extended 0.5mm below the guide 
cannula tips into the ventral hippocampus. Injectors were connected 
via flexible polyethylene tubing to 5-µl SGE micro-syringes mounted 
on a microinfusion pump (sp200IZ, World Precision Instruments). A 
volume of 0.5µl/side of either 0.9% sterile saline (control) or 
picrotoxin (C30H34013; Sigma Aldrich, UK) in saline (150ng/µl/side) 
was infused bilaterally over the course of 1 min, as used in previous 
studies (McGarrity et al., 2017). The movement of an air bubble, 
which was included in the tubing, was monitored to ensure the 
solution had been successfully injected into the brain. Injectors were 
removed and replaced by stylets 60s after the end of infusion to allow 
for tissue absorption of the infusion bolus. Picrotoxin solutions were 
prepared on the day from frozen aliquots containing 150ng/0.5µl.   
Picrotoxin, which acts as a GABA-A antagonist, has the potential to 
cause epileptiform activity in the hippocampus (Qaddoumi et al., 
2014). Therefore, all rats receiving infusions were monitored carefully 
for behavioural signs potentially related to seizure development 
during and after infusion; development of any of these signs was 
recorded. These signs include: facial twitching, wet-dog shakes, 
clonic limb movement, motor convulsions and wild jumping 
(Luttjohann et al., 2009, Racine, 1972). During previous work the 
dose of picrotoxin (150ng/0.5µl/side) used did not cause the onset of 
seizure-related behavioural signs and did not cause 
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electrophysiological signs of hippocampal seizures in anaesthetised 
recording studies (McGarrity et al., 2017).  
 
Verification of cannula placements 
After behavioural experiments rats were overdosed with sodium 
pentobarbital (Dolethal, Vetoquinol, UK) and were transcardially 
perfused with 0.9% saline followed by 4% paraformaldehyde (PFA) 
in saline. Subsequently brains were removed and stored in 4% PFA. 
Brains were sliced at 80µm thickness using a vibratome and placed 
on microscope slides, placements of infusion injectors were identified 
using light microscopy. Injector placements were mapped onto 
coronal sections of a rat brain atlas (Paxinos and Watson, 2006). 
 
Conditioned emotional response procedure with a pre-exposure 
phase to measure aversive conditioning and its latent inhibition 
The conditioned emotional response (CER) procedure used follows the 
task previously described by Nelson et al. (2011a). The basic 
procedure requires rats to be trained to robustly drink from a 
waterspout, which are subsequently either pre-exposed (PE) or non-
pre-exposed (NPE) to a conditioned stimulus (CS). Rats are 
conditioned to the CS and then the degree of conditioning to the CS 
is assessed. A reduction in conditioned suppression in the PE but not 







Six identical fully automatic conditioning chambers comprised of 
sound attenuating cases and ventilation fans (Cambridge Cognition, 
UK) were used. The inner chambers consist of a plain steel box (25 x 
25 x 22cm) with a Plexiglas door (27 x 21cm). The floor of the inner 
conditioning chamber comprises of a shock delivery system, 
consisting of 1cm spaced steel bars. These are positioned 1cm above 
the lip of a 7cm deep sawdust tray. Mounted 5cm above the grid floor 
is a waterspout connected to a lickometer supplied by a water pump. 
Licks were registered by breaking a photo beam within the spout 
which triggered water delivery of 0.05ml per lick. The spout was only 
illuminated when water was available. Three wall mounted lights and 
the house light flashing on (0.5s) and off (0.5s) for 5 s functioned as 
the conditioned stimulus (CS). Scrambled foot-shock of 1mA intensity 
for 1s provided the unconditioned stimulus. The shock was delivered 
through the grid floor by a constant current shock generator (pulsed 
voltage: output square wave 10ms on, 80 ms off, 370 V peak under 
no load conditions; MISAC Systems, UK). Stimulus control and data 
collection were recorded using an Acorn RISC computer programmed 
in basic with Arachnid extension (Cambridge Cognition, UK).  
 
Behavioural procedure  
One day prior to behavioural testing rats were water restricted for 
between 18-22h. Subsequently, they received 1 h and 15 min of ad 
libitum access to water in their home cages for the duration of the 
experiment once daily testing was completed and in addition to the 
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access to water in the experimental chambers. The conditioned 
emotional response procedure consisted of several stages (Fig. 1), 
which are detailed below.  
 
Pre-training  
Rats were shaped for 1 day until all rats drank from the waterspout 
and were assigned an individual experimental chamber for the 
duration of the procedure. Subsequently, rats were given a 15-min 
session (timed from first lick) per day for 5 days to drink from the 
waterspout. During the sessions, the waterspout was illuminated 
throughout but no other stimuli were present. Total number of licks 
was recorded during each session to assess any pre-existing 
differences in drinking prior to infusions.  
 
Pre-exposure  
The pre-exposed (PE) animals received 30 5s flashing light CS 
presentations with an average inter-stimulus interval of 60s. The non-
pre-exposed (NPE) control animals were confined to the experimental 
chamber for an identical period of time (32mins) without receiving 
any CS presentations. Water was not available during the session and 
the waterspout was not illuminated. 
 
Conditioning 
One day after pre-exposure, rats were conditioned by two light-foot 
shock pairs, with the foot shock (1 mA/1s) delivered immediately 
following the termination of the flashing light (5s). 
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The first CS-UCS was presented after 5mins had elapsed and the 
second pairing 5-minutes after the first, followed by a further 5min in 
the chamber. Water was not available during the session and the 
waterspout was not illuminated for the duration of the session. 
 
Reshaping  
The day after conditioning, rats were reshaped using the same 
procedure as used during pre-training. This was to re-establish 
drinking behaviour after the conditioning session. Latency to first lick 
during reshaping was used as a measure of contextual fear 
conditioning to the conditioning chamber (Nelson et al., 2011a, 
Nelson et al., 2013). 
 
Test 
The day after re-shaping, rats underwent a test session to assess 
conditioning to the CS. During the session water was available 
throughout and the waterspout was illuminated. Once the rats had 
performed 50 licks the CS was presented continuously for 15 minutes. 
The time taken to complete 50 licks before CS presentation (excluding 
latency to first lick) provides a measure of individual baseline 
variation (A period). This time was compared to the time taken to 
complete 50 licks after CS presentation (B period). A suppression 
ratio (A / (A+B)) was used to assess the overall level of conditioning 





Experimental design and data analysis  
Both experiments 1 and 2 were run in a between subjects design with 
a target sample size for both experiments of 16-18 per group. This 
would give us a power of > 80% to detect effect sizes of d=1 for 
differences between groups (using between-subjects pairwise 
comparisons, two-tailed, with a significance threshold of p<0.05), 
which has been suggested to be appropriate for neurobiological 
studies of aversive conditioning (Carneiro et al., 2018). Experiment 1 
was run in 3 identical series of 24 rats per series. Experiment 2 was 
planned as a sequential design, consisting of 2 identical series of 
experiments, each containing 32 rats. Experiment 2 was ended after 
the first series due to futility, as there was clearly no evidence that 
the target effect size the study was powered for could be achieved 
(Neumann et al., 2017).  
 
Two of the four rats in each cage were randomly assigned to the 
saline and the other two to the picrotoxin infusion group, and 
subsequently one rat of each pair was randomly assigned to either 
pre-exposed or non-pre-exposed conditions. The experimenters were 
blinded with respect to the group allocation at the start of the 
experiment. In both experiments, several rats had to be excluded 
from the analysis of the whole experiment or some later stages of the 
experiment. During Experiment 1, 13 rats fell ill, with presumed 
meningitis, before testing, two further rats sustained blocked guide 
cannulae resulting in exclusion from the experiment, and one rat 
showed adverse effects, extended convulsive seizures, after 
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picrotoxin infusion. During Experiment 2, one rat died during surgery 
and a further three rats fell ill, with presumed meningitis, before 
testing. The final sample sizes contributing to the analysis of 
performance measures at the different test stages in Experiment 1 
and 2 are shown in Table 1.  
 
For Experiment 1 drug infusions took place before both pre-exposure 
and conditioning sessions, whereas during experiment 2 drug 
infusions took place before pre-exposure only (Fig. 1). Rats were 
infused in batches of two pairs, by two experimenters, with each pair 
including one rat to receive saline and one rat to receive picrotoxin 
infusions. The two experimenters infused one pair, then the second 
pair, and testing started 10 min after the infusions for both rats of 
the second pair had been completed. This meant all rats had at least 
a 10 min period between the end of the infusion and the start of 
testing, but for the rats from the first pair (and often also one rat of 
the second pair) the period was slightly longer, by the time it took to 
complete the infusion of the second pair (typically about 2 min).    
 
 Experiment 1 Experiment 2 
Group Reshaping Test Reshaping Test 
Saline NPE 14 14 7 7 
Saline PE 13 10 8 8 
PTX NPE 15 15 6 6 
PTX PE 17 17 7 7 
Table 1. Final number of animals included for data analysis per group for each 





Statistical analysis was performed using a 2x2 analysis of variance 
(ANOVA) with between subject factors of pre-exposure group 
(NPE/PE) and drug infusion (Saline/Picrotoxin). All statistical tests 
and graphs were completed using SPSS (version 23, IBM Corp, USA), 
JASP (JASP Team: version 0.12.2, 2020) and GraphPad prism 
(version 8, GraphPad software, USA). The accepted level of 
significance was p < 0.05. Raw latency data (time to first lick during 
reshaping) or time ‘A’ data (time to 50 licks during test) were log 
transformed, as they showed unequal variance (Levene’s test, all F > 
5, p<0.002), to ensure a normal distribution and suitability for 
parametric analysis (Nelson et al., 2011; Nelson et al., 2012).   
 
Locomotor activity testing  
Locomotor activity was measured as in a previous study from the 
group (McGarrity et al., 2017), using 12 clear Perspex chambers 
(39.5 cm long × 23.5 cm wide × 24.5 cm deep) with metal grid lids 
Figure 1. Task design for latent inhibition experiments. In Experiment 1, 
hippocampal infusions took place before both pre-exposure and conditioning. In 




placed in a dimly lit (45-65 lux) chamber. The chambers were placed 
in frames containing 2 levels of a 4 × 8 photo beam configuration 
(Photobeam Activity System; San Diego Instruments, USA). All 
photocells were connected to a PC running the PAS software (version 
2), two consecutive breaks of adjacent beams within the lower level 
of photo beams generated a locomotor count. To start a session, rats 
were placed into the centre of the chambers. Total locomotor counts 
were calculated for each 10 minute block of testing. 
 
Baseline locomotor activity was assessed for 30 minutes without 
infusion to identify any differences between groups prior to infusion. 
The following day rats were placed in the boxes for 30 minutes to 
habituate, after this period rats were infused with either saline or 
picrotoxin and placed in the boxes for a further 60 minutes to 
measure any effects of drug treatment. We expected picrotoxin 
infusion into the ventral hippocampus to induce hyper locomotion 
(McGarrity et al., 2017), therefore a pre-infusion habituation period 
would allow any differences in locomotor activity caused by drug 
micro-infusions to not be occluded by high baseline activity.  
 
Locomotor activity testing was conducted after the CER paradigm in 
experiment 1, as a positive control and for comparison with previous 
studies. Ventral hippocampal disinhibition has been previously shown 
to induce robust locomotor hyper-activity (Bast et al., 2001a, 
McGarrity et al., 2017) and therefore hyper-activity would reflect a 
behavioural impact of picrotoxin infusion. Rats were infused in pairs 
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simultaneously, and post-infusion testing began immediately after 
completion of the infusion. Rats were allocated to the same drug 
condition during LMA testing as they were during the previous 
infusions during the LI paradigm. Locomotor activity was measured 
in 1-min intervals and calculated in 10-minute bins pre and post 
infusion. Locomotor activity data was analysed using repeated 
measures ANOVA, with drug treatment as the between subject’s 
factor and 10-min bins as the within subject’s factor. Data was 



















Verification of infusion cannula placements 
Cannula tips were mapped onto coronal sections adapted from the 
Paxinos and Watson (2006) rat brain atlas. All cannula tips were 
located between 4.8 and 6.3mm posterior to bregma within the 










Experiment 1: Effect of ventral hippocampal picrotoxin 
infusion at pre-exposure and conditioning stages of the CER   
Pre-training 
Analysis of latencies to lick at the end of pre-training, prior to pre-
exposure, showed no overall effect of infusion group (F < 1) or of 
Figure 2. Approximate locations of infusion cannula tips (black dots) as verified 
by light microscopy of coronal brain slices (80µm) for rats in experiment 1 (A) 
and 2 (B). Placements are mapped onto coronal sections adapted from Paxinos 
and Watson rat brain atlas, number on the right indicate level relative to bregma. 
C: Illustrative coronal brain section showing placement of infusion cannula as 
seen by light microscopy.  
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conditioning group to be (F < 1) and there were no interactions of 
these factors (F < 1) (data not shown).  
 
Reshaping 
Ventral hippocampal picrotoxin, compared to saline, infusion reduced 
latency to first lick after reintroduction to the conditioning context 
during the reshaping session in the NPE group, which reflects reduced 
contextual fear conditioning; in the PE group, both saline and 
picrotoxin groups showed similarly low levels of contextual 
conditioning, as measured by low latencies to lick and reflecting that 
PE reduced contextual conditioning in the saline group (Fig. 3A). 
These observations were supported by a significant infusion x pre-
exposure interaction: F (1, 55) =4.736, p=0.034, effect size: 0.051 
omega2 (ω2). Hippocampal picrotoxin reduced conditioning in the NPE 
group (F (1, 55) =11.878, p=0.001), but this was not apparent in the 
PE group due to a floor effect where there is a low baseline of 
conditioning (F (1, 55) =0.154, p=0.697). In addition, pre-exposure to 
the CS reduced conditioning in saline infused rats, this is reflected by 
a significant reduction in latency in the PE group as compared to the 
NPE group (F =9.006, p=0.004), this effect was not present in 
picrotoxin infused animals (F (1, 55) =0.003, p=0.956), probably 
reflecting a floor effect, i.e. the already low latencies in the PE group.  
 
Light Test 
There was no difference in time to 50 licks (Time A) between infusion 
group and pre-exposure groups (Effect of infusion, pre-exposure and 
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interaction: All F <3, p>0.09 (data not shown). The group difference 
in latency to first lick that were evident at reshaping were not present 
during the test stage, probably reflecting extinguished contextual 
conditioning in the saline NPE group. The suppression ratios during 
the light test revealed that hippocampal disinhibition markedly 
disrupted conditioning to the light CS in the NPE group, but did not 
affect conditioning in the PE group, i.e. there was no evidence that 
hippocampal disinhibition would have affected salience modulation 
(Fig. 3B). In saline-infused rats, the suppression ratio was markedly 
increased in the PE compared to the NPE group, reflecting reduced 
conditioning, i.e. LI (Fig. 3B, left). This difference between PE and 
NPE groups was not apparent in the picrotoxin-infused rats (Fig. 3B, 
right). However, this was due to picrotoxin-infused NPE rats showing 
a markedly higher suppression ratio than saline-infused NPE rats, i.e. 
reduced conditioning to the light CS (compare white bars in Fig. 3B). 
In contrast, suppression ratios were similar in picrotoxin and saline-
infused PE rats (compare grey bars in Fig. 3B), not supporting that 
hippocampal disinhibition reduces the impact of CS pre-exposure on 
conditioning. These observations were supported by a significant 
infusion x pre-exposure interaction (F (1, 52) =4.142, p=0.047, effect 
size: 0.043 ω2). Further examination of the interaction by simple 
main effects analysis revealed a main effect of infusion in the NPE 
group (F (1, 52) =10.014, p=0.003) reflecting increased suppression, 
i.e. reduced conditioning, caused by picrotoxin, compared to saline, 
whereas there was no effect of infusion in the PE group (F (1, 52) 
=0.028, p=0.867).  
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This resulted in the absence of a difference between PE and NPE in 
the picrotoxin infused rats (F (1, 52) =0.878, p=0.353), i.e. no LI, 
whereas saline infused rats showed markedly higher suppression in 
the PE compared to the NPE group (F (1, 52) =12.111, p=0.001).  
 
Experiment 2 – Effect of ventral hippocampal picrotoxin 
infusions at pre-exposure 
Pre-training 
Analysis of latencies to lick at the end of pre-training, prior to pre-
exposure, showed no overall effect of infusion group (F (1,24) =2.851, 
Figure 3. A: Mean (± SEM) latency to first lick values (s) (log transformed) in 
the conditioning chamber following the aversive conditioning session for non-pre-
exposed (NPE: white bars) and pre-exposed (PE: grey bars) groups after saline 
or picrotoxin micro-infusions. Saline NPE animals show longer latencies 
compared to all other groups. B: Mean suppression ratio (±SEM) to the light 
conditioned stimulus for control (NPE: white) and PE (grey) groups that had 
previously had saline or picrotoxin infusions at pre-exposure and conditioning. 
Pre-exposure reduced fear responding to the CS in saline infused animals, 






p=0.104) or of conditioning group to be (F < 1) and there were no 
interactions of these factors (F < 1) (data not shown).  
 
Reshaping 
Hippocampal picrotoxin infusion only at pre-exposure had no effect 
on conditioning to the context, as reflected by latencies to first lick 
during reshaping, and there was no difference between conditioning 
groups (Fig. 4A). The latter contrasts with the finding in Experiment 
1, that pre-exposure reduced latencies to first lick in saline infused 
rats (Fig. 3A). Analysis of latency to first lick after reintroduction to 
the conditioning context revealed no effect of conditioning group (F 
(1, 24) =0.17, p=0.68), infusion (F (1, 24) =1.71, p=0.20) or interaction 
of these factors (F (1, 24) =1.46, p=0.24) (Fig. 4A).  
 
Light test 
There were no differences in the A period (time to 50 licks in the 
absence of light CS) between groups (F (1, 24) =0.01, p=0.91) or 
infusion condition (F (1, 24) =1.12, p=0.30) (data not shown). This 
indicates there was no difference between groups prior to the 
suppression test.  
Figure 4B shows an effect of pre exposure in both drug infusion 
conditions, where pre-exposed groups have greater suppression 
ratios, therefore LI is present in both infusion groups. This is 
supported by ANOVA which shows an effect of conditioning group (F 
(1, 24) =8.44, p=0.0078, effect size: 0.221ω2), but not of infusion (F (1, 
59 
 
24) =0.13, p=0.72) and no interaction of these factors (F (1, 24) =0.15, 
p=0.70).  
 
Hippocampal picrotoxin infusion induces locomotor hyper-
activity  
There was no difference between the locomotor activity in saline and 
picrotoxin groups during the first 30 min of testing prior to drug 
microinfusion (effect and interaction involving infusion: both F < 1.5, 
p > 0.24) only a significant reduction of locomotor activity over the 
three 10-min bins (main effect of 10-min bins: F (2, 106) =189.9, p< 
0.0001), reflecting habituation to the activity boxes in both groups 
(Fig. 5, left). Consistent with previous findings (Bast et al., 2001a, 
Figure 4. A: Mean (± SEM) latency to first lick values (s) (log transformed) in the 
conditioning chamber following the aversive conditioning session for non-pre-exposed 
(NPE: white bars) and pre-exposed (PE: grey bars) groups after saline or picrotoxin 
micro-infusion at pre-exposure. All groups show similar levels of contextual 
conditioning, indicated by similar latency to first lick. B: Mean suppression ratio (±SEM) 
to the light conditioned stimulus for control (NPE: white) and PE (grey) groups that had 
previously had saline or picrotoxin infusions at pre-exposure only. Pre-exposure reduced 
fear responding to the CS in both saline and picrotoxin infused animals, indicated by 





McGarrity et al., 2017), picrotoxin infusions into the ventral 
hippocampus markedly increased locomotor activity, especially 
during the first 20 minutes of the 60-min testing period post infusion 
(Fig. 5, right). This increase was reflected by a significant 10-min bin 
x infusion interaction (F (5, 265) =17.61, p< 0.0001).   
 
Potential seizure-related behavioural effects of hippocampal 
picrotoxin 
Although the dose of picrotoxin used did not show signs of seizure 
activity either behaviourally or using electrophysiology in previous 
work (McGarrity et al., 2017), in the present study we observed 
seizure-related behavioural effects in several rats following 
hippocampal picrotoxin infusion. In several rats receiving 
hippocampal picrotoxin infusions in Experiment 1 (23 out of 33 rats 
receiving picrotoxin) and 2 (6 out of 15 rats receiving picrotoxin) we 
observed seizure-related behavioural signs, including facial twitching, 
Figure 5. Hippocampal picrotoxin infusion causes increased locomotor activity. 
No change is observed in the 30min period prior to infusion in locomotor activity 
as represented by photo-beam breaks (±SEM). Ventral hippocampal picrotoxin 




wet-dog shakes and wild running, which can often be observed before 
full motor seizures (Luttjohann et al., 2009, Racine, 1972). These 
signs were only observed after infusions of picrotoxin and not after 
saline infusions and are detailed in table 2. Symptoms were observed 
within 5 min after the end of the picrotoxin infusion. Seizure-related 
behavioural signs were short-lived (30-45mins) and following these 
signs rats typically showed no persistent adverse effects of infusion, 
with the exception of one rat which showed long lasting seizure like 
behaviour and was culled. 
 
The ventral hippocampus and subiculum show the earliest seizure 
activity in spontaneous model of seizures (Toyoda et al., 2013) and 
GABA network dysfunction of the limbic system is strongly implicated 
in the onset of seizures (Avoli and de Curtis, 2011). These behavioural 
changes initially provide good evidence that the hippocampal 
picrotoxin infusions have effectively disrupted GABA transmission and 
Observed 
behaviour 
First infusion Second infusion Third infusion 
Facial 
twitching 
1 2 3 
Wet dog 
shakes 
17 8 7 
Wild running 9 3 5 
Clonic limb 
movement 
3 0 1 
Table 2. Seizure-related behavioural signs observed after ventral hippocampal 
picrotoxin micro-infusions. Type of behaviour observed, and number of rats 
showing this sign is indicated. Number of incidences per infusion collated from 
both experiments 1 and 2 is shown.  
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suggest the local network has been disrupted. Interestingly 
population studies show epileptic patients have a higher risk of 
psychosis related illness than in the general population (Clancy et al., 
2014, Clarke et al., 2012) suggesting a possible shared aetiology 























In Experiment 1, ventral hippocampal picrotoxin infusion at pre-
exposure and conditioning abolished fear conditioning to the light CS 
and, therefore, the reduction of fear conditioning in the PE compared 
to NPE group, which would reflect LI, could not be detected. Picrotoxin 
and saline infused rats in the PE group did not differ, showing similarly 
low conditioning, which does not support that hippocampal 
disinhibition affected salience modulation. In addition to disrupting 
conditioning to the light CS, ventral hippocampal infusion of 
picrotoxin also impaired contextual conditioning as reflected by 
reduced conditioning (lower latency to first lick) after reintroduction 
to the conditioning context. In Experiment 2, which specifically 
examined the impact of hippocampal disinhibition at the pre-exposure 
stage (and avoiding the disruption of aversive conditioning), there 
was no evidence for any impact on LI, with a pronounced CS pre-
exposure effect present in both picrotoxin and saline infusion groups.  
 
Robust LI in the CER paradigm 
Using a between-subjects, off-baseline, CER procedure (Nelson et al., 
2011a), we demonstrated robust LI Lister hooded rats. The procedure 
was designed to support LI in vehicle control rats, whilst allowing for 
identification of suppressed LI. We observed robust LI in saline 
control rats in Experiment 1 and in both infusion groups in Experiment 
2, reflected by a significant increase in suppression of licking 
behaviour in the NPE group as compared to the PE group. The reduced 
suppression after pre-exposure to the conditioned stimuli indicates 
64 
 
an intact LI effect, where these rats have not associated the 
previously inconsequential flashing lights with the aversive foot-shock 
applied to them in a subsequent conditioning session. This effect is in 
line with previous experiments using the same procedure in Wistar 
rats (Cassaday and Thur, 2020, Nelson et al., 2012, Nelson et al., 
2011a).  
 
PE-induced enhancement of contextual fear conditioning 
Intriguingly there is a significant difference in latency to lick during 
reshaping between conditioning groups in the saline infused group in 
Experiment 1. The NPE rats have a significantly longer latency to lick 
compared to PE rats and therefore are more conditioned to the 
context compared to the PE group. The enhanced conditioning in the 
NPE group is somewhat unexpected. It may have been anticipated 
that rats that had not been pre-exposed to the CS would have paid 
less attention to the context, because this may have been 
overshadowed by the more salient CS (Odling-Smee, 1978). More 
specifically, due to the novelty of the flashing light stimulus during 
pre-exposure, rats may have been expected to pay increased 
attention to the highly salient light stimuli and consequently less 
attention to the general context. However, in this case, the opposite 
effect has occurred, whereby NPE rats were generally more fearful of 
the context. Such enhancement of contextual conditioning by pre-
exposure to the light stimulus may reflect increased arousal due to 
the novelty of the light stimulus, which could lead to novelty 
enhanced memory formation (King and Williams, 2009). The added 
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novelty of the light CS in the NPE group during conditioning could also 
enhance hippocampal memory formation. Novelty induces dopamine 
release in the hippocampus (Moreno-Castilla et al., 2017), which 
contributes to memory encoding (Pezze and Bast, 2012), 
subsequently resulting in stronger context representation memory 
(Duszkiewicz et al., 2019, Lisman and Grace, 2005). Therefore, a 
novelty induced increase in arousal could lead to amplified association 
of the context during aversive conditioning and therefore an increase 
in contextual fear conditioning. However, the difference between NPE 
and PE groups in saline infused rats which was seen in Experiment 1 
was not present in Experiment 2. This discrepancy could be explained, 
at least in part, by a ceiling effect in conditioning which masks any 
differences between NPE and PE group in Experiment 2. The level of 
contextual conditioning in Experiment 1 is substantially lower than 
during Experiment 2, which could be due to behavioural effects of the 
microinfusion procedure itself. More specifically, in contrast to 
Experiment 1, the rats in Experiment 2 were not subjected to drug 
infusions just before conditioning, which may have resulted in 
stronger conditioning and, thereby, may have prevented the 
detection of any PE-induced enhancement of contextual fear 
conditioning.  In line with this explanation, previous studies reported 
a tendency for un-operated rats to show stronger fear conditioning 
than cannulated rats that received control infusions (see discussion 
in: (Zhang et al., 2001). 
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Ventral hippocampal disinhibition during PE and conditioning 
abolishes fear conditioning in the CER paradigm, but no evidence for 
an impact on salience modulation in the PE group 
In Experiment 1, ventral hippocampal picrotoxin infused at both pre-
exposure and conditioning eradicated fear conditioning to the light CS 
in the NPE group, resulting in similar levels of conditioning in both 
NPE and PE groups. Whilst disinhibition within the ventral 
hippocampus resulted in similar levels of conditioned suppression 
between NPE and PE groups, the effect is not mediated by the PE 
group and therefore is not due to aberrant salience allocation. 
Instead, the reduction in lick suppression in the NPE group indicates 
reduced conditioning to the CS (see discussion below). Similar to the 
present study, Pouzet et al. (2004), using a similar LI paradigm, 
demonstrated ventral hippocampal NMDA infusions reduced 
conditioned suppression in the NPE group, although there was also 
some evidence for disrupted LI with a trend towards greater 
conditioned suppression in PE compared to NPE rats. Overall, the 
results from Experiment 1 suggest the reduction of conditioned 
suppression in the NPE group reflects reduced associative learning of 
the CS-US pairing, which subsequently masks the expression of LI.  
In addition to reduced conditioning to the light CS, hippocampal 
picrotoxin infusion in Experiment 1 also reduced behavioural 
suppression, as reflected by reduced latencies to lick, when rats were 
re-exposed to the conditioning context during the reshaping session. 
The readiness to lick in the picrotoxin group suggests these rats were 
less fearful of the conditioning chamber context after aversive 
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conditioning and therefore, that ventral hippocampal picrotoxin 
infusions reduced conditioning to the context. 
 
Disruption of elemental and contextual fear conditioning by ventral 
hippocampal disinhibition might reflect disruption of regional and 
distal processing 
These results are consistent with the role of the ventral hippocampus 
in both conditioning to context and explicit auditory or visual cues. 
Lesions, inactivation (via sodium channel blockers), functional 
inhibition and stimulation of the ventral hippocampus have been 
found to disrupt both contextual and cue conditioning (Bast et al., 
2001b, Maren, 1999, Kjelstrup et al., 2002, Zhang et al., 2001). 
However, manipulation of inhibitory neurons using the GABA-A 
agonist muscimol only disrupts contextual but not cue conditioning 
(Bast et al., 2001b, Maren and Holt, 2004, Zhang et al., 2014), 
whereas antagonism of hippocampal GABA-A receptors in this study 
disrupted conditioning to both cue and context. The difference in 
effects caused by opposing GABA manipulations could be due to the 
local and distal effects of these manipulations. Using measurements 
of cerebral blood flow to examine brain wide activation changes 
caused by ventral hippocampal disinhibition, we identified prominent 
changes in neural activity in regions implicated in fear conditioning, 
including the dorsal hippocampus, septum, hypothalamus and 
extended amygdala (see chapter 3). Furthermore, reduced ventral 
hippocampal GABA transmission could disrupt intra-hippocampal 
connections across the longitudinal dorso-ventral axis (Sik et al., 
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1994, Sik et al., 1997), which could impair dorsal hippocampus 
information processing. Correct functioning of the dorsal 
hippocampus is necessary for the acquisition and expression of 
contextual conditioning (Matus-Amat et al., 2004), and it has been 
suggested that the dorsal hippocampus produces a contextual 
representation, which subserves contextual conditioning (Hunsaker 
and Kesner, 2008). In addition, ventral hippocampal disinhibition 
disrupts one trial place learning in the delayed-matching-to-place 
watermaze (McGarrity et al., 2017) and, therefore, disruption of 
contextual conditioning could be driven by impaired spatial memory, 
whereby visual cues are not processed, and a representation of the 
context is not established.  
 
In addition to disruptions of hippocampal mechanisms of contextual 
fear, deficits in conditioning could be caused by disruptions in 
information processing in distal extra-hippocampal sites. Pavlovian 
fear conditioning is controlled by a circuit including the ventral 
hippocampus, amygdala and mPFC (Tovote et al., 2015). The ventral 
hippocampus has strong reciprocal projections to the basal amygdala 
(Petrovich et al., 2001, Pitkänen et al., 2000) and weaker projections 
to the central amygdala (Cenquizca and Swanson, 2007, Kishi et al., 
2006), while also sending projections to the medial prefrontal cortex 
(Hoover and Vertes, 2007). The amygdala plays a central role in both 
the acquisition and expression of contextual and cue conditioned fear 
(LeDoux, 2000, Maren, 2001). Amygdala dependent fear expression 
can also be modulated by the prelimbic cortex, as well as by ventral 
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hippocampus inputs (Sierra-Mercado et al., 2011). The ventral 
hippocampus can modulate the input of information into the 
amygdala directly or via the mPFC. Projections from prelimbic cortex 
innervate the basal amygdala (Vertes, 2004) and lesions of the 
prelimbic cortex reduce fear expression (Corcoran and Quirk, 2007), 
while input from prelimbic cortex and ventral hippocampus to the 
basal amygdala have been shown to mediate contextual fear 
extinction (Orsini et al., 2011). Additionally, double projecting 
neurons to the amygdala and mPFC from the ventral hippocampus 
are activated during encoding and retrieval of context fear (Kim and 
Cho, 2017). Therefore, it is possible GABA dysfunction of the ventral 
hippocampus causes excitation of projections to the amygdala and 
mPFC which subsequently disrupts processing of cue and contextual 
information leading to disrupted fear conditioning in the CER 
paradigm.  
 
Disrupted fear conditioning could also be driven by ventral 
hippocampal connectivity to other efferent brain regions. The lateral 
septum, a key output structure of the ventral hippocampus (Risold 
and Swanson, 1997) has long been implicated in anxiety and related 
behaviours (Sheehan et al., 2004). The septum receives strong 
connections from the hippocampus and is connected to the amygdala, 
mesolimbic dopamine system and hypothalamus (Deller et al., 1994, 
Risold and Swanson, 1997, Swanson and Cowan, 1979). The septum 
is therefore a potential modulator of hippocampal fear conditioning 
effects and glutamatergic transmission between the hippocampus 
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and septum has been shown to be important for the expression of 
cue and contextual conditioning (Calandreau et al., 2010, Vouimba et 
al., 1998). Therefore, aberrant septal activity caused by disinhibited 
ventral hippocampal firing could disrupt information processing in the 
septum and disrupt fear conditioning.  
 
Whilst ventral hippocampal picrotoxin infusions disrupt the acquisition 
of cue and contextual fear conditioning, one factor that needs to be 
taken into account is state dependent learning i.e. information 
learned in one neural state can, in some cases, only be retrieved in 
the same state (Overton, 1964). In our case ventral hippocampal 
infusions take place during pre-exposure and conditioning but not 
during reshaping and test, thus the ventral hippocampus is in a 
different state during the expression of contextual and cue 
conditioning. To confirm the disruption of fear conditioning was not 
due to state dependence, animals would need to receive picrotoxin 
infusions before the test session and subsequently continue to show 
reduced conditioned fear as demonstrated with pre-conditioning 
infusions. However, pre-expression inactivation of the ventral 
hippocampus during a classical Pavlovian paradigm disrupts the 
expression of conditioned fear (Sierra-Mercado et al., 2011). 
Therefore, perturbation of ventral hippocampal activity during test 
may disrupt conditioned fear independent of state dependence, which 
would make assessing any state dependent effects of fear expression 
problematic. However, several studies have shown that state 
dependent learning does not account for the conditioning deficits of 
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specific local microinfusions, these include infusions of dopamine 
agonists or antagonists in the PFC (Pezze et al., 2003) and amygdala 
(Guarraci et al., 2000), and dorsal hippocampal infusion of NMDA 
(Bast et al., 2003). In addition, previous experiments using a similar 
3 stage fear conditioning paradigm designed to elucidate drug effects 
on LI found no evidence for state-dependent effects (Barad et al., 
2004). Altogether the reduced conditioned suppression driven by 
hippocampal picrotoxin infusions prior to conditioning seem to reflect 
actual deficits in associative processes that underlie the formation of 
fear memory.  
 
Hippocampal disinhibition during PE has no effect on the formation of 
LI 
Whilst conditioning is thought to be the critical stage of the effect of 
dopamine in LI (Morrens et al., 2020, Young et al., 2005), disruption 
of the acquisition of LI due to other neural mechanisms have been 
described (Hitchcock et al., 1997, Lacroix et al., 2000b). This includes 
disrupted LI due to aberrant activity in the mPFC, a prominent 
hippocampal projection site, during the pre-exposure stage (Lingawi 
et al., 2017, Lingawi et al., 2018). Intra-hippocampal infusion of 
picrotoxin at the pre-exposure stage of the CER paradigm had no 
observable effect on LI at test. Therefore, decreased GABA 
transmission in the ventral hippocampus during PE had no effect on 
the acquisition of LI, not supporting that this manipulation disrupts 




It has been hypothesised (Maren and Holt, 2000) that the 
hippocampus is involved in the CS-no event association which is then 
subsequently stored at a distal site. Our data suggest that GABA 
dysfunction in the ventral hippocampus does not disrupt the 
formation of a CS-no event association as LI is spared which reflects 
the recollection of such an association. Whilst the formation of LI 
appears to be dependent on balanced neural activity in the infralimbic 
cortex (Lingawi et al., 2017, Lingawi et al., 2018), and the ventral 
hippocampus can modulate PFC activity (Degenetais et al., 2003), 
ventral hippocampal disinhibition during pre-exposure did not affect 
LI formation. This suggests any changes in neural activity in the 
mPFC, driven by ventral hippocampal disinhibition (see chapter 3), 
are not sufficient to disrupt the formation LI. This could be explained 
by the relationship between neural activity and behavioural function 
which can have distinct characteristics (Bast et al., 2017). The 
disruption of a CS-no event association memory in the infralimbic 
cortex reported in the aforementioned studies is driven by reduced 
neural activity and this may reflect a monotonic relationship whereby 
reduced activity disrupts LI but increased activity has no effect on 
behaviour. 
 
Whereas the present experiments did not provide evidence that 
ventral hippocampal disinhibition during pre-exposure affects LI, 
previous experiments have shown that activity within the ventral 
subiculum plays a role in the formation of LI. Specifically, deactivation 
of the ventral subiculum deactivation using TTX during pre-exposure 
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disrupts LI as reflected by reduced conditioning in the PE group using 
a conditioned taste aversion (CTA) paradigm (Peterschmitt et al., 
2005, Peterschmitt et al., 2008). This data implies the ventral 
hippocampal formation is important in encoding the information 
related to the CS–no event association. Considering the results of our 
study showing that ventral hippocampal disinhibition during PE does 
not affect the formation of LI, whilst LI is disrupted by inactivation of 
the hippocampus suggests that hippocampal activity is necessary for 
LI. However, hippocampal hyperactivity has a less detrimental effect 
on behaviour and therefore balanced activity during PE within the 
hippocampus is not required for the formation of LI.  
 
However, the divergent associative paradigms used in these 
experiments does need to be taken into account when comparing 
these findings. There are apparent differences in the effects of 
dopaminergic manipulations when comparing between the CER and 
CTA paradigms. Nucleus accumbens shell lesions disrupt LI when 
using the CER paradigm (Tai et al., 1995) but conversely potentiate 
LI using a CTA paradigm (Pothuizen et al., 2006). In addition 
amphetamine administration at PE is enough to disrupt LI using CTA 
(Bethus et al., 2006) whereas this is not the case for CER (Young et 
al., 2005). In accordance with this, during the CER paradigm changes 
in dopamine efflux between PE and NPE groups are confined to the 
NAc shell (Murphy et al., 2000), whereas using CTA changes are seen 
in both shell and core regions of the NAc (Jeanblanc et al., 2002). 
Therefore, the disruption of LI by hippocampal manipulations could 
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be dependent on the type of associative paradigm used, possibly due 
to the conflicting effects on the dopamine system. 
 
Any role for ventral hippocampal disinhibition in clinically relevant LI 
deficits?  
The absence of any effects of ventral hippocampal picrotoxin infusion 
on the formation of LI in the present study does not support that 
dysfunctional ventral hippocampal GABA transmission contributes to 
the LI deficits seen in acute schizophrenia patients (Gray et al., 
1995b, Rascle et al., 2001). However, LI is known to be sensitive to 
changes in context, reflected by attenuated LI when pre-exposure 
and conditioning take place in different contexts (Hall and Channell, 
1986, Westbrook et al., 2000), and the hippocampus is important in 
the processing of contextual cues (Hobin et al., 2006, Maren and Holt, 
2000). Complete hippocampal lesions remove the context specificity 
of LI, which is reflected by the transfer of LI across different contexts 
(Honey and Good, 1993). In addition, dorsal hippocampal inactivation 
using muscimol during the retrieval phase disrupts the contextual 
gating of LI (Holt and Maren, 1999), whilst ventral subiculum lesions 
also disrupt the context specificity of LI (Quintero et al., 2011). 
Therefore, hippocampal disinhibition might disrupt the expression of 
LI by disrupting the recall of contextual memory during retrieval. 
However, because ventral hippocampal disinhibition disrupts cued 
fear conditioning (experiment 1), it is difficult to assess this possibility 
using a CER paradigm. This is because infusions during the test phase 
could disrupt the expression of cued fear rather than disrupting 
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contextual gating of LI per se, therefore deficits in LI could be masked 
by deficits in conditioned fear. Future experiments investigating the 
impact of hippocampal disinhibition on the expression and contextual 
gating of LI would be important to understand if contextual 
processing deficits caused by ventral hippocampal disinhibition also 
impact on LI. Therefore, providing clarity on the behavioural impact 




Using the CER paradigm, we show ventral hippocampal disinhibition 
causes both elemental and contextual fear conditioning deficits. 
These deficits in associative processing resemble data from 
schizophrenia patients where participants showed abnormal learning 
in a Pavlovian conditioning paradigm (Jensen et al., 2008). 
Specifically, schizophrenia patients did not distinguish between the 
aversive CS+ (aversive audible stimuli) and non-aversive CS-, where 
they showed increased tolerance to the CS+ compared to controls. 
Similarly, deficits in discriminative aversive conditioning in patients 
with schizophrenia (Hofer et al., 2001), and abnormal hippocampal 
BOLD responses during fear conditioning compared to controls have 
been reported (Holt et al., 2012). These combined clinical studies 
suggest a similar mechanism could be responsible for abnormal 
conditioning seen in our data and in human studies, whereby there is 
a dysfunctional emotional processing circuit, caused by increased 
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hippocampal drive to projection sites, however the neural basis for 
this remains to be determined.  
 
Conclusion 
In conclusion, ventral hippocampal disinhibition caused contextual 
and elemental fear conditioning deficits, whilst the present study did 
not provide evidence that this manipulation affects the acquisition of 
LI. The conditioning deficits seen in this study demonstrate ventral 
hippocampal GABA dysfunction causes aberrant associative 
processing of aversive stimuli. This data suggests ventral 
hippocampal GABA dysfunction could underlie associative processing 
abnormalities in schizophrenia patients. However, disruptions of LI 
may not be driven by hippocampal disinhibition as the formation of 










Chapter 3: SPECT imaging: Brain-wide 
activation changes caused by hippocampal 




Hippocampal metabolic hyperactivity and neural disinhibition have 
been strongly associated with psychiatric disorders, including early 
stage schizophrenia and age-related cognitive decline (Bakker et al., 
2012, Heckers and Konradi, 2015, Weiss et al., 2004). This aberrant 
hippocampal activity could drive cognitive impairments and 
psychological symptoms of these disorders, partly through the array 
of connections to other brain regions (Bast, 2011, Bast et al., 2017, 
Lisman et al., 2008, Small et al., 2011). One prominent idea is that 
hyperactivity of the hippocampus is part of a mechanism which drives 
increased dopaminergic firing, which leads to the characteristic 
hyper-responsiveness of the striatal dopamine system found in 
schizophrenia and is thought to underlie positive symptoms (Grace, 
2010, Grace, 2012, Mitchell et al., 2000). In addition, the 
hippocampus has significant efferent connection to the PFC 
(Cenquizca and Swanson, 2007, Jay and Witter, 1991) and the PFC 
is implicated in important clinically relevant cognitive functions, 
including sustained attention (Pezze et al., 2014) and behavioural 
flexibility (Birrell and Brown, 2000, Floresco et al., 2008, McAlonan 
and Brown, 2003). Significantly, disruption of connectivity between 
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the hippocampus and PFC has been found in schizophrenia patients 
(Benetti et al., 2009), and this could contribute to the cognitive 
deficits seen in schizophrenia (Lesh et al., 2011). A significant body 
of work over the last few decades has implicated hippocampal 
hyperactivity at rest as a key feature of both schizophrenia and mild 
cognitive impairment (MCI), including studies of glucose metabolism, 
regional cerebral blood flow (rCBF) and BOLD (blood-oxygen-level-
dependent) measurements (Heckers and Konradi, 2015). In the early 
1990s, PET studies of glucose metabolism identified markedly 
increased basal hippocampal activity in patients with schizophrenia 
(Liddle et al., 1992a, Tamminga et al., 1992). Since then, a significant 
number of studies have shown consistent increases in basal 
hippocampal activity in patients with schizophrenia, using SPECT, PET 
and fMRI imaging respectively (Malaspina et al., 2004, Medoff et al., 
2001, Scheef et al., 2010, Talati et al., 2016). In addition, 
hippocampal hyperactivity has been observed in patients with MCI 
compared to aged control participants without cognitive impairments 
(Dickerson et al., 2005, Putcha et al., 2011).  
 
Thanks to more sophisticated MRI technology and analysis techniques 
(Ekstrom et al., 2009, Malykhin et al., 2010), recent studies have 
found evidence that there are differences in activity across the 
different cytoarchitectural subfields of the hippocampus, where 
increases in cerebral blood volume (CBV) have been identified 
specifically within the CA1 region of the hippocampus (Schobel et al., 
2009b, Talati et al., 2014). Interestingly, CA1 hyperactivity appears 
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to correlate with progression to schizophrenia from high risk groups 
and with positive symptoms of the disorder (Schobel et al., 2009b, 
Schobel et al., 2013). In addition, Tregellas et al. (2014) found 
increased basal hippocampal activity is associated with a number of 
cognitive deficits and negative symptoms observed in schizophrenia 
patients. Subsequently several studies have also shown an increase 
in hippocampal perfusion in populations who are at high risk of 
developing schizophrenia, including high schizotypy individuals 
(Modinos et al., 2018a) and in individuals who hold delusional beliefs 
(Wolthusen et al., 2018). In addition to the many studies showing 
increased hippocampal resting activity, task-related activation of the 
hippocampus has also typically been found to be reduced (Heckers et 
al., 1998). Reduced recruitment of the anterior hippocampus during 
memory task has been identified in multiple studies in early psychosis 
and chronic schizophrenia (McHugo et al., 2019, Jessen et al., 2003, 
Ragland et al., 2001, Weiss et al., 2004).  
 
To complement human imaging methods, which mostly reveal 
correlations but not causal relationships, between aberrant 
hippocampal activity and other neuro-behavioural measures, pre-
clinical animal models of hippocampal dysfunction can help to 
characterise the functional deficits caused by aberrant hippocampal 
activity. Acute reduction of inhibitory GABA transmission within the 
ventral hippocampus, by blockade of GABA receptors or 
pharmacogenetic inhibition of GABAergic neurons causes behavioural 
alterations related to schizophrenia, such as hyper-locomotor activity 
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and sensorimotor gating deficits, although these deficits may be 
strain sensitive (Bast et al., 2001a, McGarrity et al., 2017, Nguyen et 
al., 2014). In addition acute blockade of ventral hippocampal GABA-
A receptors can also cause attentional deficits usually mediated by 
prefrontal circuits and impairments in hippocampal dependent 
memory (McGarrity et al., 2017). These data suggest that regional 
disinhibition could cause aberrant drive of projections, leading to 
disrupted information processing at distal sites, thereby causing 
cognitive deficits (Bast, 2011, Bast et al., 2017). 
 
Aims 
Hippocampal hyperactivity and GABA dysfunction have been heavily 
associated with psychiatric disorders (Heckers and Konradi, 2015), 
but a causal link between disinhibition and metabolic hyperactivity 
within the hippocampus remains to be demonstrated. Moreover, the 
impact of hippocampal neural disinhibition on hippocampal projection 
sites remains to be determined. Therefore, we utilised high resolution 
multi-pinhole SPECT (Kolodziej et al., 2014, Oelschlegel and 
Goldschmidt, 2020) combined with ventral hippocampal picrotoxin 
(GABA-A antagonist) infusions (McGarrity et al., 2017) to examine 
changes in metabolic activation within the hippocampus and its 
projection sites caused by hippocampal GABA dysfunction. Increases 
in cerebral blood flow are correlated with increased metabolic demand 
and thus higher neuronal activity in that region (Attwell et al., 2010). 
Therefore, changes in regional cerebral blood flow (rCBF) are 
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indicative of changes in neuronal activity. The multi-pinhole SPECT 
method has several advantages over more widely used in vivo 
imaging modalities, including BOLD-fMRI and PET (Oelschlegel and 
Goldschmidt, 2020). Firstly, fMRI requires animals to be 
anaesthetised or severely restrained (Steward et al., 2005) and, 
secondly, PET has a typically lower spatial resolution when using 
small fields of view, as are used in rodent studies (Rodriguez-
Villafuerte et al., 2014), which makes this method less attractive for 
measuring spatial patterns of neuronal activity in rodents. Using 
multi-pinhole SPECT permits sub-millimetre spatial resolution 
(Kolodziej et al., 2014, van der Have et al., 2009), allowing for more 
accurate spatial representation of neuronal activity. Using this 
method allowed us to map whole brain wide activity patterns caused 
by ventral hippocampal disinhibition to understand if and how 
metabolism within the hippocampus and in distal sites is affected by 
hippocampal GABA neuronal disinhibition. This includes regions, 
which not only receive direct unilateral projections, such as the PFC, 
but also those with reciprocal connections and those sites which have 
been indirectly linked to hippocampal activity. We hypothesised that 
picrotoxin infusions cause changes in rCBF both within the 
hippocampus and in distal sites, which may also explain some of the 
cognitive and behavioural changes caused by acute hippocampal 







12 male Lister hooded rats (Charles River, Germany, weighing 260-
370g, 9-11 weeks old) were used for SPECT studies (see 
experimental design for a justification of sample size). Rats were 
housed in groups of 4 in translucent laboratory cages, type IV 
(Techniplast Deutschland GmbH, Germany) with temperature and 
humidity control (22 ± 2 °C, 55 ± 5%) and an alternating 12h 
light/dark cycle (lights on at 0600). Animals had ad libitum access to 
food and water. All rats were habituated to handling by experimenters 
for at least 5 days prior to any experimental procedure. All 
experimental procedures were conducted during the light phase. The 
experiments were performed according to EU Directive 2010/63/EU 
for animal experiments and approved by the local ethical committee. 
All SPECT experiments were carried out at the Leibniz institute for 
neurobiology, Magdeburg, Germany. 
Implantation of guide cannula and drug microinfusion into the ventral 
hippocampus 
Stereotaxic implantation of guide cannula into the ventral 
hippocampus was performed as in chapter 2, with the exception of a 
different analgesia used (Metacam, 5mg/ml, 0.02/100g s.c, 
Boehringer Ingelheim, Germany). After surgery, rats were allowed at 
least between 4-5 days of recovery before jugular vein 
catheterisation. During this period rats underwent daily health checks 
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and were habituated to the manual restraint necessary for drug 
micro-infusions. 
Jugular vein catheterisation 
4 or 5 days after ventral hippocampal cannulae implantation, rats 
were implanted with a silicon catheter (Gaudig Laborfachhandel GbR, 
Germany; OD: 1.3 mm, ID: 0.5 mm, total catheter length 11 cm into 
the right external jugular vein under isoflurane anaesthesia as 
described previously for rodents (Mannewitz et al., 2018, Vincenz et 
al., 2017). The catheter was filled with catheter lock solution (Cath-
Loc HGS, SAI Infusion Technologies, USA) to prevent clogging. 
After implantation, animals were given at least two days to recover 
from surgery before they received intra-hippocampal microinfusions 
followed by SPECT scans. 
Intracerebral microinfusion procedure    
Drug microinfusions were performed as described previously (chapter 
2) and all animals were monitored for behaviour that might be related 
to seizure development. After hippocampal microinfusion of 
picrotoxin, but not of saline, we observed wet-dog shakes in each of 
the 12 animals used in this study within 5mins after the end of 
infusion, but no other seizure-related behavioural signs (as detailed 
in chapter 2). These effects were short lived (<10mins) and all rats 
showed no persistent adverse effects of infusions.  For the timing of 





Preparation of 99mTc-HMPAO 
The 99mTc-HMPAO injection solutions were prepared from 
commercially available kit preparations (CeretecTM, GE Healthcare, 
Germany). 30 mins before the experiments HMPAO aliquots were 
thawed. Five to ten min before use, the 99mTc-HMPAO solution was 
prepared by adding 270 MBq 99mTc-pertechnetate to the HMPAO-
aliquots. 25 μl of a 200 μM SnCl2 solution was added just after mixing 
the 99mTc-pertechnetate solution with the HMPAO-aliquots. The 
200 μM SnCl2-solution was prepared just before use by adding 50 mg 
SnCl2 x 2H2O (Sigma-Aldrich, purissimum grade) to 1 L double-
distilled H2O and stirring for 30 sec.  
Intravenous injection of 99mTc-HMPAO 
For tracer injection, a Teflon tube (CS-Chromatographie Service 
GmbH, Germany, OD: 1/16-inch, ID: 0.5 mm), 40 cm in length and 
filled with 0.9% NaCl, was connected to the jugular vein catheter. A 
syringe filled with 270 MBq 99mTc-HMPAO (volume 400-500µl) was 
connected to the Teflon tube and placed in a syringe infusion pump 
(Harvard Instruments, USA). Injections were made at flow rates of 
80 μl per min for 7 min. After 99mTc-HMPAO injection, the Teflon tube 
and the catheter were cleared with 0.9% NaCl solution for 3 min.  
SPECT/CT imaging 
Immediately after the completion of intravenous injection of the flow 
tracer, rats were briefly induced with 4% isoflurane and transferred 
to the SPECT/CT-scanner and scanned under inhalation anaesthesia 
(2.0% isoflurane in 2:1 O2:N2O volume ratio). A four head 
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NanoSPECT/CTTM scanner (Mediso/Hungary) was used for co-
registered SPECT/CT imaging. SPECT scans of the rats’ head were 
made using nine-pinhole apertures with 1.5mm pinhole diameter and 
a nominal resolution of < 1.2mm over a scan time of 2 hours. The 
Axial field of view (FOV) was 38.9 mm. Photopeaks were set to the 
default values of the NanoSPECT/CT (140 keV +/− 5%) for 99mTC. 
SPECT images were reconstructed using the manufacturer´s software 
(HiSPECTTM, SCIVIS, Germany) at an isotropic voxel size of 500μm. 
CT scans were acquired from the same FOV as SPECT scans (55 kVp, 
360 projections, 500 ms per projection) and reconstructed with the 
manufacturer´s software (InVivoScopeTM 1.43, Bioscan Inc, USA) at 
an isotropic voxel-size of 200 μm. Each rat underwent two CT scans 
per imaging session, one before and one after the SPECT scan to 
control for movement during SPECT scans. Rats were excluded if 
motion artefacts were detected in the CT images. The CT scans were 
also used to confirm the cannula placements within the ventral 
hippocampus. 
Experimental design and data analysis  
The experiment was run in a within-subjects crossover design, with 
two counterbalanced series of measurements performed, where 
possible, resulting in four hippocampal infusions, two of picrotoxin 
and two of saline, followed by SPECT measurements for each rat. A 
period of at least 48 hours between SPECT measurements, in 
combination with drug micro-infusion, was observed for each rat to 
allow for Technetium-99m decay and for recovery from anaesthesia. 
The 10 min intravenous tracer injection began 10 min after the end 
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of the hippocampal microinfusion. The timing of tracer injection was 
based on our previous electrophysiological measurements to capture 
the peak effect of the hippocampal picrotoxin infusion on hippocampal 
neuron firing, which occurs between 10 and 30 min following infusion 
(McGarrity et al., 2017). A sample size of n=12 was chosen to give 
>80% power to detect an effect size of d=1 at a significance threshold 
of p=0.05 using two-tailed paired t-tests to compare saline versus 
picrotoxin infusions (power analysis conducted with GPower 3.1, (Faul 
et al., 2007). Data analysis was performed using pooled data from 
the two scans in each infusion condition (saline or picrotoxin), if rats 
had completed all four scans. 10 rats completed both series of 
measurements, and for these 10 rats the mean of the two 
measurements in each infusion condition (picrotoxin or saline) was 
used for analysis. Two animals completed only one series of 
measurements, one after picrotoxin and one after saline infusion, due 
to blockage of the jugular catheters. For the two rats who only 
completed one series of measurements, the single values from the 
first series of measurements were used. 
SPECT/CT-images were aligned to an MR template based on skull 
landmarks and the best fit of CT- and MR images for each rat using 
the MPI-ToolTM software (Advanced Tomo Vision, Germany). The MR 
template used was a high-resolution (isotropic resolution of 0.15 mm) 
MR-rat brain data set based on 8 male Lister hooded rats, weighing 
approximately 300g (Prior et al, 2019 (under revision). The 
alignments were based solely on the best fit of CT- and MR images. 
SPECT-brain data were cut out of the overall SPECT-data using a 
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whole-brain VOI (volume of interest) with OsirixTM software (Pixmeo, 
Switzerland) and intensity normalised to the same global mean with 
the MPI-ToolTM software (Multi-Purpose Image Tool V6.42, ATV 
GmbH, Kerpen, Germany). For visualisation of the spatial patterns of 
the average blood flow for each drug condition, global mean 
normalized SPECT images of all animals in each drug infusion group 
were combined. For statistical analysis voxel-wise paired t-tests were 
performed (MagnAn-software, version 2.4, BioCom GbR, Germany) 
comparing mean tracer uptake between saline and picrotoxin 
infusions. In accordance with previous small animal radionuclide 
imaging uncorrected p values are given, and p < 0.05 was used as 
the significance threshold (Endepols et al., 2010, Thanos et al., 
2013). SPECT/MR fusions images were produced using OsirixTM 
software and arranged for illustration using PhotoshopTM software 








The CT images averaged over all rats and overlaid on the MR brain 
template confirmed that the infusion cannula were all placed within 
the ventral hippocampus (Fig. 6A) 
Increased rCBF in the ventral hippocampus 
Infusions of the GABA-A antagonist picrotoxin as compared to saline 
infusion, caused an increase in 99mTc-HMPAO uptake around the 
infusion site in the hippocampus (Fig. 6B), which reached the 
Figure 6. Increased rCBF at the site of neural disinhibition in the ventral 
hippocampus. A: CT overlaid onto a Lister hooded rat MR template indicating 
cannulae positions and infusion sites in the ventral hippocampus; co-ordinates 
relative to bregma (mm) are indicated below the CT/MR fusion image. (R/L) 
indicate right or left hemispheres. B: Mean differences in tracer uptake between 
saline and picrotoxin conditions at the indicated bregma position (-5.4) overlaid 
on an MR template. Mean increases are represented in yellow (up to 25%) and 
decreases in red/black (up to 25%). C: Shown is a map indicating significant 
changes in tracer uptake in the picrotoxin infusion condition versus saline infusion 
(paired t-test) overlaid on an MR template. Significant decreases in tracer uptake 
are represented as blue-purple (p<0.01-0.001) with significant increases shown 
as red-yellow (p<0.01-0.001). Significant increases in tracer uptake were found 





statistical significance threshold (p<0.01) in many voxels bilaterally 
(Fig. 6C). The increase was somewhat more pronounced in the left 
hippocampus, where a larger number of voxels showed increases that 
were significant at p<0.01. The increased rCBF observed at the site 
of drug infusion was contained within the ventral to intermediate 
hippocampus, showing no spread to more dorsal parts.  
Reduced rCBF in the dorsal hippocampus 
In contrast to the metabolic activation in the ventral hippocampus a 
striking deactivation, which was significant at p<0.01 for several 
voxels, was observed in the dorsal hippocampus (Fig. 7I), with the 
deactivation in the left dorsal hippocampus extending further 
posterior than in the right dorsal hippocampus (e.g., see Fig. 6C 
where deactivation is evident in left dorsal hippocampus).  
Extra-hippocampal activation changes caused by hippocampal 
picrotoxin infusion 
SPECT data also revealed significant activation changes in multiple 
regions beyond the hippocampus. This included both activations and 
deactivations across both cortical and subcortical sites. Picrotoxin 
infusion into the ventral hippocampus caused CBF changes in several 
extra-hippocampal regions including: ventromedial prefrontal cortex, 
anterior cingulate cortex, lateral/medial septum, lateral 
hypothalamus, nucleus reuniens, dorsal raphe nuclei, entorhinal 
cortex and piriform cortices, anterior olfactory nucleus, olfactory bulb 




Medial prefrontal cortex 
We observed increases in blood flow that reached the p>0.05 
significance level in the anterior cingulate cortex (Fig. 7D). These 
significant activations were found ipsilateral to the more prominent 
activation in the left ventral hippocampus. In addition, there was also 
an increase in activation which reached the p<0.05 significance level 
in the most ventral part of the medial prefrontal cortex, which 
corresponds to the dorsal tenia tecta and dorsal peduncular cortex 
(Fig. 7C). 
Medial and lateral septum  
Ventral hippocampal picrotoxin infusion caused a very marked 
activation in the septum, including both medial and lateral parts, 
which extended from the most anterior to most posterior portions of 
the septum and was significant at p<0.01 in many voxels (Fig. 7D 
and G).  
Hypothalamus and thalamus 
We also detected significant activations of the nucleus reuniens and 
lateral hypothalamus at the p<0.05 and p<0.01 significance 
threshold (Fig. 7E and H), with the most robust activation of the 
lateral hypothalamus (significant at p<0.01 for some voxels, Fig. 7H) 





Figure 7. Brain-wide activation changes caused by ventral hippocampal 
disinhibition. Mean difference and significance maps illustrating differences in tracer 
uptake between picrotoxin and saline infusion conditions across the brain. Difference 
maps indicate increased tracer uptake in yellow (up to 25%), and decreased uptake 
in red/black (up to 25%). Significant increases (paired t-test) in tracer uptake in the 
picrotoxin compared to saline infusion condition are shown in yellow/red with 
significant decreases shown in blue/purple. Selected p-map sections are shown at 
either p<0.05 (left) or p<0.01 (right). Sections are arranged from anterior to 
posterior. Numbers on the left of the sections indicate positon relative to bregma 
(mm); (R) right, (L) left. Significant increases in tracer uptake are seen in the anterior 
olfactory nucleus (arrow in B), most ventromedial prefrontal cortex (dorsal tenia tecta 
and dorsal peduncular cortex) (arrow in C), anterior cingulate cortex (arrow in D), 
lateral septum (arrows in D/G), medial septum (arrow in G), medial thalamus (arrows 
in E/H), lateral hypothalamus (arrows in E/H), entorhinal cortex (arrow in F) and dorsal 
raphe nuclei (arrow in J). Significantly decreased tracer uptake is seen in the olfactory 
bulb (arrow in A), piriform cortex (arrows in C), gustatory cortex (arrows in D), 
extended amygdala (arrow in E) and dorsal hippocampus (I). 
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Entorhinal cortex  
Hippocampal disinhibition also caused increased bilateral activation in 
the entorhinal cortex with voxels exceeding the p<0.05 significance 
threshold (Fig. 7F). Activation was centred on the medial entorhinal 
cortex and extending into parts of the lateral entorhinal cortex. 
Activation of the entorhinal cortex was more prominent in the left 
hemisphere with a greater extent of voxels exceeding the significance 
threshold. 
Amygdala and extended amygdala  
Ventral hippocampal picrotoxin also lead to deactivation of a region 
centred on the interstitial nucleus of the posterior limb of the anterior 
commissure (IPAC) and extended into adjacent regions of the central 
amygdala and extended amygdala, reflected by voxels exceeding the 
p<0.05 significance threshold (Fig. 7E). The deactivation centred on 
the IPAC was prominent in the left IPAC and extended amygdala, 
which coincides with the robust activation in the left ventral 
hippocampus.  
Olfactory regions 
We also observed significant changes in olfactory regions including a 
marked bilateral deactivation in the piriform cortex which ranged 
from the anterior to posterior limits of the structure (Fig. 7C, E, and 
H). Tracer content in the piriform cortex decreased at the p<0.05 
level with peaks at p<0.01 (Fig. 7H). Reductions in tracer content 
also extend dorsally to the gustatory/granular cortex (Fig. 7D). In 
addition, we also observed significantly decreased tracer uptake in 
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the medial and right olfactory bulb (p<0.05) (Fig. 7A) and increased 
activation centred in the dorso-lateral part of the anterior olfactory 
nucleus, ipsilateral to the more marked activation in the left ventral 
hippocampus (Fig. 7B).  
Dorsal raphe nuclei 
Increased activation at the P<0.05 significance level was also seen in 
















We used SPECT imaging to reveal brain-wide activation changes 
caused by hippocampal disinhibition in freely moving rats. Ventral 
hippocampal disinhibition markedly increased blood flow around the 
infusion site within the ventral hippocampus, whereas activation 
within the dorsal hippocampus was markedly decreased. In addition 
to activation changes within the hippocampus, we observed changes 
within cortical and subcortical sites. Within medial prefrontal cortical 
sites, we observed increases in rCBF in areas of the ventromedial 
prefrontal cortex, anterior cingulate cortex and entorhinal cortex. At 
subcortical sites, ventral hippocampal disinhibition caused a 
prominent increase in activation within the septum, the nucleus 
reuniens, lateral hypothalamic and dorsal raphe nuclei. In addition we 
observed significant activation changes in olfactory regions, including 
activation of the anterior olfactory nucleus and deactivation of the 
olfactory bulb and piriform cortex. In addition, we also observed 
significant deactivation of the extended amygdala.  
 
Activation in ventral hippocampus and deactivation in dorsal 
hippocampus 
Picrotoxin infusions into the ventral hippocampus caused a significant 
increase in rCBF around the infusion site in this region of the 
hippocampus. This finding is consistent with the increased 
hippocampal burst firing caused by local picrotoxin infusion 
(McGarrity et al., 2017), although it was not a foregone conclusion 
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that increased bursting corresponds to increased CBF as revealed by 
the SPECT findings. This significant increase in activity is localised to 
the area around the infusion tip, which indicates the infused drug is 
contained in the ventral region of the hippocampus. The metabolic 
hyperactivity in the ventral hippocampus caused by disinhibition in 
the present study resembles clinical findings of hippocampal 
hyperactivity in schizophrenia and age-related cognitive decline 
(Bakker et al., 2012, Heckers and Konradi, 2015). This finding is 
consistent with the idea the hippocampal GABA dysfunction may 
underlie the characteristic hippocampal hyperactivity seen in these 
disorders.   
 
Interestingly, in contrast to a significant increase in activity in the 
ventral hippocampus after picrotoxin infusion, there was a marked 
deactivation of the dorsal hippocampus. The deactivation in the dorsal 
hippocampus is seen bilaterally across the entire dorsal hippocampus. 
This differentiation in activity could be driven by increased 
feedforward inhibition driven by interneurons that longitudinally 
project from the ventral to dorsal hippocampus (Sik et al., 1997). In 
line with the existence of feedforward inhibition from the ventral to 
dorsal hippocampus, Bast et al. (2009) demonstrated that cytotoxic 
lesions to the ventral hippocampus increased excitability in the dorsal 
hippocampus, as reflected by increases in evoked potential in the 
dorsal dentate gyrus. The contrasting activation changes between 
poles of the hippocampus observed in this study resemble different 
activation changes along the hippocampal longitudinal axis that have 
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been observed in schizophrenia. More specifically, hippocampal 
hyperactivity is mainly limited to the anterior hippocampus, which 
corresponds to rodent ventral hippocampus (Schobel et al., 2009b). 
In contrast, reduced activation was reported in the posterior 
hippocampus, analogous to dorsal hippocampus in rats, in a cohort 
of patients with schizophrenia, whereas anterior hippocampal activity 
was markedly increased in this cohort, reflecting an activity 
differentiation gradient across the hippocampal structure (Ragland et 
al., 2017). Our findings suggest the pattern of anterior hyperactivity, 
alongside posterior deactivation, in the hippocampus of patients with 
schizophrenia could be driven by disinhibition of the anterior 
hippocampus.  
 
The differentiation in activation changes across the hippocampal 
dorso-ventral axis could have important functional significance. The 
dorsal hippocampus is important for the encoding of accurate place 
information and of learning about spatial contexts (Bast, 2007, 
Kjelstrup et al., 2008, Pothuizen et al., 2004, Moser and Moser, 
1998). Notably, inhibition of the dorsal hippocampus causes 
contextual fear conditioning deficits (Esclassan et al., 2009, Wang et 
al., 2012, Zhang et al., 2014), and this may reflect disruption of the 
formation of  contextual representations (Rudy and O'Reilly, 2001, 
Matus-Amat et al., 2004). On the other hand, inactivation and 
activation of the ventral hippocampus disrupts both contextual and 
cued fear conditioning (see chapter 2 and (Bast et al., 2001b, Maren, 
1999, Zhang et al., 2001). In addition, both the dorsal and ventral 
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hippocampus are necessary for rapid place learning (Bast et al., 
2009), and disinhibition of the ventral hippocampus also disrupts 
rapid place learning (McGarrity et al., 2017). The finding of reduced 
dorsal hippocampal activity caused by ventral disinhibition raises the 
possibility that disruption of rapid place learning and contextual 
conditioning caused by ventral hippocampal manipulations could be 
in part due to aberrant dorsal hippocampal mechanisms of encoding 
spatial representations. 
 
Extra-hippocampal changes  
Medial prefrontal cortex changes  
In addition to activation changes in the ventral and dorsal 
hippocampus, significant changes in rCBF were identified in cortical 
and subcortical sites. This included medial prefrontal activations, 
which exceeded the significance threshold in the anterior cingulate 
cortex (ACC). These findings are supported by the anatomical 
connections that run between the hippocampus and prefrontal cortex 
(Jay and Witter, 1991), which include ventral hippocampal 
projections to the prelimbic (PL), infralimbic (IL) and ACC (Hoover 
and Vertes, 2007, Jay et al., 1989). The prefrontal cortex plays an 
important role in the control of several behavioural functions, 
including decision making, goal directed learning, behavioural 
flexibility and sustained attention (Birrell and Brown, 2000, 
Chudasama et al., 2003, Dalton et al., 2016, Euston et al., 2012, 
Floresco et al., 2008, Passetti et al., 2002, Pezze et al., 2014). 
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Significantly, the ACC has been shown to play a key role in mediating 
cost-benefit decision making in rats (Hillman and Bilkey, 2010, 
Walton et al., 2003) and in addition, ACC lesions reduce accuracy on 
the 5 choice serial reaction time task (5CSRT) (Chudasama et al., 
2003).  
 
Ventral hippocampal disinhibition also caused activation changes in 
ventromedial regions of the prefrontal cortex (vmPFC). Specifically, 
an increase in activation was seen in a region centred on the dorsal 
peduncular cortex and dorsal tenia tecta (DPP/DTT). Ventral 
hippocampus projections to the DPP/DTT have been identified 
(Arszovszki et al., 2014, Cenquizca and Swanson, 2007), but the 
functional significance of these connections remains unclear. Ventral 
mPFC lesions, including DP/DTT, cause response errors on the 5CSRT 
task whilst dorsal lesions caused omissions, which suggests a possible 
role for the vmPFC in some aspects of cognitive function (Maddux and 
Holland, 2011). Although, the lesions performed in this study also 
affected the infralimbic cortex. A recent study suggests the DP/DTT 
is involved in the sympathetic and behavioural response to stress and 
possibly integrates emotional and stress information, which is 
transmitted to the dorsomedial hypothalamus (Kataoka et al., 2020). 
Further studies are required to characterise hippocampal inputs to 
these regions and to understand the physiological and behavioural 




Overall, the increase in activation in prefrontal regions observed in 
the present study could provide a mechanism to explain the deficits 
in sustained attention caused by hippocampal disinhibition (McGarrity 
et al., 2017). Therefore, raising the possibility that imbalanced 
activity in the PFC, caused by hyperactivity in the hippocampus, could 
contribute to the cognitive deficits seen in psychiatric disorders such 
as schizophrenia. 
 
Medial and lateral septum activation  
A striking area of activation caused by hippocampal picrotoxin was 
observed across the whole septum, including both the medial and 
lateral areas, with increases of up to 25% compared to controls. This 
consistently significant (p<0.05-0.01) increase in activation across 
the whole structure of the septum contrasts with other regions such 
as the mPFC, where statistically significant increases were only seen 
in sections of specific regions. The septum is a key nucleus which 
receives connections from the hippocampus, amygdala and thalamus, 
and subsequently projects to the hippocampus, thalamus and ventral 
tegmental area amongst other regions (Risold and Swanson, 1997). 
Recent neuroanatomical evidence from mice shows that hippocampal 
efferents to the lateral septum are significantly denser than those 
projecting to cortical sites (Tingley and Buzsaki, 2018). Interestingly, 
a hippocampal dorso-ventral gradient of inputs to the septum exists, 
whereby more ventral regions of the hippocampus project to the 
lateral septum, whilst in contrast only sparse dorsal hippocampal 
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projections to the lateral septum exist (Risold and Swanson, 1996, 
Risold and Swanson, 1997). The reciprocal connections between the 
hippocampus and septum are important for maintaining theta 
rhythms (Hangya et al., 2009), which are implicated in the memory 
and navigation functions of the hippocampus (Buzsaki and Moser, 
2013). This reciprocity provides a key pathway for the hippocampal 
modulation of sensorimotor functions including locomotor activity 
(Bender et al., 2015). Locomotor activity is increased by hippocampal 
disinhibition (Bast et al., 2001a, McGarrity et al., 2017) and 
hippocampal stimulation by other means (Bast and Feldon, 2003), 
and our present findings support that this could be driven via the 
hippocampo-septal pathway. Reducing septal activity by muscimol 
infusion causes a reduction in the onset of locomotor activity (Wang 
et al., 2015), and septal connections to the raphe nucleus and VTA 
might control the onset and speed of locomotion (Fuhrmann et al., 
2015). Thus, hyperactivity of the hippocampus could drive increased 
locomotor activity via the septum and is possibly an important 
pathway for the expression of other sensorimotor processes.  
 
Hypothalamus and thalamus activation  
The increased activation within the lateral hypothalamus following 
ventral hippocampal disinhibition is consistent with the strong 
projections from the ventral CA1 region of the hippocampus to the 
hypothalamic nuclei (Cenquizca and Swanson, 2006, Hahn and 
Swanson, 2015). Specifically, the ventral CA1 region of the 
101 
 
hippocampus provides the strongest hippocampal projection to the 
lateral hypothalamus (Cenquizca and Swanson, 2006), whilst the 
medial hypothalamus is strongly innervated by projections originating 
across the septo-temporal axis of the subiculum (Kishi et al., 2000). 
In addition, the substantial increase seen in the lateral hypothalamus 
could also partly be driven via the lateral septum. Our findings show 
a marked increase in activity in the lateral septum and the lateral 
septum has strong bidirectional projections to the lateral 
hypothalamus (Risold et al., 1997). The significant interconnections 
between, the hippocampus, septum and lateral hypothalamus 
produces a neural circuitry that can drive several aspects of behaviour 
including arousal and motivation (Hahn and Swanson, 2010, Hahn 
and Swanson, 2012). Recent findings suggest ventral hippocampus-
lateral hypothalamus connections can modulate some anxiety related 
behaviours (Jimenez et al., 2018) and therefore aberrant 
hippocampal activity could affect the response to anxiogenic stimuli. 
Interestingly, the prevalence of anxiety related disorders is higher in 
schizophrenia than the general population (Buckley et al., 2009). The 
hippocampus, appears to modulate activity of the hypothalamic-
pituitary-adrenal axis (HPA) (Herman et al., 2005), a key stress 
response system, and therefore hippocampal disinhibition could 
disrupt the response to stressors. Significantly, dysfunctional HPA 
axis function has been linked to schizophrenia pathophysiology 
(Walker et al., 2008).  
In addition to the strong activation present in hypothalamic areas, we 
also observed significant activation of the nucleus reuniens (NR) 
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which is part of the midline thalamic region. The NR is a significant 
hub between the limbic system and cortical regions, it receives 
significant afferents from the mPFC (PL, IL, ACC) and ventral 
hippocampus (CA1 and subiculum) whilst also sending projections to 
both the hippocampus and mPFC  (Bokor et al., 2002, McKenna and 
Vertes, 2004, Reep et al., 1996, Varela et al., 2014, Wouterlood et 
al., 1990). Additionally the NR provides a relay for PFC regions to the 
ventral hippocampus as there are no direct connections between the 
PFC and ventral hippocampus (Hoover and Vertes, 2012, Vertes, 
2002, Vertes et al., 2007). The NR is also innervated by afferents 
from the hypothalamus, lateral septum and amygdala (McKenna and 
Vertes, 2004), which may contribute to its hyper-activation in the 
present study. Studies have shown the NR is critical in working 
memory tasks which are dependent on both the hippocampus and 
PFC. Inactivation or lesion of the NR disrupts performance on the 
delayed-non-match to position task (DNMTP) and radial arm maze 
task, which are dependent on hippocampal and PFC function 
(Hembrook and Mair, 2011, Hembrook et al., 2012). Inactivation of 
the NR can also disrupt behavioural flexibility; infusions of muscimol 
into the NR lead to increased perseverative spatial responding on a 
delayed non-match to sample spatial alternation T-maze task (Viena 
et al., 2018). Alongside the role the NR plays in memory and 
attention, it has also been shown to be required for hippocampal 
dependent contextual fear memory (Ramanathan et al., 2018). 
Considering the behavioural effects of aberrant NR activity and the 
extensive hippocampal-mPFC-NR circuitry, aberrant NR activation 
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caused by hippocampal disinhibition may contribute to impairments 
in important clinically relevant cognitive function, including spatial 
and working memory and behavioural flexibility. This could include 
deficits in behavioural flexibility and reversal learning which can be 
mediated by the NR (Linley et al., 2016), and impairments in these 
cognitive functions have been identified in schizophrenia patients 
(Prentice et al., 2008). In addition, work by Zimmerman and Grace 
(2016) showed that increased activity in the NR led to an in increase 
in VTA neuron activity and enhanced amphetamine induced 
locomotion, this increase in VTA population activity is also dependent 
on ventral subiculum activity. Therefore, this suggests the circuitry 
between the ventral hippocampus and NR is important for the 
regulation of dopamine neuron firing in the VTA and hyperactivity 
within this circuit could lead to dopaminergic dysregulation which is a 
key feature of schizophrenia (Howes and Kapur, 2009). However, we 
found no evidence for activation of the VTA, reflected by increased 
rCBF, caused by hippocampal disinhibition in this study. Although, 
this does not necessarily exclude an effect of ventral hippocampal 
hyperactivity on VTA dopaminergic neuron activity as the relationship 
between dopaminergic neuronal activity and hemodynamic responses 
is debated. Specific activation of midbrain dopamine neurons has only 
minor effects on neurovascular responses within the mesolimbic 
dopamine system compared to less non-cell-type specific electrical 
stimulation (Brocka et al., 2018). Therefore, it is thought 
neurovascular changes caused by un-specific stimulation of the VTA 
are mostly mediated by glutamatergic mechanisms, with dopamine 
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playing a modulatory role (Brocka et al., 2018, Helbing et al., 2016). 
Consequently, the use of cerebral blood flow measurements in this 
study may not reveal changes specifically related to midbrain 
dopamine systems.   
 
Activation changes in the entorhinal cortex  
In addition to activation changes seen within the hippocampus, 
picrotoxin infusions also caused a significant increase in rCBF in both 
the medial (MEC) and lateral entorhinal cortex (LEC), with highly 
significant increases more prominent in the medial aspect. The 
increases in neural activation, as reflected by increased rCBF, are 
consistent with the strong functional and anatomical connectivity 
between the hippocampus and entorhinal cortex. Output connections 
from the CA1 subfield and subiculum provide the strongest 
innervation of the entorhinal cortex from the hippocampal formation, 
with the bulk of these connections innervating deep entorhinal layers 
(Nilssen et al., 2019, Tamamaki and Nojyo, 1995), although there 
are connections from the hippocampus to the superficial layers of the 
entorhinal cortex (van Strien et al., 2009). The connections from the 
hippocampus and subiculum to the entorhinal cortex follow a 
topographical arrangement whereby ventral hippocampal outputs 
project to the ventro-medial portion of the entorhinal cortex 
(Cenquizca and Swanson, 2007, Naber et al., 2001, van Strien et al., 
2009, Witter et al., 2000), with the ventral hippocampus 
preferentially projecting to the medial band of the MEC (Kerr et al., 
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2007). The entorhinal cortex is the key interface between the 
neocortex and hippocampus and plays a substantial role in memory, 
learning and the assimilation of spatial information (Eichenbaum et 
al., 2007, Moser and Moser, 2013). There is a general consensus that 
the MEC predominantly provides visuospatial information input to the 
hippocampal formation, whilst the LEC provides non-spatial 
environmental information (McNaughton et al., 2006, Navawongse 
and Eichenbaum, 2013, Yoganarasimha et al., 2011). However, it has 
been suggested that this information is integrated within the 
entorhinal cortex itself (Van Cauter et al., 2013, van Strien et al., 
2009). Therefore, aberrant activity in the entorhinal cortex, caused 
by ventral hippocampal GABA dysfunction, could disrupt the flow of 
spatial and non-spatial information which could disturb the unified 
representation of information required for accurate episodic memory 
formation.  
 
Changes in the amygdala and extended amygdala  
Whilst ventral hippocampal disinhibition caused increases in neural 
activity across a range of brain regions, reduced rCBF was observed 
in a region of the extended amygdala centred on the IPAC. The IPAC 
is a dopamine rich region extending from the central amygdala, which 
forms part of the extended amygdala complex (Alheid et al., 1999, 
Shammah-Lagnado et al., 2001) and is directly innervated by the 
ventral hippocampus and subiculum (Groenewegen et al., 1987, 
Shammah-Lagnado et al., 1999). The IPAC and extended amygdala 
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have been suggested to be involved in motivational and affective 
behaviours (Otake and Nakamura, 2003), although the functional role 
of the IPAC is not well understood. However, neurons in the extended 
amygdala, including the IPAC, have previously been shown to be 
activated by the systemic administration of both typical and atypical 
antipsychotics and antidepressant drugs (Morelli et al., 1999, Pinna 
and Morelli, 1999, Pinna et al., 2019). In addition, neurons of the 
IPAC are activated by stress, and this activation is potentially 
mediated by D1 expressing neurons in the mPFC (Numa et al., 2019). 
These studies suggest the extended amygdala circuitry plays a role 
in the mediation of affective disturbances and aberrant activity of the 
extended amygdala driven by ventral hippocampal disinhibition could 
be a mechanism which contributes to these deficits.  
 
Activation changes in olfactory regions   
We also observed robust activation changes across the olfactory 
system including deactivation of the piriform cortex across the 
anterior-posterior axis, increased activation of anterior olfactory 
nucleus (AON) and deactivation of the olfactory bulb (OB) itself.  
Ventral hippocampal CA1 axons project to all layers of piriform cortex 
and dorsal endopiriform cortex through the longitudinal association 
bundle (Cenquizca and Swanson, 2007), with particularly prominent 
connections to the posterior piriform cortex (Wang et al., 2020). The 
piriform cortex is connected to multiple brain regions including the 
olfactory bulb and amygdala and is seen as ‘sensory association like’ 
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cortex (Johnson et al., 2000). The piriform cortex is a 3 layered 
cortical structure consisting of both GABAergic interneurons and 
pyramidal cells (Haberly and Bower, 1989, Kapur et al., 1997). 
GABAergic circuity has a strong influence on excitatory neurons in 
piriform cortex (Luna and Schoppa, 2008), and reduction of activation 
in piriform cortex could be caused by increased local GABAergic 
influence over pyramidal cells. In addition, the piriform cortex also 
has significant reciprocal connections to the lateral entorhinal cortex 
(LEC) and medial entorhinal cortex (MEC) (Agster and Burwell, 2009, 
Burwell and Amaral, 1998). The entorhinal cortex is strongly 
connected to the ventral hippocampus and is a gateway for olfactory 
information to the hippocampus (Kerr et al., 2007). In addition, the 
LEC provides strong modulation of the piriform cortex; inactivation of 
the LEC causes increased spontaneous firing in the piriform cortex 
which consequently disrupts odour discrimination (Chapuis et al., 
2013). Therefore, hippocampal disinhibition could disrupt piriform 
cortex activity through direct innervation, or via modulation of 
entorhinal-piriform circuitry. 
 
In addition to the deactivation of the piriform cortex, we see a robust 
deactivation of the anterior region of the olfactory bulb, whilst 
observing increases in activity in the contralateral anterior olfactory 
nucleus (AON) caused by hippocampal disinhibition. The 
hippocampus sends dense projections to the ipsilateral AON 
(Aqrabawi et al., 2016, van Groen and Wyss, 1990) and these 
projections have a topographical gradient across the ventral-
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intermediate hippocampal axis, whereby the most ventral outputs 
innervate the more medial AON and intermediate outputs terminate 
at the more lateral areas of the AON (Aqrabawi and Kim, 2018). The 
AON’s location between the olfactory bulb and piriform cortex has led 
to suggestions it is a key olfactory processing region, with reciprocal 
inputs from both the piriform cortex and olfactory bulb (Brunjes et 
al., 2005). Recent studies of the AON have highlighted its role in the 
processing of olfactory stimuli, where chemogenetic inhibition of the 
AON enhances olfactory sensitivity and the performance of olfaction-
dependent behaviours whereas, AON activation produces the 
opposite effect (Aqrabawi et al., 2016). In addition, the same study 
found optogenetic stimulation of ventral hippocampal inputs to the 
AON impair olfaction-dependent behaviours, which demonstrates a 
functional-behavioural circuit between the hippocampus and olfactory 
regions (Aqrabawi et al., 2016).  
In addition to hippocampal-AON connectivity, lateral regions of the 
ventral hippocampus (CA1) innervate the olfactory bulb (Gulyas et 
al., 1998, van Groen and Wyss, 1990), although this connectivity only 
equates to roughly 1% of connections to the olfactory bulb 
(Padmanabhan et al., 2018). In addition, the vast majority of 
connections to the olfactory bulb come from AON (63%), which 
includes 58% from the ipsilateral side and 5% from the contralateral 
AON. The present findings of AON activation and contralateral 
olfactory bulb deactivation could be driven by glutamatergic 
projections from AON to olfactory bulb interneurons, or by direct 
innervation of the olfactory bulb by the ventral hippocampus. AON 
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projections to the olfactory bulb make connections with OB inhibitory 
cells and these connections can modulate activity of olfactory mitral 
cells (Markopoulos et al., 2012). Therefore, the deactivation of 
olfactory bulb we see in this study could be explained by a mechanism 
where ventral hippocampal hyperactivity causes increased 
glutamatergic activity in the AON, which subsequently causes 
increased inhibitory transmission in the olfactory bulb through strong 
connectivity between the AON and olfactory bulb interneurons. 
Additionally, hippocampal glutamatergic projections could connect 
directly to olfactory bulb interneurons and inhibit neural activity 
directly, as efferents from the ventral hippocampus appear to 
terminate in the granule cell layer which is mostly occupied by 
inhibitory neurons (Cenquizca and Swanson, 2007, Nagayama et al., 
2014). These results suggest hyperactivity in ventral hippocampus, 
caused by GABA dysfunction, can cause downstream effects in 
olfactory regions due to the connectivity between olfactory bulb, AON, 
piriform cortex and ventral hippocampus, which in turn could affect 
contextual information processing associated with sensory 
information.  
 
In addition to blood flow changes within olfactory regions a decrease 
in rCBF is seen bilaterally in the gustatory cortex. This region is poorly 
researched and, in comparison to other sensory systems, such as the 
olfactory and visual regions, has received little attention. The 
posterior region of the gustatory cortex receives light input from 
ventral hippocampal CA1 through the longitudinal association bundle 
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(Cenquizca and Swanson, 2007) and therefore these connections 
could be responsible for activation changes seen in the gustatory 
cortex. As discussed in relation to the olfactory system, hippocampal 
disinhibition could disrupt gustatory functions which are integral for 
the representation of taste (Yiannakas and Rosenblum, 2017), 
although the role of hippocampal-gustatory cortex circuitry remains 
to be clarified.  
 
Importantly olfactory deficits have been observed in schizophrenia, 
epilepsy and Alzheimer’s disease (Burns, 2000, Kohler et al., 2001, 
Mathur et al., 2019, Masurkar and Devanand, 2014, Moberg et al., 
1999), which have all been associated with hippocampal dysfunction 
(Nakahara et al., 2018). Furthermore, olfactory hallucinations have 
been described in psychiatric disorders, including schizophrenia and 
bipolar disorder; such hallucinations have been relatively overlooked 
compared to auditory and visual hallucinations, although olfactory-
gustatory hallucinations are strongly associated with delusions in 
patients with bipolar disorder and schizophrenia (Baethge et al., 
2005). The robust activation changes we observe in the piriform 
cortex, anterior olfactory nucleus and olfactory bulb suggests 
hyperactivity in the ventral hippocampus caused by GABA dysfunction 
could affect the processing of olfactory information and this could 
contribute to the olfactory pathology which has been associated with 




Dorsal raphe nuclei activation 
Hippocampal disinhibition also caused a significant increase in 
activation across the dorsal raphe nuclei (DRN). The DRN is a major 
constituent part of the serotonergic system, containing up to half of 
the serotonin neurons in the rat brain (Descarries et al., 1982). It is 
however a heterogeneous region and in addition to 5HT neurons a 
number of neuronal types are present including; GABA, dopamine and 
peptidergic neurons (Jacobs and Azmitia, 1992, Kirby et al., 2003, 
Michelsen et al., 2007). The DRN is not innervated by the 
hippocampus directly, but strong lateral hypothalamus projections to 
the raphe nuclei exist alongside inputs from orbital, cingulate, 
infralimbic and insular cortices (Peyron et al., 1997). The input from 
the prefrontal cortex is organised topographically whereby more 
ventral parts of the medial PFC provide stronger input to the DRN 
than the dorsal regions of the medial PFC (Goncalves et al., 2009). 
In addition, lateral hypothalamic neurons provide dense innervation 
of serotonin, rather than GABA, dorsal raphe neurons (Ogawa et al., 
2014). The increase in DRN activation after hippocampal picrotoxin 
infusion we see in this study could be driven through a poly-synaptic 
route via the lateral hypothalamus. Ventral hippocampal disinhibition 
causes robust increases in lateral hypothalamic activity and through 
the dense innervation of the DRN by the lateral hypothalamus this 
could result in increased DRN activity. The dorsal raphe has been 
shown to be involved in reward processing and aversive information 
processing (Li et al., 2013, Nakamura, 2013) and dopaminergic 
neurons within this structure contribute to behavioural modulation 
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and salience induced arousal (Cho et al., 2017). Dysregulated 
aversive conditioning and reward processing have both been 
identified as features of psychiatric disorders such as schizophrenia 
(Jensen et al., 2008, Strauss et al., 2014, Waltz et al., 2009) and 
dysfunctional activity within the dorsal raphe nuclei could contribute 
to these cognitive impairments.  
 
Conclusion 
The present results show that hippocampal disinhibition causes wide-
spread neural activity changes, both within and beyond the 
hippocampus. The changes in activation within and beyond the 
hippocampus could help to explain some of the behavioural and 
cognitive deficits caused by hippocampal disinhibition, including 
attentional impairments, locomotor hyperactivity and fear 
conditioning deficits (see chapter 2; (Bast, 2011, McGarrity et al., 
2017). The present study suggests ventral hippocampal disinhibition 
could lead to impairments in clinically relevant functions, due to 
changes in neural activation at projection sites, such as behavioural 





Chapter 4: Effect of ventral hippocampal 
disinhibition on the neurochemical profile 
of the medial prefrontal cortex as revealed 
by 1H MRS 
 
Introduction  
In the previous chapter, we showed that ventral hippocampal 
disinhibition increased neural activation, reflected by increased blood 
flow, in several projection sites of the ventral hippocampus. This 
included activation changes in distal sites such as the septum, 
thalamus and medial prefrontal cortex. Importantly, dysfunctional 
hippocampo-prefrontal connectivity has been linked to cognitive 
deficits seen in schizophrenia patients (Godsil et al., 2013, Meyer-
Lindenberg et al., 2005). In addition, a previous study in rats has 
shown that hippocampal disinhibition disrupts attentional 
performance on the 5CSRT test, which is highly dependent on the 
medial prefrontal cortex but does not normally require the 
hippocampus (McGarrity et al., 2017). Therefore, understanding the 
relationship between hippocampal GABA dysfunction and prefrontal 
cortex activity may help to explain the underlying mechanisms, which 
cause the manifestation of cognitive symptoms relevant to 
schizophrenia. To further explore the relationship between 
hippocampal disinhibition and mPFC function we used in vivo proton 
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magnetic resonance spectroscopy (1H MRS), which allows for the non-
invasive quantification of neurotransmitters and metabolites. The 
neurochemical profile measured using MRS contains compounds that 
may act as neurotransmitters, or are components of neurotransmitter 
metabolic pathways, including glutamate, glutamine and GABA, and 
compounds involved in energy turnover such as lactate and glucose 
(Duarte et al., 2012). MRS therefore allows more detailed analysis of 
the neurochemical mechanisms which underlie changes in neural 
activity. 
 
Importantly, MRS may serve as a translational bridge between 
findings in the rat model of hippocampal disinhibition and 
neurochemical findings in human patients. Localised MRS has been 
widely used in recent years to investigate changes in neuro-
metabolite concentrations in psychiatric disorders, such as 
schizophrenia (Poels et al., 2014, Wijtenburg et al., 2015). Studies of 
glutamine and glutamate concentrations in the prefrontal cortex of 
unmedicated schizophrenia patients have generally reported 
increases in glutamatergic metabolites (Kegeles et al., 2012, 
Theberge et al., 2007, Theberge et al., 2002, van Elst et al., 2005). 
However, a recent meta-analysis identified increased glutamate and 
glutamine in high risk individuals, but not in first episode psychosis 
or chronic patients (Merritt et al., 2016). In addition, Reid et al. 
(2019) reported decreased anterior cingulate cortex glutamate in first 
episode schizophrenia, although these patients were treated with 
antipsychotic medication. Notably, increased glutamatergic 
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metabolites in the anterior cingulate cortex were found to correlate 
with increased symptom severity (Egerton et al., 2018, Egerton et 
al., 2012), psychotic symptoms (Bustillo et al., 2014) and treatment 
resistance (Demjaha et al., 2014, Iwata et al., 2019, Mouchlianitis et 
al., 2016). Furthermore, an elevated glutamine/glutamate ratio has 
been observed in the prefrontal cortex of patients with schizophrenia 
(Bustillo et al., 2010, Wijtenburg et al., 2017), which suggests an 
increase in excitatory neurotransmission as increased levels of 
glutamine have been suggested to reflect increased 
neurotransmission (Marsman et al., 2013). Conversely decreased 
concentrations of glutamate have been observed in patients with 
chronic schizophrenia (Kumar et al., 2020, Liemburg et al., 2016, 
Natsubori et al., 2014, Rowland et al., 2013, Theberge et al., 2007). 
Reduced glutamate concentrations in chronic patients could be 
caused by longitudinal brain changes reflecting an excitotoxic 
mechanism (Miller et al., 2009) or the continued use of antipsychotic 
medication which has been associated with reduced brain glutamate 
(Egerton et al., 2017a).  
 
In addition to studies of glutamatergic metabolites, multiple studies 
have investigated the levels of GABA in the prefrontal cortex of 
patients with schizophrenia, although these findings have been 
inconsistent. Some studies reported increased GABA concentrations 
(Kegeles et al., 2012, Ongur et al., 2010), whilst others reported 
decreased or similar GABA levels compared to controls in both patient 
and ultra-high-risk populations (Marsman et al., 2014, Rowland et 
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al., 2012, Wenneberg et al., 2020) (for review see Egerton et al. 
(2017b). However, Modinos et al. (2018b) reported increased medial 
prefrontal GABA concentrations which correlated with increased 
hippocampal perfusion in individuals who develop psychosis. This 
suggests hippocampal hyperactivity could mediate alterations in 
neurotransmitter concentrations in the mPFC and that this may have 
functional consequences.  
 
In recent years, several studies in rodents have been performed to 
probe the effects of both systemic pharmacological manipulations and 
peripheral nerve stimulation on metabolite concentrations using MRS 
(Crofts et al., 2020, Just et al., 2013, Seuwen et al., 2015, Sonnay 
et al., 2017). Notably, Iltis et al. (2009) reported an increased 
glutamine/glutamate ratio in the mPFC after systemic administration 
of the NMDA receptor antagonist phencyclidine (PCP). In addition, a 
transient increase in glucose and corresponding decrease in lactate 
concentration was reported. The study by Iltis et al. (2009) suggests 
manipulations of excitatory neurotransmission can lead to 
measurable changes in the neurochemical profile of the mPFC. 
Similarly, systemic administration of the NMDA receptor antagonist 
ketamine, at sub anaesthetic doses, also increased glutamine within 
the PFC (Napolitano et al., 2014). This study also revealed a ketamine 
induced reduction in PFC GABA concentrations in socially isolated but 
not normally reared rats, which is a putative developmental model of 
schizophrenia. Importantly, systemic NMDA receptor antagonism 
may induce disinhibition and increase neural activation in several 
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brain regions, including the hippocampus and prefrontal cortex 
(Grunze et al., 1996, Homayoun and Moghaddam, 2007).  
 
Aims 
Here, we use MRS to examine the neurochemical impact of a brain 
site-specific manipulation using intra-cerebral drug microinfusion 
(hippocampal disinhibition by picrotoxin infusion) in a distal brain 
region (mPFC). We aimed to investigate the effect of ventral 
hippocampal disinhibition on the neurochemical profile of the mPFC. 
To do this we combined disinhibition of the ventral hippocampus by 
local picrotoxin infusion (as in previous chapters) and in vivo 1H MRS 
at 7 Tesla to measure neuro-metabolite concentrations in the mPFC. 
We hypothesised that ventral hippocampal disinhibition would 
increase metabolite concentrations that would reflect increased 
neurotransmission, including changes in the concentration of 












16 male Lister hooded rats (Charles River UK), weighing 270-360g 
prior to surgery (9-11 weeks old) were used in the present study, of 
which 14 contributed to the MRS data (for a sample size justification 
and reasons for exclusion of two rats, please see experimental design. 
Animal housing and husbandry were as described previously in 
chapter 2. 
 
Cannula implantation and verification of placements  
Ventral hippocampal cannula implantation was performed as 
described previously in chapter 2, but using MR compatible infusion 
guide cannula (PEEK, 26 gauge, 8.5mm below pedestal; Plastics One 
USA) and MR compatible nylon screws (Plastics One, USA). After 
surgery, rats were allowed at least 5 days of recovery before any 
further procedures were carried out. During this period, rats 
underwent daily health checks. At the end of the MRS experiments, 
rats were transcardially perfused with saline followed by 4% PFA and 
brains were extracted for verification of cannula placements.  
 
In vivo magnetic resonance spectroscopy combined with hippocampal 
microinfusions 
 
Animal preparation  
Rats were anaesthetised using isoflurane (5%) in a mixture of O2 and 
N2O (ratio: 0.33:0.66L/min). Rats were then transferred to a pre-
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warmed cradle and their heads were immobilised using a tooth bar 
and ear bars. Eye lubricant was used to prevent ocular drying during 
scanning, and temperature was controlled by a rectal thermal probe 
and maintained at 37±1°C body temperature via a water-pump 
system connected to tubing embedded in the base of the rat cradle. 
Respiratory rate was monitored to provide an index of anaesthetic 
depth, using an ERT control/gating module (Model 1032, SA 
Instruments, Stony Brook, USA) and isoflurane concentration was 
adjusted (1-2.5%) to maintain a stable respiration rate (60±10 
breaths per minute).  
 
Intracerebral microinfusion  
Stylets were replaced with MR compatible injectors (PEEK, 33-gauge; 
Plastics One, USA), which extended 0.5mm below the guide cannula 
tips into the ventral hippocampus. 1-µL syringes (Hamilton, USA) 
were connected to the infusion injector via flexible Teflon tubing 
(0.65mm OD x 0.12mm ID; BASi, UK). Injector and infusion tubing 
were filled with picrotoxin solution or saline before the injector was 
inserted into the guide cannula. To prevent leakage and drug diffusion 
before the infusion, the piston of the syringe was pulled back to draw 
up a 0.25-µL air “plug”, separating the infusion solution from the 
brain’s extracellular space. The movement of an air bubble, which 
was included in the tubing at the end where it was connected to the 
syringe, was monitored to ensure the solution had been successfully 
injected into the brain. The air plug (0.25 µl), plus a volume of 
0.5µl/side of either 0.9% sterile saline (control) or picrotoxin 
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(C30H34013; Sigma Aldrich, UK) in saline (150ng/µl/side) was infused 
bilaterally over the course of approximately 90secs. For further 
details of the timings of microinfusions in relation to the MRS 
measurements, see experimental design. 
 
1H MRS acquisition  
All experiments were undertaken using a Bruker Biospec 70/30 USR 
7T horizontal bore small animal scanner (Bruker, Germany). A 
surface reception coil (consisting of 4 coils) was placed over the 
prefrontal cortex. A quick gradient echo acquisition scan was 
performed to ensure the correct positioning of the area of interest, 
containing the medial prefrontal cortex, in the centre of the magnet 
(TE=6ms, TR=100ms). Anatomical reference images were obtained 
in three orthogonal planes using a rapid acquisition with relaxation 
enhancement (RARE) sequence (Hennig et al., 1986) (TR=5s, 
TE=25ms, TEeff=50ms, rare factor-8, flip angle: 180, matrix 
256x256 over 40x40mm) with a slice thickness of 1mm 
sagittal/dorso-ventral, 0.5mm coronal. A voxel of 2 x 2 x 2mm3 was 
positioned in the medial prefrontal cortex (mPFC) for the acquisition 
of MRS data (Fig. 8A). Subsequently, a phase difference map was 
calculated using a gradient echo sequence to map the homogeneity 
of the overall magnetic field which was used to enhance B0 
homogeneity. Local magnetic field homogeneity was adjusted within 
the region of interest by applying FASTMAP (Gruetter, 1993). The 
average water line width for all spectra was 8.72 (±0.51) Hz (full-
width half maximum) of the unsuppressed water peak across the 
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spectroscopy voxel. Localised proton MR spectroscopy was obtained 
using a Point Resolved Spectroscopy (PRESS) sequence (Bottomley, 
1987) over 34 minutes (acquisition parameters: TE= 13.5ms, 
TR=2000ms, spectral width of 4000Hz with 2048 points and 1024 
averages with eddy current compensation) after water suppression 
with variable power and optimized relaxation delays (VAPOR) (Tkáč 
et al., 1999).  
 
Processing of MRS data  
Quantitative analysis of the 1H MRS data was carried out using 
LCModel software (Provencher, 1993) in a fully automated pipeline 
(Fig. 8B demonstrates an example in vivo 1H MRS spectrum acquired 
from the voxel positioned within the mPFC). The average signal to 
noise ratio of the spectra as reported by LCModel was 8.93±1.46, and 
the analysis window chosen was 0.2-4.0 ppm. Data were fitted to a 
basis set containing 21 metabolites: alanine (Ala), aspartate (Asp), 
creatine (Cr), phosphocreatine (PCr), gamma-Aminobutyric acid 
(GABA), glucose (Glc), glutamine (Gln), glutamate (Glu), 
glycerophosphorylcholine (GPC), phosphorylcholine (PCh), 
glutathione (GSH), myo-inositol (m-Ins), lactate (Lac), n-acetyl 
aspartate (NAA), n-acetyl aspartate glutamate (NAAG), scyllo-inositol 
(Scyllo), taurine (Tau), total creatine (Cr+PCr), total choline 
(GPC+PCh), NAA+NAAG (tNAA) and glutamate + glutamine (Glx). 
Metabolite concentrations were determined as a ratio to total creatine 
(Cr+PCr). Cramér-Rao lower bounds (CRLB) was used as a measure 
of reliability of the metabolite quantification. For the majority of 
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metabolites a CRLB value under 20% was deemed to indicate reliable 
spectral fitting (Oz et al., 2014). For some metabolites that exist at 
low concentrations (Glc, Lac, Ala, Asp), measurements were included 
if the CRLB value did not exceed 50% (Just et al., 2013, Kreis, 2016), 
metabolites exceeding this range were excluded from further 
analysis.  
 
In most acquired spectra scyllo-inositol, GPC and NAAG were below 
the detection threshold (CRLB >20%) and excluded from analysis, 
whilst lactate was not fitted in twelve individual spectra, glucose in 
twelve spectra, alanine in eleven spectra, aspartate in one spectrum 
Figure 8. A: Localisation of the voxel of interest (2 x 2 x 2mm3) in the medial prefrontal 
cortex (red box) used for quantification of relative metabolite concentrations.  
B: Example spectrum generated with LCmodel. The bottom panel shows the original 
spectrum data, represented by the black line, and the LCmodel fitted spectrum shown 
in red. The top panel shows the residual error obtained after LCModel fitting (original 
data minus the fitted data). Labelled peaks indicate the following metabolites: Creatine 
+ phosphocreatine (Cr+PCr), Glutamate (Glu), Glutamine (Gln), myo-inositol (mI), 
Taurine (Tau), Total Choline (tCho), gamma-Aminobutyric acid (GABA), Glutathione 









and phosphocholine in six spectra. If the concentration of any 
metabolite was not measurable in any of the four spectra taken in the 
same rat (i.e. baseline and post infusion in both drug conditions), this 
rat was then excluded from analysis for this metabolite. The final 
numbers of rats contributing to the measurements, are indicated for 
all metabolites measured in table 3. 
 
Experimental design and analysis 
The effects of picrotoxin and saline infusions on MRS measurements 
were compared in a within-subjects design, where each rat received 
two hippocampal infusions, one with picrotoxin and one with saline, 
on different days and the testing order was counterbalanced using a 
cross-over design. Pre-infusion baseline spectra were acquired from 
the voxel positioned in the medial prefrontal cortex prior to intra 
hippocampal drug microinfusions. Intra-hippocampal drug infusions 
took place immediately following the completion of the baseline scan. 
Post infusion MRS acquisition was performed 10min following the end 
of hippocampal infusion; the timing of spectral acquisition was chosen 
based on electrophysiological measures to capture the peak effect of 
picrotoxin infusion (McGarrity et al., 2017). We aimed for a sample 
size of at least n=12 to give >80% power to detect an effect size of 
d=1 at a significance threshold of p=0.05, using pairwise 
comparisons (power analysis conducted with GPower 3.1 (Faul et al., 
2007). Two rats were lost prior to MRS acquisition due to loss of the 
cement/cannula head cap, before we reached the target sample size 
of n=12. As we house our rats in groups of 4, we added another batch 
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of 4 rats, resulting in a final sample size of n=14. Metabolite 
concentrations were analysed using a 2X2 repeated measures ANOVA 
with drug infusion condition (saline or picrotoxin) and time (pre-
infusion or post-infusion period) as within-subjects factors. In 
addition, we calculated difference scores, indicating the difference 
between pre-infusion and post-infusion concentrations in the saline 
and the picrotoxin condition. The difference score was produced by 
subtracting the concentration obtained from the pre-infusion baseline 
spectrum from the post-infusion concentration for each quantified 
metabolite. Statistical analysis of difference scores for each 
metabolite was performed using 2-tailed paired t-tests. Statistical 
significance was considered as p<0.05. All statistical analyses and 
graphs were produced using GraphPad prism (version 7, GraphPad 

















Cannulae tips were mapped onto coronal sections adapted from the 
Paxinos and Watson (2006) rat brain atlas. All cannulae tips were 
located between 4.8 and 6.3mm posterior to bregma within the 











Table 1 depicts the average concentration and corresponding CRLB 
values for the 17 metabolites quantified in this study before and after 
intra-hippocampal infusion of saline and picrotoxin. Most metabolites 
(Glu, Gln, Glx, m-ins, tCho, NAA, tNAA, tau, Cr, PCr) were quantified 
with a CRLB value of less than 15%, although glutathione, GABA and 
phosphocholine had CRLB values between 15 and 20%, which 
indicates reliable metabolite quantification (Cavassila et al., 2000, 
Cavassila et al., 2001, Oz et al., 2014). The quantification of alanine, 
aspartate, glucose and lactate was less reliable with a CRLB greater 
than 20%. 
Figure 9. Approximate position of 
infusion cannulae tips as verified by 
light microscopy. Placements were 
mapped onto coronal sections modified 
from the Paxinos and Watson rat brain 
atlas. Numbers on the right indicate 
distance from bregma and black dots 




Figure 10 shows the calculated difference score (post-infusion minus 
pre-infusion) for each of the metabolites measured in this study in 
both infusion conditions (saline vs. picrotoxin). Analysis of the 
difference scores revealed a significant decrease in GABA (t=2.845, 
df=13, p=0.0138) and a significant increase in myo-inositol 



















0.16±0.03 30.4±6.8 0.17±0.04 32.2±8.0 0.13±0.04 36.8±13.1 0.17±0.03 29.4±5.9 
Asp 
n=13 




0.29±0.05 18.6±3.8 0.33±0.06 16.4±3.0 0.34±0.06 15.5±3.7 0.31±0.05 16.4±3.7 
Glc 
n=4 
0.32±0.11 21.3±9.0 0.28±0.11 26.0±12.8 0.40±0.08 16.8±7.6 0.30±0.10 24.5±13.4 
Gln 
n=14 
0.60±0.11 11.5±2.7 0.58±0.08 11.9±2.6 0.63±0.10 10.6±3.1 0.57±0.12 11.7±3.4 
Glu 
n=14 
1.76±0.24 3.9±0.6 1.74±0.23 4.0±0.8 1.73±0.29 4.0±0.7 1.71±0.25 3.9±0.7 
Glx 
n=14 
2.35±0.31 4.1±0.6 2.32±0.27 4.1±0.7 2.36±0.37 3.9±0.8 2.28±0.34 4.0±0.7 
GSH 
n=14 




0.25±0.07 29.6±10.4 0.31±0.07 21.6±4.2 0.18±0.02 33.4±9.3 0.33±0.06 19.0±2.0 
m-Ins 
n=14 
0.72±0.06 7.4±1.7 0.71±0.09 7.7±1.9 0.74±0.08 6.9±2.3 0.79±0.09 6.5±1.9 
PCh 
n=8 
0.18±0.03 18.8±13.0 0.17±0.03 23.6±16.2 0.17±0.03 17.0±14.7 0.17±0.02 19.5±10.1 
tCho 
n=14 
0.23±0.03 5.3±1.0 0.22±0.03 5.2±0.8 0.24±0.03 7.2±8.4 0.23±0.02 6.5±5.6 
NAA 
n= 14 
1.02±0.07 4.1±0.5 1.03±0.07 4.4±0.7 1.00±0.09 4.1±0.9 1.01±0.10 4.1±0.9 
tNAA 
n=14 
1.15±0.09 4.5±0.7 1.16±0.09 4.4±0.5 1.15±0.13 5.1±3.1 1.17±0.09 5.3±2.8 
Tau 
n=14 
0.94±0.11 5.7±1.3 0.91±0.07 5.9±1.1 0.94±0.10 5.7±1.8 0.94±0.08 5.2±1.3 
PCr 
n=14 
0.52±0.06 12.7±1.6 0.51±0.09 13.6±6.3 0.55±0.10 12.6±6.1 0.56±0.05 11.4±3.4 
Cr 
n=14 
0.48±0.06 13.5±3.4 0.49±0.08 12.9±3.0 0.45±0.10 13.1±6.4 0.44±0.05 13.5±6.0 
Table 3. Average (mean ±SEM) concentration as a ratio to total creatine 
(phosphocreatine and creatine) and corresponding CRLB values for each metabolite 
measured using 1H spectroscopy for both saline and picrotoxin infusion groups before 






hippocampal picrotoxin infusion compared to saline infusion. No 
further significant differences between saline and picrotoxin 
conditions were observed for the differences sores of any of the other 
quantified metabolites (glutamate, glutamine, glutathione, glucose, 
lactate, N-acetylaspartate, phosphocholine, taurine, alanine, 
creatine, phosphocreatine, and aspartate) or the 
glutamine/glutamate ratio (All: t<1.78, p>0.149).  
Figure 10. Changes in mPFC neuro-metabolite concentrations induced by ventral 
hippocampal picrotoxin and saline infusion. Infusion-induced changes are expressed as 
differences scores, i.e. the difference between the pre-infusion concentrations (as a 
ratio to total creatine) and the post-infusion concentrations. Black bars represent the 
difference between pre and post saline infusion, white bars represent the difference 
between pre and post picrotoxin infusion. Data are depicted as mean (±SEM) of n=14. 
There was a significant difference in mPFC GABA and myo-inositol concentration 
between saline and picrotoxin groups (* indicates significant difference between saline 







We further investigated the changes in metabolite concentrations 
using a 2x2 (drug infusion x time point) ANOVA of metabolite/Cr+PCr 
concentrations before and after infusion in the saline and the 
picrotoxin infusion conditions. 
 
Consistent with the analysis of differences scores, this analysis 
revealed hippocampal picrotoxin significantly decreased mPFC GABA 
concentrations (Fig. 11A) and increased mPFC myo-inositol 
concentrations (Fig. 11B). The 2x2 ANOVA of GABA concentrations 
during the pre-infusion baseline and the post-infusion period revealed 
a significant interaction of drug infusion and time point (F (1, 13) 
=8.094, p=0.014, ω2=0.118). This interaction reflected that GABA 
concentration increased from pre-infusion baseline to post-infusion 
scan in the saline condition (F (1, 13) =6.842, p=0.021), whereas there 
was no significant change between pre-infusion baseline and post-
infusion scan in the picrotoxin condition (F (1, 13) =1.672, p=0.218). 
In other words, hippocampal picrotoxin infusions attenuated the 
increase of GABA from pre-infusion baseline to post-infusion scans 
that was evident in the saline infusion condition.  
 
The 2X2 ANOVA of myo-inositol concentrations revealed a significant 
interaction of infusion condition and time (F (1, 13) = 5.962, p=0.030, 
ω2 = 0.041). Simple main effect analysis demonstrates that myo-
inositol concentration significantly increased from pre-infusion 
baseline to post-infusion scan in the picrotoxin condition (F (1, 13) 
=9.535, p=0.009), whereas there was no significant difference 
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between pre-infusion and post-infusion myo-inositol concentrations 
in the saline condition (F (1, 13) < 1, p>0.55). The 2X2 ANOVA of all of 
the other metabolite concentrations or of the glutamine/glutamate 
ratio did not reveal any additional interactions or main effects 









The 2x2 ANOVA also revealed significant overall differences between 
baseline and post infusion measurements, regardless of infusion 
conditions, for several metabolites. This included a significant 
increase in lactate in the post-infusion compared to pre-infusions 
measurements (Fig. 12A), reflected by a significant effect of time (F 
(1, 4) =26.20, p =0.007) but no effect of drug infusion condition or 
interaction of these factors (Drug x Time interaction: F (1, 4) =3.176, 
Figure 11. Concentrations (mean ± SEM) of GABA (A) and myo-inositol (B) as 
a ratio to total creatine (Cr+PCr) for both drug infusion conditions, saline (black) 
and picrotoxin (grey), measured before and after hippocampal drug infusion. 
GABA concentrations increased between pre and post infusion in the saline 
condition but reduced in the picrotoxin group after infusion. The concentration of 
myo-inositol remained stable after saline infusion, whilst increasing in the 





p =0.149, drug effect: F (1, 4) =0.45, p =0.539). It should be noted 
that it was not possible to fit lactate from all of the acquired spectra: 
data from nine rats CRLB values for lactate above 50% and were 

















Figure 12. Concentrations (mean ± SEM) of lactate (A), aspartate (B) and total 
choline (C) as a ratio to total creatine (Cr+PCr) for both drug infusion conditions, 
saline (black) and picrotoxin (grey), measured before and after hippocampal drug 
infusion. The overall concentration of lactate significantly increased between pre 
and post measurements with no difference present between infusion conditions. 
Concentrations of total choline and aspartate in both infusion conditions (saline 






The concentrations of both aspartate (Fig. 12B) and tCho (Fig. 12C) 
were significantly lower post infusion compared to pre infusion (tCho: 
F (1, 13) =8.69, p=0.012; Asp: F (1, 12) =9.24, p=0.01) with no effect of 
drug group or significant interaction of these factors (tCho: Drug x 
Time interaction: F (1, 13) =0.15, p =0.71, drug effect: F (1, 13) =0.66, 
p =0.43; Asp (Drug x Time interaction: F (1, 12) =0.58, p =0.48, drug 
effect: F (1, 12) =1.2, p =0.30). These changes therefore reflect 
baseline drift from the pre-infusion to the post-infusion 
measurement.  
 
In addition, glucose was not fitted from the acquired spectra prior to 
intra-hippocampal infusion, according to our exclusion criteria, in two 
animals in the saline group and two animals in the picrotoxin group. 
Interestingly, after the hippocampal infusion, however, glucose was 
not fitted for seven animals in the picrotoxin condition, whilst in only 
3 animals that received saline it was not possible to accurately fit 
glucose. This indicates that glucose was fitted with less precision after 
picrotoxin infusion compared to saline infusion, suggesting a possible 
decrease in glucose concentrations by hippocampal picrotoxin. 
However, the lack of sensitivity to gain accurate measurements of 








This study investigated the effect of picrotoxin induced ventral 
hippocampal disinhibition on the concentrations of neuro-metabolites 
within the mPFC, using short-TE 1H MRS in anaesthetised rats. Using 
this method, we were able to compare the concentration of seventeen 
metabolites before and after hippocampal picrotoxin infusion. The 
results of this study revealed a significant decrease in mPFC GABA 
and significant increase in mPFC myo-inositol concentrations caused 
by hippocampal picrotoxin, compared to saline infusion. Hippocampal 
disinhibition did not clearly affect the concentrations of any of the 
other measurable metabolites in this study, including glutamate and 
glutamine, and also did not affect the glutamine/glutamate ratio. 
Although direct comparison with other studies is difficult due to 
methodological differences, the concentrations as a ratio to total 
creatine, and CRLB values of neurometabolites including glutamate, 
glutamine, myo-Inositol, taurine and NAA are consistent with those 
of several studies using MRS in rodent models at similar magnetic 
field strengths (Napolitano et al., 2014, Jupp et al., 2020, Vernon et 
al., 2015, Zhou et al., 2012). For example, metabolites including 
glutamate and NAA show comparatively high concentrations 
compared to glutamine, glutathione and GABA. Therefore, using MRS 
in combination with intra-cerebral pharmacological manipulations it 
was possible to reliably quantify alterations in concentration of a 





Hippocampal disinhibition increased prefrontal myo-inositol 
Ventral hippocampal disinhibition caused a significant increase in 
myo-inositol concentration in the mPFC. Myo-inositol is often seen as 
a marker of glial cells (Brand et al., 1993) and is considered as a 
proxy for neuro-inflammation (Chang et al., 2013), although it does 
have a diverse role in several processes including autophagy (Sarkar 
and Rubinsztein, 2006), osmotic regulation (Fisher et al., 2002) and 
intracellular signalling transduction via the phosphatidyl-inositol (PI) 
pathway (Berridge, 2009, Kim et al., 2005). However, the distribution 
of myo-inositol in the brain is not well understood and while it appears 
to be present in greater quantities in glial cells (Brand et al., 1993), 
myo-inositol is also present in neuronal cells (Fisher et al., 2002, 
Novak et al., 1999). Brain myo-inositol can be regulated by several 
processes including by de novo synthesis from glucose-6-phosphate 
(G-6-P), mediated by myo‐inositol‐3‐phosphate synthase, recycling 
via the PI pathway, and uptake from cerebral blood flow via plasma 
membrane inositol transporters (Rae, 2014). Therefore, increased 
mPFC myo-inositol seen in this study could be due to several 
mechanisms including, increased uptake from cerebral blood supply, 
changes in osmotic regulation, and increased recycling via the PI 
cycle. However, only around 3% of brain myo-inositol is taken up 
from the blood stream (Spector, 1988). and it can take several hours 
for significant uptake of myo-inositol from the bloodstream to the 
brain (Patishi et al., 1996). Therefore, it is unlikely that uptake from 
cerebral blood flow accounts for the increased myo-inositol 
concentrations caused by hippocampal disinhibition in this study. It is 
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also unlikely that increased mPFC myo-inositol concentration caused 
by hippocampal disinhibition reflect changes in osmotic regulation as, 
in the present study, there were no corresponding changes in NAA 
concentration, which also acts as an intracellular osmolyte (Taylor et 
al., 1995). Importantly, the majority of brain myo-inositol is derived 
from recycling inositol containing compounds as part of the PI cycle 
and de novo synthesis from G-6-P (Colodny and Hoffman, 1998, 
Fisher et al., 1992). Considering the major source of myo-inositol in 
the brain is produced by the PI cycle and many neurotransmitter 
receptors, including glutaminergic, serotonergic, adrenergic, 
dopaminergic and cholinergic, are coupled to the PI secondary 
messenger system (Fisher et al., 1992) it is possible the increase in 
myo-inositol is caused by increased neurotransmission. It has been 
shown previously that NMDA can potentiate muscarinic receptor 
stimulated PI turnover (Vadnal and Bazan, 1987) and 
electroconvulsive stimulation induces IP3 accumulation (Challis et al., 
1994), which suggests increased neural activity drives increases in 
myo-inositol concentrations. Therefore, the increase in myo-inositol 
caused by hippocampal disinhibition likely reflects increased PI 
turnover which is driven by increased mPFC neurotransmission. 
However, using MRS does not allow for the resolution of metabolites 
at a cell type specific or metabolic pathway level and, therefore, it is 
not possible to probe specific mechanisms or pathways, which control 




Whilst it is unclear which mechanism drives increased myo-inositol 
concentration in the mPFC, this finding is interesting considering 
changes in myo-inositol have been reported in schizophrenia. 
Increased myo-inositol concentrations have been reported in the 
striatum of first episode psychosis patients (de la Fuente-Sandoval et 
al., 2013, Plitman et al., 2016), although a recent meta-analysis of 
mPFC myo-inositol levels in schizophrenia found a small overall 
reduction (Das et al., 2018). However, reduced PFC myo-inositol is 
correlated with depressive symptoms in patients with schizophrenia 
and major depressive disorder (Chiappelli et al., 2015, Coupland et 
al., 2005). Therefore, the finding of reduced myo-inositol in the PFC 
may not be exclusive to schizophrenia. Overall, it seems that changes 
in myo-inositol metabolism might have implications in the onset and 
treatment of psychiatric disorders. Recently, Jupp et al. (2020) 
identified a functional relationship between ventromedial PFC myo-
inositol concentration and the control of behavioural impulsivity, 
whereby rats with higher impulsivity have reduced myo-inositol 
concentrations compared to low impulsive rats. Therefore, the 
increase in mPFC myo-inositol caused by ventral hippocampal 
disinhibition could have functional consequences related to 
psychiatric disorders, although the functional effects of this alteration 
in metabolism are yet to be examined.  
 
Hippocampal disinhibition decreased prefrontal GABA  
We also found a significant change in mPFC GABA concentration 
following hippocampal picrotoxin, compared to saline, infusion. The 
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difference between infusion conditions was mostly mediated by an in 
increase in GABA concentration from pre-infusion baseline to post-
infusion spectra in the saline condition, which was absent in the 
picrotoxin condition. The increase in GABA from baseline in the 
control condition is likely due to the effect of isoflurane anaesthesia 
on the GABAergic pathway. Basal GABA release is increased in cortical 
nerve terminals by isoflurane anaesthesia (Westphalen and 
Hemmings, 2006), and the overall concentration of GABA in the brain 
is increased by isoflurane as measured using in vivo MRS (Boretius et 
al., 2013). However, in the picrotoxin condition, there was no 
increase in GABA concentration from the pre-infusion to the post-
infusion period, if at all, the picrotoxin infusion caused a small 
numerical (albeit non-significant) reduction in GABA concentration. 
This suggests that hippocampal disinhibition negatively modulates 
prefrontal GABA concentrations. Consistent with this finding Iltis et 
al. (2009) and Napolitano et al. (2014) also reported decreased PFC 
GABA concentrations caused by systemic administration of NMDA 
antagonists. NMDA receptor antagonism reduces GABAergic 
interneuron activity, subsequently leading to increased pyramidal cell 
activity (Homayoun and Moghaddam, 2007). Therefore, the negative 
modulation of GABA concentrations by hippocampal disinhibition in 
the present study may also reflects changes in the 
excitatory/inhibitory balance within the mPFC.  
 
GABA is synthesised from glutamate by glutamate decarboxylase 
(GAD 65/67) and is taken up by both GABA neurons and astrocytes 
137 
 
after its release during neurotransmission (Waagepetersen et al., 
2007). In neurons, GABA then either re-enters vesicles for 
neurotransmission or is recycled via the TCA cycle into glutamate and 
subsequently converted to GABA. Astrocytic GABA is also recycled via 
the TCA cycle into glutamate, which is converted to glutamine and 
released into the extracellular space and then taken up by either 
glutamatergic or GABAergic neurons (Bak et al., 2006, Rae et al., 
2003). Two pools of GABA exist in neurons, which are cytoplasmic or 
vesicular, and most GABA under basal conditions is thought to be in 
the cytoplasmic pool and is synthesised by GAD67 which is widely 
localised across the neuron (Dericioglu et al., 2008, Maddock and 
Buonocore, 2012). However, GAD65, which is localised to nerve 
terminals, can be upregulated to increase production of the vesicular 
GABA pool (Patel et al., 2006). 
 
How much of the vesicular pool can be detected using MRS is unclear, 
and it is likely that GABA measured using MRS mainly corresponds to 
the large cytoplasmic pool (Maddock and Buonocore, 2012). 
Therefore, reductions in GABA concentrations as measured using MRS 
likely reflect a reduction in the overall pool of cytoplasmic GABA. The 
functional significance of this pool is not clear; it could contribute to 
replenishing vesicular GABA stores, although some evidence suggests 
the cytoplasmic GABA pool could be an important source for 
extrasynaptic GABA release, which plays a role in mediating tonic and 
phasic GABA activity (Dericioglu et al., 2008, Farrant and Nusser, 
2005, Wu et al., 2007). However, the reduction in GABA caused by 
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hippocampal disinhibition could reflect a reduction in cytoplasmic 
GABA pools caused by an increase in prefrontal metabolism, whereby 
GABA recycled via the TCA cycle is used in cellular metabolic 
processes.  
 
Hippocampal disinhibition did not affect glutamate and glutamine 
In contrast to our hypothesis, we observed no changes in 
glutamatergic metabolism, reflected by stable levels of glutamine, 
glutamate and the ratio of these metabolite after picrotoxin infusion. 
Previous studies in rats reported changes in glutamate metabolism 
after neural manipulations, including increased mPFC glutamine 
concentrations caused by systemic administration of either PCP or 
ketamine (Iltis et al., 2009, Napolitano et al., 2014). However, the 
use of high doses of systemic PCP and ketamine used by Iltis et al. 
(2009) and Napolitano et al. (2014) make direct comparison to this 
study challenging. Systemic administration of NMDA antagonists can 
cause increased activation of pyramidal cells within the PFC, but may 
also affect distal brain regions and thus metabolite changes caused 
by systemic NMDA antagonists may be related to activation changes 
in several regions.  
 
We also might have expected to identify reductions in glucose 
concentration similar to that reported in human MRS studies, where 
visual stimulation leads to reductions in glucose concentrations 
(Mangia et al., 2009). This decrease in glucose concentration is linked 
to increased utilisation of glucose (Mangia et al., 2009), and 
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glutamate release is strongly correlated with glucose oxidation (Hyder 
and Rothman, 2012). In addition, Just and Faber (2019) reported 
decreased glucose concentrations within the somatosensory cortex 
upon forepaw stimulation in rats, suggesting increased cortical 
activity causes transient reductions in overall glucose concentrations. 
Furthermore, increased lactate concentrations have been reported 
under trigeminal nerve stimulation within the barrel cortex of rats 
(Just et al., 2013). In contrast, Iltis et al. (2009) reported transient 
increases in mPFC glucose concentrations with corresponding 
reductions in lactate after systemic PCP administration. However, 
systemic PCP administration can disrupt glucose utilisation 
(Weissman et al., 1987), which likely accounts for these conflicting 
findings. In line with a negative impact of hippocampal picrotoxin 
infusion on mPFC glucose, we were unable to quantify glucose in the 
majority of rats after picrotoxin infusion. This finding suggests an 
overall decrease in glucose concentration caused by hippocampal 
disinhibition as the levels of glucose were below the detection 
threshold. However, as it was not possible to reliably quantify glucose 
from all spectra this limits the conclusions concerning the effect of 
hippocampal disinhibition on mPFC glucose concentrations.  
 
One major difference between this study and that of Iltis et al. (2009) 
is their use of higher magnetic field strengths (9.4T), which may have 
enabled more accurate quantification of glucose and lactate as 
reflected by lower CRLB values (<20%). Although Just et al. (2013) 
achieved CRLB values more comparable to those achieved in this 
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study, between 30-40%, for the quantification of glucose and lactate 
at 9.4T. This was, however, achieved with much shorter acquisition 
times (10mins) compared with the acquisition time used in this study 
(34mins). Therefore, to achieve reliable measurements of glucose 
and lactate concentrations use of spectral editing techniques (de 
Graaf et al., 2000, Lange et al., 2006) and higher magnetic field 
strengths are necessary. This notwithstanding, those spectra which 
enabled the quantification of lactate exhibited a significant increase 
in concentration over time, with no difference between drug infusion 
groups. This finding is consistent with the known effects of isoflurane 
anaesthesia, which has been shown to increase baseline lactate 
concentrations (Boretius et al., 2013, Valette et al., 2007).  
 
Technical limitations  
Whilst using 1H MRS is a powerful tool which allows for the 
quantification of a complex neurochemical profile and possible direct 
translation between pre-clinical and clinical studies, the use of 
anaesthesia is a confounding factor which has to be considered. The 
use of anaesthesia is necessary when using rodent models for MRS 
acquisition to remove movement artefacts and reduce the stress of 
restraint and significant noise generated by MR scanners (Haensel et 
al., 2015). However, inhalant anaesthetic regimens such as isoflurane 
can modulate basal neuronal activity, modify neurovascular coupling 
and reduce cerebral metabolic consumption of oxygen and glucose 
(Alkire et al., 1997, Masamoto et al., 2007, Masamoto and Kanno, 
2012, Toyama et al., 2004). In addition, isoflurane has the potential 
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to impact the neurochemical profile measured by MRS (Boretius et 
al., 2013). Therefore, general anaesthesia used during MRS 
acquisition could mask infusion related effects on neuronal activity 
and subsequent changes in metabolism confounding the analysis of 
spectroscopy data. Nevertheless, previous studies in rodents have 
identified changes in neuro-metabolites using acute pharmacological 
manipulations (albeit systemic injections) under anaesthesia (Iltis et 
al., 2009, Napolitano et al., 2014), and we see some moderate 
changes in the neurochemical profile acquired under isoflurane in this 
study. In addition to anaesthesia related effects on neural activity and 
metabolism, the acquisition of data from the entire PFC may have 
impacted the findings from this study. Our previous brain-wide SPECT 
imaging experiments (chapter 3) revealed significantly increased 
neural activation only in small sub-regions of the mPFC, including the 
anterior cingulate cortex and the most ventral mPFC. However, the 
voxel positioning in the mPFC used for MRS acquisition covers a 
heterogeneous region containing ventral and dorsal prefrontal 
regions. The duration of 1H MRS acquisition required (~34mins) to 
achieve sufficient signal to noise for the accurate quantification of 
neuro-metabolites prevented the analysis of multiple VOIs within the 
mPFC. Therefore, specific localised changes in metabolism in 
individual sub regions might not be revealed across the overall voxel 







In summary, using 1H MRS allowed for the non-invasive exploration 
of the effect of ventral hippocampal disinhibition in the mPFC. In this 
study we were able to reliably measure a number of neuro-
metabolites in combination with intra-cerebral drug infusion. 
Picrotoxin infusions into the ventral hippocampus increased myo-
inositol and decreased GABA concentration in the mPFC, whilst having 
little effect on the rest of the measured neurochemical profile. The 
cellular mechanisms which cause these changes are unclear, however 
the findings of this study suggests aberrant hippocampal function 
may contribute to changes in GABA and myo-inositol which have been 
















General discussion   
The work in this thesis addressed the effect of hippocampal 
disinhibition (i.e. reduced inhibitory GABA transmission) on cognitive 
deficits related to the positive symptoms of schizophrenia and on 
neural activity within and beyond the hippocampus. Clinical imaging 
studies have shown that hippocampal hyperactivity is a key feature 
of psychiatric disorders, including schizophrenia, and is thought to be 
caused by dysfunctional inhibitory neurotransmission (Heckers and 
Konradi, 2015). In addition, hippocampal hyperactivity is correlated 
with the severity of the positive symptoms of schizophrenia and the 
progression to psychosis (Schobel et al., 2013). Therefore, disrupted 
hippocampal GABA transmission could cause hippocampal 
hyperactivity and disrupt neural circuits leading to the onset of 
psychosis. To determine the neural and behavioural effects of 
hippocampal disinhibition we combined pharmacological manipulation 
of hippocampal GABA transmission, behavioural testing and 
neuroimaging approaches. Overall, the key findings of this project 
demonstrate hippocampal disinhibition had no effect on latent 
inhibition, but disrupted aversive conditioning; caused prominent 
metabolic hyperactivity in the hippocampus around the site of drug 
infusion, plus marked activation changes in projection sites as 
measured by SPECT; and caused moderate reductions in prefrontal 




To explore the relationship between hippocampal disinhibition and 
psychosis symptoms we performed two experiments using a 
conditioned emotional response paradigm to test the effects of 
hippocampal disinhibition on aversive conditioning and its latent 
inhibition (chapter 2). Aberrant allocation of salience to irrelevant 
stimuli is thought to be the psychological process which causes 
delusions and hallucinations (Kapur, 2003), and latent inhibition is 
commonly used in preclinical research to model such deficits (Weiner 
and Arad, 2009). In the first latent inhibition experiment we 
performed ventral hippocampal infusions prior to the pre-exposure 
and conditioning phases of the CER paradigm. The paradigm 
generated robust LI in controls, whilst ventral hippocampal picrotoxin 
infusions disrupted conditioning to the light cue as reflected by 
reduced fear conditioning in the non-pre-exposed animals, which 
abolished LI in these rats. Ventral hippocampal disinhibition also 
disrupted contextual fear conditioning compared to controls. 
However, we found no evidence for disrupted LI due to a ceiling effect 
of conditioning. These findings are in agreement with previous studies 
which have shown ventral hippocampal hyperactivity disrupts cue and 
contextual conditioning (Zhang et al., 2001) and suggest that 
hippocampal disinhibition may contribute to the impaired aversive 
conditioning that has been reported in patients with schizophrenia 
(Jensen et al., 2008).  
 
Following on from this we carried out a second LI experiment, in 
which we performed hippocampal infusions prior to pre-exposure 
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only, which would remove any detrimental effect of disrupted 
conditioning caused by ventral hippocampal disinhibition at 
conditioning. Ventral hippocampal infusion of picrotoxin prior to pre-
exposure resulted in a similar level of conditioning to that in saline 
infused animals and thus latent inhibition was unaffected. These data 
suggest that ventral hippocampal disinhibition disrupts associative 
processing, reflected by reduced cue and contextual conditioning, but 
does not cause deficits in LI, at least not by disrupting attention or 
salience processing during pre-exposure. Whilst we found no 
evidence for the disruption of LI by hippocampal disinhibition, future 
studies are necessary to further understand the effects of 
hippocampal hyperactivity on salience processing. One possible 
future experiment would be to use an appetitive LI paradigm which 
would remove the confounding effects of hippocampal disinhibition at 
conditioning and allow for the evaluation of disrupted hippocampal 
activity on the processing of irrelevant stimuli.  
 
To investigate the relationship between dysfunctional GABA 
transmission and neural activation patterns within and beyond the 
hippocampus we used brain-wide SPECT imaging. This technique 
allows the measurement of spatial patterns of cerebral blood flow, 
which reflects regional neural activity (Oelschlegel and Goldschmidt, 
2020). The findings from our whole-brain neuroimaging analysis 
(chapter 3) demonstrate that ventral hippocampal disinhibition 
causes neural activation changes within local hippocampal circuits 
and in a range of distal sites to the drug infusion site. The metabolic 
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hyperactivity seen in the ventral hippocampus after picrotoxin 
infusion resembles the anterior metabolic hyperactivity seen in 
schizophrenia, and thus provides evidence for a causative relationship 
between disrupted GABAergic function and hippocampal neural 
hyperactivity (Heckers and Konradi, 2015). In addition, ventral 
hippocampal disinhibition caused a significant reduction in neural 
activity within the dorsal hippocampus, which could have significance 
when considering the impact of ventral hippocampal hyperactivity on 
contextual fear conditioning as shown in chapter 2. This deactivation 
also resembles deactivation of the posterior hippocampus 
accompanied by anterior hippocampal hyperactivity seen in patients 
with schizophrenia (Ragland et al., 2017). Furthermore neural 
activation changes were seen across cortical and subcortical sights 
which might have relevance to the disruption of cognitive functions in 
psychiatric disorders. In particular, hippocampal disinhibition caused 
significant increases in neural activity within regions of the prefrontal 
cortex consistent with anatomical connectivity between the two 
regions. Significantly, aberrant hippocampal-prefrontal connectivity 
may have functional significance as hippocampal disinhibition 
disrupts prefrontal-dependent attentional processes (McGarrity et al., 
2017).  
 
We also observed strong increases in neural activity within the medial 
and lateral septum, which are again consistent with strong functional 
and anatomical connectivity (Muller and Remy, 2018, Risold and 
Swanson, 1997). In addition, hippocampal infusion of picrotoxin 
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induced neural activation changes within olfactory regions including 
the piriform cortex and anterior olfactory nucleus. Olfactory deficits 
are present in early stage schizophrenia and preclinical evidence has 
demonstrated a link between olfactory processing and ventral 
hippocampal circuits (Aqrabawi et al., 2016, Moberg et al., 2014). In 
addition, hippocampal disinhibition also caused significant 
hyperactivity of the lateral hypothalamus, which could have particular 
importance considering hippocampal-hypothalamic circuits are 
implicated in the modulation of anxiety (Jimenez et al., 2018).  
 
Following on from the SPECT studies, we investigated the neuro-
metabolic effects that are associated with mPFC neural activation 
caused by ventral hippocampal disinhibition. To this end, we used 1H 
MRS in combination with hippocampal picrotoxin infusions (chapter 
4). To the best of our knowledge, there are currently no reported 
studies which have performed site-specific neuronal manipulations at 
a distal region to the area of MRS measurements. This technique 
allows for the measurement of a neurochemical profile including 
neurotransmitters and energy metabolites. Overall, we were able to 
robustly acquire a neurochemical profile comparable to previous 
rodent studies. This study revealed hippocampal disinhibition causes 
increased myo-inositol within the mPFC. As discussed in Chapter 4, 
this finding may reflect increased recycling of intracellular messenger, 
which is consistent with increased cellular activity. We also found 
some evidence for a reduction in mPFC GABA. This change was in part 
mediated by an increase in GABA concentration in the control group, 
148 
 
probably due to changes in baseline GABA caused by isoflurane 
anaesthesia (Boretius et al., 2013). However, this increase was not 
present in the picrotoxin infusion group, suggesting hippocampal 
disinhibition negatively modulates mPFC GABA concentrations 
possibly by depletion of the overall metabolic pool of GABA. However, 
hippocampal disinhibition had little effect on the remaining neuro-
metabolites measured in this study including glutamate containing 


















Ventral hippocampal neural disinhibition causes associative 
processing deficits, reflected by reduced cue and contextual 
conditioning, and wide-spread neural activation changes both within 
and beyond the hippocampus. The findings from this study provide 
evidence of a causative relationship between disrupted GABA 
transmission and hippocampal hyperactivity which is a key feature of 
schizophrenia pathophysiology (Heckers and Konradi, 2015). In 
addition neural activation changes at hippocampal projection sites 
could help to explain some of the behavioural and cognitive deficits 
caused by hippocampal disinhibition, including attentional 
impairments, locomotor hyperactivity and fear conditioning deficits 
(Bast et al., 2001a, McGarrity et al., 2017). Future experiments would 
be important to investigate the functional consequences of changes 
in neural activation caused by aberrant drive of hippocampal 
projections. Whilst we reported disrupted cue and contextual 
conditioning mediated by hippocampal disinhibition we found no 
evidence for an effect on LI. Further studies are necessary to 
understand the effects of hippocampal disinhibition on salience and 
attentional processing, considering the hypothesised link between 
dysfunctional hippocampal activity and psychosis (Katzel et al., 
2020). Overall this work adds to the idea that hippocampal neural 
disinhibition can disrupt behaviours relevant to psychiatric disorders 
by disrupting neural activity both locally within the hippocampus and 
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I  
A role for the nucleus accumbens in the hippocampal 
learning-behaviour translation  
Adam Seaton1, Rebecca Hock1, Miriam Gwilt1, Stuart Williams1, 
Charles Greenspon2, Robert Mason2, Tobias Bast1  
1University of Nottingham, Psychology, Nottingham, United Kingdom  
2University of Nottingham, Life Sciences, Nottingham, United 
Kingdom  
 
The hippocampus is required for important types of rapid everyday 
learning, including place learning. However, the pathways via which 
hippocampal place learning is translated into behaviour remain to be 
determined. The intermediate hippocampus is critical for the 
hippocampal learning-behaviour translation and combines neural 
substrates of accurate place encoding with links to prefrontal and 
subcortical behavioural control sites, which may contribute to this 
translation(Bast et al.,2009,PLoSBiol; Bast,2011,CurrOpinNeurobiol). 
The nucleus accumbens (NAc) is a main candidate due to strong 
hippocampo-NAc projections that have been implicated in behaviour 
based on place memory (Humphries & Prescott, 2010, Prog 
Neurobiol). To examine the role of the NAc, we combined functional 
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inhibition (via microinfusion of the GABA agonist muscimol) with 
measurements of behavioural performance based on hippocampus-
dependent rapid place learning using the watermaze delayed-
matching-to-place (DMP) test (Bast et al., 2009). Electrophysiological 
and sensorimotor experiments (locomotor activity, startle 
response/prepulse inhibition) showed that muscimol (125-250ng/0.5 
μl/side) reduced NAc neuron firing around the infusion site by about 
50% and caused, if at all, only moderate sensorimotor effects. 
Watermaze Experiment 1, testing the impact of NAc muscimol within-
subjects, supported that the NAc is required for DMP performance; 
however, there appeared to be a carry-over effect, with NAc muscimol 
eroding the typical DMP search strategy on subsequent test days, 
possibly reflecting that NAc is required to reinforce the strategy. 
Watermaze Experiment 2, using a between-subjects design, 
confirmed that NAc muscimol impairs expression of hippocampus-
dependent rapid place learning on the DMP test. Overall, these 
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Theme: Animal studies: Pharmacology of learning and memory - part 
I  
Too little and too much: impact of functional inhibition and 
disinhibition of the medial prefrontal cortex on cognitive 
flexibility assessed using an operant strategy-shifting task  
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1University of Nottingham UK, School of Psychology, Nottingham, 
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Attentional performance requires balanced medial prefrontal cortex 
(mPFC) activity, with functional inhibition or disinhibition (by micro-
infusion of GABA agonist muscimol or antagonist picrotoxin, 
respectively) causing impairments (Pezze et al., 2014, J Neurosci). 
Cognitive flexibility has also been suggested to require balanced 
mPFC activity (Brady & Floresco, 2016, JoVE). To confirm this, we 
examined how mPFC muscimol and picrotoxin affect cognitive 
flexibility in Lister-hooded rats, using an operant strategy-shifting 
task involving shifts from egocentric-spatial to cue light-based 
responses or vice versa (Brady&Floresco,2016). Remarkably, Lister-
hooded rats (irrespective of infusion) required three times as many 
trials compared to previous studies in other strains to shift from 
egocentric to cue light-based responses (Brady & Floresco, 2016). 
These slow shifts were unaffected by the prefrontal manipulations. 
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However, disinhibition, but not inhibition, impaired egocentric-
response expression and increased trial omissions, showing that 
regional neural disinhibition can disrupt functions not normally 
requiring the disinhibited region (Bast et al., 2017, BrJPharmacol). 
Additional behavioural studies showed that although Lister-hooded 
rats struggled to shift from egocentric to cue-based responses, they 
readily acquired cue-based responses when they had not first been 
trained the egocentric strategy. Moreover, they then readily shifted 
from cue-based to egocentric strategy, and could perform egocentric-
response reversals. However, there was always a higher shift-cost for 
egocentric-to-cue than for cue-to-egocentric shifting. Overall, 
although Lister hooded rats readily acquired both strategies, they 
overcame the egocentric strategy very slowly, and this slow strategy 
change was not mPFC dependent. Contrastingly, rats readily 
performed cue-to-egocentric-strategy shifts; we are currently 
examining the impact of mPFC functional inhibition and disinhibition 
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Poster number: PM028   
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Too little and too much: impact of functional inhibition and 
disinhibition of the medial prefrontal cortex on behavioural 
flexibility assessed using an operant strategy-shifting task 
Rebecca Hock1, Stuart Williams1, Miriam Gwilt1, Mr Adam Seaton1, 
Sara Gonçalves2, Stan B. Floresco3, Paula M. Moran1, Tobias Bast1  
1School of Psychology, The University Of Nottingham, Nottingham, 
United Kingdom, 2School of Life Sciences, The University Of 
Nottingham, Nottingham, United Kingdom, 3Department of 
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Attentional performance requires balanced medial prefrontal cortex 
(mPFC) activity, with functional inhibition or disinhibition by micro-
infusion of the GABA agonist muscimol or antagonist picrotoxin, 
respectively, causing impairments (Pezze etal.,2014,JNeurosci). 
Aspects of behavioural flexibility, linked to the mPFC and local GABA 
transmission (Brady&Floresco,2016,JoVE), may also require balanced 
mPFC activity. We examined how mPFC muscimol (62.5ng/side) and 
picrotoxin (300ng/side), as compared to saline control infusions, 
affect behavioural flexibility in male Lister Hooded rats, using an 
operant strategy-shifting task. The task involved ‘shifts’ (across three 
sessions) from a spatial-response condition, where food reward was 
associated with left or right lever responses, to a cue light-based 
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response condition, where food reward was associated with panel 
light illumination, or vice versa (Brady&Floresco,2016)(see Figure). 
Trials to criterion and percentage of correct responses, omissions and 
errors (perseverative or never reinforced) were analysed by ANOVA 
using infusion group as between-subjects factor and, if appropriate, 
shift session as within-subjects factor. Fisher's LSD test was used for 
post-hoc comparisons. Remarkably, irrespective of infusion, to shift 
from spatial-response to cue light-based responses, Lister hooded 
rats required three times as many trials as reported in previous 
studies in other strains (e.g. Brady&Floresco,2016). These slow shifts 
were not impaired by mPFC inhibition or disinhibition. However, in 
addition to increasing trial omissions, disinhibition impaired spatial-
response expression and, during shifts, reduced perseveration of the 
spatial-response condition. Although Lister-Hooded rats struggled 
with spatial-response-to-cue-response shifts, they readily acquired 
cue-based responses when they had not first been trained in the 
spatial-response condition. Moreover, they then readily performed 
cue-to-spatial-response-strategy shifts. Interestingly, there was a 
strong trend for mPFC disinhibition to slow down the cue-to-spatial-
response-shift, with picrotoxin infused rats showing a lower 
percentage of correct responses than saline-infused rats during shift 
session 2. In conclusion, although Lister hooded rats readily acquired 
both spatial-response and cue strategies they were slow to shift from 
the spatial-response strategy. This was unaffected by mPFC inhibition 
or disinhibition. In contrast, they readily performed a cue-to-spatial-
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response-strategy shift, and prefrontal functional disinhibition, but 
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The hippocampus is required for rapid place learning, but the 
pathways via which hippocampal place learning is translated into 
behaviour remain to be determined. The intermediate hippocampus 
is critical for the hippocampal learning-behaviour translation and 
combines neural substrates of accurate place encoding with links to 
prefrontal and subcortical behavioural control sites, which may 
contribute to this translation (Bast et al.,2009,PLoSBiol; 
Bast,2011,CurrOpinNeurobiol). The nucleus accumbens (NAc) is a 
main candidate due to strong hippocampo-NAc projections that have 
been implicated in behaviour based on place memory 
(Humphries&Prescott,2010,ProgNeurobiol). We combined NAc 
functional inhibition in Lister Hooded rats by microinfusion of the 
GABA agonist muscimol with in vivo electrophysiological 
measurements around the infusion site to verify neural effects and 
with locomotor and startle/prepulse-inhibition (PPI) assays to rule out 
gross sensorimotor impairments (adapting methods from Pezze et 
al.,2014,JNeurosc). We then tested the impact of NAc muscimol on 
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behavioural performance based on hippocampus-dependent 1-trial 
place learning using the watermaze delayed-matching-to-place 
(DMP) test (Bast et al.,2009), with muscimol infused between trial 1 
(learning) and 2 (expression of memory). ANOVA was used whenever 
the independent variable had more than two levels or to analyse the 
impact of multiple independent variables. Muscimol (125-250ng/0.5 
µl/side) dose-dependently reduced NAc neuronal firing around the 
infusion site by 30-50% and caused moderate sensorimotor effects. 
Interestingly, NAc muscimol impaired between-session locomotor 
habituation. With habituation memory linked to the hippocampus 
(Fanselow,2000,BehavBrainRes), this is consistent with the idea that 
NAc is important for hippocampal memory expression. Our first 
watermaze experiment, testing the impact of NAc muscimol within-
subjects, indicated that the NAc is required for DMP performance. 
However, there appeared to be a carry-over effect: after repeated 
testing with muscimol, rats failed to show the typical DMP search 
strategy (persistent searching in correct location) even on drug-free 
test days, possibly reflecting that NAc is required to reinforce the 
strategy. A second watermaze DMP experiment, using a between-
subjects design to avoid carry-over effects, confirmed that NAc 
muscimol impairs expression of hippocampus-dependent rapid place 
learning. Overall, these findings support that the NAc contributes to 
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Hippocampal neural disinhibition (decreased GABA function) has been 
implicated in cognitive disorders, including schizophrenia and age-
related cognitive decline (Bast et al, 2017, BrJPharmacology). We 
previously showed that hippocampal disinhibition in rats by local 
microinfusion of the GABA-A antagonist picrotoxin disrupts memory 
and attention, increases locomotor activity, and enhances 
hippocampal multi-unit burst firing under anaesthesia (McGarrity et 
al,2017,CerebCortex). Low doses of levetiracetam, the second-
generation antiepileptic, have been shown to decrease both age-
related hippocampal neural hyperactivity and cognitive deficits in 
humans and rodent models (Haberman et al, 2017, 
Neurotherapeutics). Here, we tested if systemic levetiracetam would 
antagonize 1) the enhanced hippocampal burst firing and 2) the open-
field locomotor hyperactivity caused by hippocampal disinhibition by 
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picrotoxin. 1) Using multi-unit recordings under anaesthesia, we 
replicated that hippocampal picrotoxin (150ng) enhances 
hippocampal burst firing. Levetiracetam selectively attenuated the 
increased burst duration, with this effect being significant at 10mg/kg 
(i.p.), but not 50mg/kg; 50mg/kg slightly reduced the peak 
frequency in bursts under baseline conditions. Based on these 
findings, we used 10mg/kg for the locomotor studies. 2) 
Levetiracetam (10mg/kg) attenuated locomotor hyperactivity caused 
by hippocampal disinhibition; this was supported by a strong trend 
towards an interaction of systemic injection (levetiracetam vs. saline) 
and hippocampal infusion (picrotoxin vs. saline) in a 2X2 within-
subjects study (p=0.0523). Low-dose levetiracetam attenuated some 
neural and behavioural effects of hippocampal disinhibition. 
Levetiracetam’s impact on clinically relevant cognitive impairments 
caused by hippocampal disinhibition (McGarrity et al, 2017, 
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Attentional performance requires balanced medial prefrontal cortex 
(mPFC) activity, with both functional inhibition or disinhibition (by 
micro-infusion of GABA agonist muscimol or antagonist picrotoxin) 
causing impairments (Pezze etal.,2014,JNeurosci).  Does this finding 
extend to behavioural flexibility? We examined effects of mPFC 
muscimol (62.5ng/side) and picrotoxin (300ng/side), as compared to 
saline-control infusions, on behavioural flexibility in male Lister-
hooded rats, using a food-reinforced operant (lever-press) strategy-
shifting task (Brady&Floresco,2016,JoVE). The task involved ‘shifts’ 
(across three sessions) from a spatial (left/right) response to a cue-
light-based response, or vice versa. Irrespective of infusion, shifting 
from spatial to cue responses required three times as many trials as 
reported in studies using other rat strains (e.g., 
Brady&Floresco,2016). These slow shifts were unaffected by mPFC-
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manipulations. However, mPFC-disinhibition increased trial omissions 
and impaired spatial-response expression. 
However, Lister-hooded rats readily acquired cue responses when 
they had not first been trained to perform spatial responses; then, 
they readily shifted from the cue to the spatial response. mPFC 
disinhibition tended to slow this shift, reducing the percentage of 
correct responses during shift session 2.  If mPFC was disinhibited 
both during initial-rule acquisition and shift-sessions, this also 
increased perseveration during shifting. In Lister-hooded rats, 
prefrontal disinhibition impaired aspects of behavioural flexibility, 
slowing shifting from cue to spatial responses. Rats were slow to shift 
from spatial to cue responses, which was unaffected by mPFC 
inhibition or disinhibition.  A Bayesian, trial-by-trial analysis of 
response strategies is ongoing, which may reveal additional, more 














Appendix 3: PIPS reflective statement  
Note to examiners: 
This statement is included as an appendix to the thesis in order that 
the thesis accurately captures the PhD training experienced by the 
candidate as a BBSRC Doctoral Training Partnership student. 
The Professional Internship for PhD Students is a compulsory 3-
month placement which must be undertaken by DTP students. It is 
usually centred on a specific project and must not be related to the 
PhD project. This reflective statement is designed to capture the skills 
development which has taken place during the student’s placement 
and the impact on their career plans it has had. 
 
PIPS Reflective Statement 
For my PIPS placement I spent 3 months in the experimental 
psychology department at the University of Oxford where I worked in 
the group of Professor David Bannerman and Dr Mark Walton. During 
my time in the department I was working on a project assessing the 
role of cholinergic interneurons in learning and behaviour. This 
project was a new venture for the lab which would complement the 
previous work they had done investigating the role of midbrain 
dopamine in learning and reward. The aims of the project were to 
understand how activity of cholinergic interneurons within the 
striatum effects reward related behaviours and prediction errors. This 
project was based on previous findings from Dr Stephanie Cragg’s lab 
which highlighted the role that cholinergic interneurons play in 
mesolimbic dopamine neuron activity and dopamine release. During 
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my time in the department I worked closely with Dr Lauren Burgeno, 
a research fellow based in both the Walton and Cragg labs. The 
project was carried out using in vivo techniques in a rodent model. 
Initially this required training water restricted mice on a two-step 
probability-based task which had been adapted from a human based 
task by the lab.  
 
This training period took several weeks due to the complex nature of 
the task used and necessity for robust behaviour to ascertain useful 
data. After completion of this training period we injected viruses and 
implanted fibre optics into the dorsal and ventral striatum to allow for 
specific recording of cholinergic interneurons during task completion 
using fibre photometry. Running of the task and data analysis 
required an understanding of coding using python, and therefore this 
project allowed me to gain experience in using python to complete 
data collection. Unfortunately, due to the length of the experiment 
and time taken to analyse the vast amount of photometry and 
behavioural data the results of the study were finalised after 
completion of my placement. However, the skills I gained during this 
period will be very useful for me going forward in my career.  
 
In addition to the project I was working on, I was also able to observe 
and learn about the other projects going on in the department which 
included techniques such as voltammetry and electrophysiological 
recordings in awake animals. During my time in Oxford I had the 
opportunity to go to several seminars and talks which helped broaden 
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my knowledge base and drive my scientific curiosity. I was also able 
to attend a seminar on ‘open science’ where a number of speakers, 
including one of the co-founders of bioRxiv and the CEO of eLife aired 
their views on various aspects of open access journals, pre-print 
publications and the publication process in general.  
 
Overall, my time at the University of Oxford was very useful and the 
placement gave me lots of opportunities to learn new skills such as, 
surgical techniques, photometry and coding. The placement also gave 
me the opportunity to interact and learn from a diverse group of 
people which has given me new insights into a range of scientific 
avenues. Thanks to my time in the department for experimental 
psychology, this has helped me to determine that I would like to 
continue within academia upon completion of my PhD. This is due to 
my enjoyment of working within a creative environment whereby 
there is more freedom to explore interesting scientific questions.  
 
